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ABSTRACT 
 Combined Use of Multiple Monoclonal Antibodies Targeting Epidermal Growth 
Factor Receptor for Improved Cancer Therapeutics 
Vishal G. Kamat 
 
 
 
 Epidermal growth factor receptor (EGFR) overexpression and its deregulated signaling is 
one of the hallmarks of multiple neoplasms. Although the use of monoclonal antibodies (mAbs) 
binding to the ectodomain of EGFR has shown promising results in inhibiting tumor progression, 
clinical failures in the anticipated outcome resulted in exploring new modalities for improved 
treatment. 
 During the initial phase of this thesis, we observed that combined use of two EGFR 
targeting mAbs – mAb425 (EMD55900) and C225 (Cetuximab/Erbitux), synergistically inhibited 
the growth and EGF dependent signaling of EGFR overexpressing breast cancer cells. This 
observation has led to an effort to identify the mechanisms that govern the synergistic behavior.  
  Binding competition and mutagenesis studies showed that mAb425 and C225 had 
distinct binding epitopes. mAb425/C225 combination inhibited EGF binding more efficiently 
than individual mAbs. EGF disrupted mAb–EGFR complexes containing individual mAbs but 
not the complexes with mAb combination. Further flow cytometry and surface plasmon 
resonance analysis suggested that both the mAbs were able to recognize most of the 
conformational states of EGFR. Overall, these results indicate that simultaneous binding of two 
non-competing mAbs, mAb425 and C225 stabilizes the inactive form of the receptor which EGF 
cannot recognize; thus achieving efficient inhibition of EGF binding.  
xvii 
 
We also observed that co-incubation with mAb425 and C225 resulted in enhanced EGFR 
downregulation, compared to individual mAbs. The use of Fab fragments showed no significant 
receptor internalization. Monovalent Fab fragments failed to inhibit cell growth and EGF 
dependent signal transduction, suggesting that EGFR crosslinking by bivalent IgG molecules is 
required for inhibition. Live cell confocal imaging showed that mAb combination significantly 
reduced receptor recycling. Collectively these results suggest that EGFR oligomerization by 
mAb425/C225 combination is vital for synergistic receptor downregulation. 
 We believe that the mechanisms of synergy presented may be further extended to other 
mAb combinations. Such combinations could synergize by adopting the efficient ligand blocking, 
faster EGFR downregulation, or a combination of both these mechanisms. We hope that the 
information gained from these studies may be used as a model to guide researchers to engineer 
novel mAbs and accelerate their transition from bench to clinic. 
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EXECUTIVE SUMMARY 
Epidermal growth factor receptor (EGFR) overexpression and its deregulated signaling is 
one of the hallmarks of multiple neoplasms. Although the use of mAbs binding to the 
extracellular domain of EGFR has shown promising results in inhibiting tumor progression, 
clinical failures in the anticipated outcome resulted in exploring new modalities for improved 
treatment. Combinations of mAbs showed improved efficacy, but the underlying mechanism of 
action remains unknown. Due to this insufficient understanding, significant amount of money, 
time and resources are spent in developing and validating the anti-cancer effects of such mAbs 
and their derivatives. This provides the rationale of the current study. The hypothesis, specific 
aims, rationale and highlights of the current study are described below: 
Specific Aim 1: Select two EGFR targeting mAbs that have distinct binding epitopes on the 
extracellular domain of the receptor and demonstrate synergistically inhibits growth inhibition 
and EGF dependent signal transduction of EGFR overexpressing cancer cells. 
Hypothesis for Specific Aim 1: Simultaneous binding of two non-competing EGFR targeting 
mAbs would enhance their potency in inhibiting growth and EGF dependent signal transduction. 
Rationale for Specific Aim 1: Most of the therapeutic mAbs are screened for their potency in 
inhibiting the ligand from binding to the receptor. Apart from ligand binding inhibition, every 
mAb exhibits its characteristic secondary mode of action in inhibiting tumor growth. The use of 
two non-competing mAbs in combination would harness all the mechanisms demonstrated by 
both the mAbs; thus enhancing their potency in inhibiting the growth of cancer cells. 
Informative summary for Specific Aim 1: We observe that combined use of two EGFR 
targeting mAbs – mAb425 and C225 synergistically inhibits the growth and EGF dependent 
signaling of EGFR overexpressing MDA-MB-468 breast cancer cells (Chapter 4). mAb425 and 
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C225 have distinct binding epitopes  and can simultaneously bind to EGFR without any change in 
their binding characteristics. 
Specific Aim 2: Understand the difference in the mode of EGF binding inhibition for single 
mAbs and in combination. 
Hypothesis for Specific Aim 2: Simultaneous binding of two non-competing mAbs stabilizes the 
inactive conformation of the receptor, thus achieving complete blockage of EGF binding. 
Rationale for Specific Aim 2: The X-ray resolved crystal structures of liganded and unliganded 
EGFR suggest that the receptor needs to adopt active conformation for EGF to bind with high 
affinity. Generally, high affinity antibodies are designed and screened for their potency to inhibit 
EGF binding.  The results of the western blot presented in Chapter 4 of this thesis clearly show 
significant reduction in the EGF dependent downstream signaling by mAb425/C225 combination. 
Since both the mAbs antagonize EGF binding, we believe that enhanced inhibition of ligand 
dependent signal transduction by mAb425/C225 combination could possibly be due to their 
increased potency in inhibiting EGF from binding to the receptor compared to individual mAbs. 
Informative summary for Specific Aim 2: Results presented in Chapter 5 of this thesis show 
that the combined use of mAb425 and C225 (both IgG and Fab fragments) is a better inhibitor of 
EGF binding. EGF is able to disrupt mAb–EGFR complexes containing individual mAbs but not 
the complexes with mAb425/C225 combination. Both the mAbs are able to recognize the tethered 
and untethered receptor conformation with similar affinities but fail to recognize the active 
receptor confirmation. Similar to EGF, binding of mAbs shifts the equilibrium of the receptor 
conformation towards mAb-preferred structure. Collectively, these results suggest that 
simultaneous binding of mAb425/C225 combination shifts the equilibrium towards mAb-
preferred conformation and stabilizes the inactive form of the receptor, thus achieving complete 
blockage of EGF binding. 
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Specific Aim 3: Investigate EGFR downregulation by bivalent IgG molecules – single vs 
combination and compare it with monovalent Fab fragments. 
Hypothesis for Specific Aim 3: Receptor oligomerization by the use of two non-competing 
mAbs in combination is required for enhanced EGFR downregulation and synergistic growth 
inhibition. 
Rationale for Specific Aim 3: Apart from ligand binding inhibition, receptor downregulation is 
another mode of action that therapeutic mAbs demonstrate to inhibit growth of tumor cells. 
Following ligand mediated endocytosis; the fate of the receptors present in the early endosomes 
depends on the stability of ligand-EGFR complex. If the complex is stable at the acidic pH 
environment present in the early endosomes, the receptors are trafficked to the late endosomes 
and lysosomal compartments for degradation while the unstable complexes are recycled back to 
the cell surface. Knowing that the trimolecular complex of mAb425, C225 and EGFR is more 
stable than bimolecular complex of mAb and EGFR (as hypothesized in Specific Aim 2), we 
believe that receptor internalization mediated by mAb425/C225 combination would sort the 
receptor towards late endosomes and lysosomal compartments for degradation. 
Informative summary for Specific Aim 3: Incubation of MDA-MB-468 cells with 
mAb425/C225 combination results in significantly enhanced EGFR downregulation compared to 
single mAbs (Chapter 6). However, the use of monovalent Fab fragments of Matuzumab and 
C225; single and in combination fails to mediate EGFR internalization. Unlike bivalent IgG 
molecules, Fab fragments are unable to inhibit growth of A431 cells. Moreover, Fab fragments 
could not inhibit EGF dependent signal transduction indicating that bivalent IgG molecules are 
required to antagonize EGF activity. Real time live cell imaging studies demonstrate that 
treatment with individual mAbs results in receptor recycling which is significantly reduced in the 
case of mAb425/C225 combination. 
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 Collectively, the results presented in this thesis suggest that although mAb425/C225 
combination used as bivalent IgG molecules and as monovalent Fab fragments is able to more 
efficiently block EGF binding, only IgG combination that demonstrate enhanced EGFR 
downregulation are able to inhibit cell growth and EGF activity. 
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CHAPTER 1 
GENERAL INTRODUCTION & BACKGROUND 
1.1  A short journey through the history of cancer 
 Cancer has been one of the dreadful diseases affecting people since several centuries. 
Reports about patients suffering from this frightful disease was found on Egyptian papyrus leaves 
dated roughly around 1500 B.C. They had documented 8 cases of tumors occurring on the breast. 
They believed that cancer was caused by the GODS and treated patients by cauterization, which 
is a method to destroy tissue with a hot instrument called "the fire drill." However the drill failed, 
as the writing on the papyrus said “There is no treatment.”It is believed that the famous Greek 
physician, Hippocrates first described that spreading of tumors appeared like crabs and termed 
them as “carcinos”, which also is the origin of the word “carcinoma”. Over the years the word 
“carcinoma” shortened to what we now call as cancer. The autopsy to understand the cause of 
illness and death was first performed by an Italian anatomist Giovanni Morgagni in the year 1761. 
This scientific study of cancer provided the foundation for the development of a new branch of 
science called Oncology. The invention of modern microscope in the 19th century helped 
scientists understand more about cancer biology and paved the foundation towards the 
development of modern pathologic study of cancer. 
1.2  Current cancer statistics 
 In today’s modern world, cancer is considered as the major public health problem in the 
United States and most of the other countries in the world. In the year 2008, it has been projected 
that a total of 1,437,180 new cancer cases and 565,650 deaths from cancer would occur in the US 
itself (Jemal et al., 2008). A list of the ten leading cancer types for the estimated new cancer 
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cases and deaths most commonly occurring in men and women in the year 2008 is detailed in 
Figure 1.1. 
 Cancers of the prostate, lung and bronchus, along with colon and rectum are the most 
commonly found cases in men and account for almost half of the total new cancer cases. Prostate 
cancer itself records for almost 25% of the new cases. These three cancer types are responsible 
for around 50% of the total cancer deaths. Breast cancer is the most commonly diagnosed cancer 
in women. Though only 14% of new cases in women are identified as lung and bronchus cancer, 
these cancers are responsible for nearly 26% of the total death cases in women. In the year 2005, 
cancer has been reported as one of the five leading causes of death in all age groups among males 
and females. Alarmingly, it was also the leading cause of death among women aged 40 to 79 
years and among men aged 60 to 79 years. Figure 1.2 shows the long-term trend of cancer 
occurrences and death rates for all cancer types by sex. Between 1991 and 2004, the cancer 
deaths have been reduced by 18.4% and 10.5% in men and women respectively. This decreasing 
trend in mortality rates has resulted in reducing over a half million deaths from cancer during this 
time interval. Though there is such substantial reduction in deaths, current figures show that 
almost 1 in 4 deaths in the United States is the result of cancer. 
 Despite the continuous decrease in the rates of new incidences and death, there is an 
increasing concern regarding the alarming increase in the number of cases. A recent article from 
the magazine ScienceDaily (2008) has reported that “cancer is projected to become the leading 
cause of death worldwide in the year 2010, and low- and middle-income countries will feel 
the impact of higher cancer incidence and death rates more sharply than industrialized 
countries.” Based on the existing facts on the number of new cases in cancer, it is estimated that 
the burden of cancer would double by 2020 and would nearly triple by the end of 2030. It has 
been projected that in just 20 years from now; there would be 20-26 million patients newly  
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Figure 1.1  Ten leading cancer types. 
The figure shows the ten leading cancer types for the estimated new cancer cases and deaths, 
by sex, United States, 2008. This figure has been adapted from Reference (Jemal et al., 2008). 
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Figure 1.2  Annual age-adjusted cancer incidence and death rates. 
The figure shows the annual age-adjusted cancer incidence and death rates for all sites by sex, 
United States, 1975 to 2004. This figure has been adapted from Reference (Jemal et al., 2008). 
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diagnosed with cancer and the death toll would be around 13-17 million people. The report 
claimed that this startling increase in the number of cases suffering from cancer, especially in less 
developed countries like India, China and Russia is the result of accepting western habits such as 
tobacco use, higher-fat diets, and demographic changes. Moreover, there are a number of under-
developed countries like Africa that are staggered by inadequate budgets, under-investment in 
physical infrastructure, and insufficient numbers of trained health care professionals. Such 
institutional weaknesses make it even more difficult to combat cancer; making it one of the most 
frightening realities around the globe. 
1.3  Cancer biology 
 Over the past several thousand years, evolution has engineering cells in the living 
organisms to grow and multiply in a controlled manner and replace old, infected and dead cells 
by a controlled cell death mechanism called apoptosis. Every organ is constituted of different 
types of cells which work in co-operation with one another for proper functioning of the organ. 
During their entire life span, individual cells regulate their specific function in the organ. Any 
stress or wear-out of these cells would first trigger the repair mechanism to fix the damage 
caused. Any failure in the restoration of normal cellular activity would result in cell death; 
replacing the dead cells with new ones of the same phenotype. This entire repair/replace 
mechanism is extremely complex and very tightly controlled. Any deregulation of this 
mechanism is the primary cause of cancer. 
 Cancer cells are characterized to grow and reproduce uncontrollably; disregarding the 
rules of nature and/or to spread from their original location to some other parts of the body. 
Uncontrolled cell growth and multiplication would result in tumor formation. If these cells 
continue to grow together as a single mass, they are said to be benign. Benign tumors can be  
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easily treated by surgical removal. However, if they start invading into the surrounding tissues, 
they become malignant. Once these malignant cells acquire the ability to break the cellular 
architecture and enter the bloodstream or lymphatic system to form secondary tumors in other 
parts of the body, the cancer becomes metastatic. At this stage the cancer is extremely dangerous 
and the survival of the patients is minimal. 
 The primary source of all the tumors is a small population of slightly abnormally growing 
cells which in fact are the daughter cells of a single mutated parent cell. At every round of cell 
division, each cell acquires additional mutation and the process goes on in an uncontrolled 
manner. Such mutations give daughter cells an added advantage to survive over their neighbors. It 
 
Figure 1.3  Clonal evolution of cancer caused by series of mutations 
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should be noted that the microenvironment in the core of solid tumors is not conducive for cell 
survival due to their low oxygen levels and insufficient supply of nutrients. However, newly 
grown mutated cells easily adapt themselves to survive in such environment and continue to 
divide. Thus the dominant clone from all the mutations eventually forms solid tumors (Figure 
1.3). 
1.4  The ErbB receptor/ligand network 
 There are four members in the ErbB family of receptors – EGFR also known as ErbB-
1/Her1, Her2/neu/ErbB-2, Her3/ErbB-3 and Her4/ErbB-4. All four erbB receptors have a 
common structure consisting of three distinct regions: (i) an extracellular region (ECD) which is 
the ligand binding domain and is sub-divided into four distinct domains; (ii) a transmembrane 
(TM) domain containing a single hydrophobic anchor sequence that is involved in the interaction 
between receptors; and (iii) an intracellular domain (ICD) which is responsible for enzymatic 
phosphorylation of different adaptor proteins and regulation of intracellular signaling (Figure 
1.4). Except for ErbB-3, all the other members also contain the tyrosine autophosphorylation sites 
at the carboxy-terminal tail which connect these receptors to proteins containing Src homology 2 
(SH2) and phosphotyrosine-binding (PTB) domain motifs. The extracellular domain of the ErbB 
receptors is less conserved, suggesting that these receptors can bind to different ligands. However 
the intracellular tyrosine kinase domain is highly conserved.  
 EGF family of growth factors is expressed as transmembrane proteins that are cleaved by 
cell surface proteases (Falls, 2003b; Harris et al., 2003). Once the membrane associated growth 
factors are cleaved, a process also termed as ectodomain shedding; they are released in the 
microenvironment and regulate receptor activity. The released ligands can either activate the 
same cell (autocrine signaling) or neighboring cells (paracrine signaling). Binding of the EGF-
like growth factors to the extracellular domain of these receptors is essential for receptor 
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activation. The EGF-like growth factors have the characteristic three disulphide bonds stabilizing 
the intramolecular loops and providing binding specificity. Ligands of this family can be further 
categorized in three groups listed in Table 1.1 (Antonella De Luca, 2008; Normanno et al., 
2003; Yarden, 2001). The first group of ligands containing EGF, transforming growth factor - 
alpha (TGF-), amphiregulin (AR) and epigen specifically binds to EGFR (Strachan et al., 
2001). Betacellulin (BTC), heparin-binding growth factor (HB-EGF), and epiregulin (EPR) that 
binds to both EGFR and ErbB-4 form the second group. And the third group consists of 
neuregulins (NRGs) and tomoregulin and can be further classified based on their capacity to bind 
to only ErbB-4 (NRG-3, NRG-4, and tomoregulin) or to both ErbB-3 and ErbB-4 (NRG-1 and 
NRG-2) (Carraway et al., 1997; Chang et al., 1997; Harari et al., 1999; Zhang et al., 1997). 
Her2 is the only receptor of the ErbB family whose ligand is not yet discovered. Except for Her2, 
binding of ligand to receptor ectodomain is the first step required for the dimerization of the 
receptors either with itself (homodimerization) or with other members of the family 
(heterodimerization). Receptor dimerization results in auto- and trans-phosphorylation of the 
tyrosine residues at the cytoplasmic domain of the receptor results in the activation of various 
intracellular signaling cascades like the phosphatidylinositol 3-kinase (PI3K)/Akt, the 
Ras/Raf/MEK/Mitogen-Activated Protein Kinase (MAPK), and signal transducer and activator of 
transcription (STAT) pathways. Figure 1.5 provides a detailed schematic of ErbB signaling 
network (Yarden and Sliwkowski, 2001). 
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Figure 1.4  Schematic structure of the ErbB family of receptors and their cognate 
ligands 
All members of the ErbB family of receptors consist of three distinct domains – the 
extracellular domain, the transmembrane domain and the intracellular domain.  This 
figure has been adapted from  reference (Rowinsky, 2004). 
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ErbB Receptors Ligands 
EGFR 
Epidermal growth factor (EGF) 
Transforming growth factor  (TGF-) 
Amphiregulin (AR) 
Epigen 
EGFR and ErbB-4 
Betacellulin (BTC) 
Heparin-binding growth factor (HB-EGF) 
Epiregulin (EPR) 
ErbB-2 None 
ErbB-3 and ErbB-4 
Neuregulin 1 (NRG-1) 
Neuregulin 2 (NRG-2) 
ErbB-4 
Neuregulin 3 (NRG-3) 
Neuregulin 4 (NRG-4) 
Tomoregulin 
 
Table 1.1  The ErbB receptors and their cognate ligands 
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Figure 1.5  Schematic of the ErbB receptor signaling. 
This figure has been adapted from reference (Yarden and Sliwkowski, 2001). 
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1.5  EGFR – An oncogene 
 v-ErbB was originally identified as one of the oncogenes carried by the avian 
erythroblastosis virus (Frykberg et al., 1983) which was later shown to encode the homologue of  
human EGFR (Downward et al., 1984b). Deregulated signaling through the EGFR either alone or 
in cooperation with other members of the ErbB family, notably ErbB2 and ErbB3, is a hallmark 
of multiple neoplasms predominantly of epithelial origin. Overexpression of EGFR or other 
members of the ErbB family of receptors is the most commonly found characteristic in a number 
of different cancers. Table 1.2 provides a list of different malignancies that overexpress ErbB 
receptors (Rowinsky, 2004). Apart from overexpression, the molecular mechanism leading to 
deregulated signaling is the establishment of autocrine and paracrine loops by the aberrant 
overexpression of EGFR growth factors. The high activity of EGFR present in tumors has been 
related to an increase in cell proliferation and poor prognosis. Thus, dysregulated EGFR activity 
modulates several mechanisms that control tumor pathogenesis, progression and ability to 
metastasize. 
EGFR is expressed in almost all non-transformed cell types and is responsible in 
controlling a number of critical cellular activities like growth, survival, migration and 
differentiation (Yarden and Sliwkowski, 2001). In the tumor microenvironment, abnormal EGFR 
activation and signaling by transformed cancerous cells plays an important role in influencing the 
transformation of neighboring non-malignant cell population, resulting in cancer progression. 
Reports indicate that EGFR crosstalks with other receptors and is one of the root causes for 
promoting angiogenesis and metastasis (Antonella De Luca, 2008). 
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ErbB1 ErbB2 ErbB3 ErbB4 
Breast 
(14%–91%)* 
Breast 
(10%–37%)* 
Breast Breast 
Ovary 
(30%–75%)* 
Ovary 
(20%–32%)* 
Ovary Ovary* 
Renal 
(50%–90%) 
Renal (24%–40%) Renal  
Lung (NSCLC) 
(40%–80%)* 
Lung (NSCLC) 
(3%–56%)* 
Lung (NSCLC)* 
Lung 
(NSCLC) 
Head and neck 
(squamous) 
(30%–75%)* 
Head and neck 
(squamous) 
(32%–62%)* 
Head and neck 
(squamous) * 
Head and neck 
(squamous)* 
Colorectal 
(25%–77%) 
Colorectal 
(7%)* 
 Pancreas 
Pancreas 
(30%–50%)* 
   
Glioma 
(40%–50%)* 
   
Bladder 
(31%–48%)* 
Bladder 
(7%–36%) 
  
Esophagus* 
Esophagus  
(13%–73%) 
  
Stomach* 
Stomach 
(5%–55%)* 
  
Prostate Prostate* Prostate Prostate 
Melanoma Melanoma Melanoma Melanoma 
Thyroid  Thyroid Thyroid 
Endometrial* Endometrial*   
Skin  
(squamous cell) 
  
Skin 
(squamous) 
Lung (small cell)   Lung (small cell) 
Cervical*    
Sarcomas    
   
Chronic myelogenous 
leukemia 
 
Table 1.2  Malignancies overexpressing ErbB receptors. 
* Clinical studies have linked overexpression and/or mutation of this erbB receptor to a worse 
prognosis. Table has been adapted from  reference (Rowinsky, 2004). 
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1.6  Extracellular structure of EGFR 
 EGFR was the first RTK to be discovered (Carpenter et al., 1978). It is a 170kD TM 
glycoprotein consisting of an ectodomain, a single transmembrane domain and a cytoplasmic 
domain. EGFR has a four domain structured ectodomain with two homologous large domains (L) 
and two cysteine-rich (CR) domains which occur in the order L1-CR1-L2-CR2 from the N-
terminal. The intracellular domain is further grouped into the juxtamembrane domain, followed 
by the tyrosine kinase and the carboxyl terminal tail that contains five auto-phosphorylation sites 
– Y992, Y1068, Y1086, Y1148 and Y1173 (Bogdan and Klambt, 2001). Initial quantitative 
binding studies showed that there are two subclasses of receptors on the cell surface – (i) low 
affinity receptors that bind to EGF with a KD of 1-10 nM, accounting for 95-98% of the receptors 
and (ii) the remaining 2-5% receptors represent high affinity receptors binding to EGF with a KD 
of approximately 10-100 pM  (Lax, 1989). Immediately following the finding of these sub-
classes of receptors, Defize et al. (Defize and de Laat, 1989) demonstrated that EGF mediated 
signal transduction occurs majorly through the sub-class of high affinity receptor conformations. 
Since EGF was found to be a bivalent molecule binding to both domains I and III; domain III 
being the major ligand binding domain, it was initially believed that EGFR dimerization is ligand 
mediated and that EGF holds two receptors together as a dimer by simultaneously binding to two 
separate receptors (Gullick, 1994; Lemmon et al., 1997). The premise of this hypothesis was 
based on the structural evidence of ligand mediated dimerization of growth hormone receptor. 
Since then, based on a number of different biophysical and cellular studies, a model was 
developed that suggested that the stoichiometry of EGF:EGFR required for receptor dimerization 
is 2:2 and that the binding of EGF to the ectodomain of the receptor induces a significant 
conformational rearrangement of the receptor ectodomain and stabilizes the receptor in its 
activated state, required for subsequent signaling (Gullick, 1994; Lemmon et al., 1997). 
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 Since the determination of liganded structures of EGFR dimers (Garrett et al., 2002; 
Ogiso et al., 2002), there has been a significant improvement in our understanding on the mode of 
ligand binding and the conformational rearrangement of the ectodomain required for receptor 
dimerization and activity. The X-ray crystal structure of EGF:sEGFR complex determined at 3.3 
Å resolution is shown Figure 1.6. These structures presented the first glimpse that receptor 
dimerization is purely receptor mediated. Both bivalent ligands bind exclusively to domains I and 
III and are located on the opposite sides of the dimerization interface. At the center of this 
dimerizing interface lies a 20 residue -hairpin loop located on domain II termed as “dimerization 
arm” that forms the major receptor-receptor contacts. This -hairpin loop of EGFR differentiates 
itself from other known RTKs such as insulin-like growth factor receptor (IGFR) and growth 
hormone receptor (GHR); where the ligands are involved in receptor dimerization. Binding of 
ligands seemed to induce conformational arrangement of receptor ectodomain, stabilizing the 
active receptor conformation. Unrevealing the liganded structures resulted in the evolution of 
more unresolved, convoluted questions. How can the binding of a 6kD ligand induce a 
conformational rearrangement of a 170kD receptor? This mystery was later unveiled by Ferguson 
et al. (Ferguson et al., 2003) when the structure of auto-inhibited EGFR conformation bound to 
EGF was resolved. Remarkably, it was discovered that the -hairpin loop of domain II that is 
engaged in receptor dimerization is also involved in the intramolecular interaction with domain 
IV that leaves the receptor in the autoinhibited conformation. The 2.8 Å resolution crystal 
structure of auto-inhibited sEGFR structure (Figure 1.7) clearly shows the extensive domain 
II/IV intradomain interactions, absent in the active form (Figure 1.6). The domain II/IV 
interaction buries a total of 922Å2 (466Å2 from each domain) solvent accessible area and the 
shape complementarity (Sc) parameter of this interface is 0.66. This Sc value is very typical for 
antigen-antibody interaction. By comparing the orientations of activated and auto-inhibited 
structures, it was found that there was no change in the intradomain conformation and that if the 
domain I/II rigid body (with EGF bound to domain I) was rotated by around 130º about the axis 
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close to the R310 carbon atom and then translated by 20Å along the same axis, EGF would be 
able to bind to the two interacting contacts of domain III. So based on these structures two 
probable models were proposed. One model proposed that binding of ligand to domain I or 
domain III might tether domain II/IV interaction and induce conformational rearrangement of 
EGFR ectodomain, exposing domain II -hairpin loop for receptor dimerization. However 
binding of EGF to sEGFR does not change G by more than 1-2 kcal/mol, which is the estimated 
energy necessary to disrupt domain II/IV interface. So this model was ruled out. So a new model 
was proposed, wherein sEGFR is projected to exist in a dynamic equilibrium between high 
abundance of auto-inhibited, closed conformation and low population of extended conformation. 
Binding of EGF “traps” the receptor in the active conformation, exposing the dimerization arm 
and thus drives the equilibrium towards the active conformation. The schematic representation of 
the model showing ligand mediated EGFR activation and dimerization is shown in Figure 1.8. 
. 
 
 
Chapter1
 
17 
 
 
 
 
Figure 1.6  Crystal structure of 2:2 EGF-sEGFR complex. 
(A) Ribbon representation of sEGFR dimer mediated by EGF binding. (B) Top view of (A) is 
shown in (B). (C) represents the surface model corresponding to (A). The structure of the 
complex has been adapted from reference (Ogiso et al., 2002). 
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Figure 1.7  Crystal structure of the autoinhibited sEGFR monomer. 
(A) Ribbon representation of sEGFR in its inactive form. (B) Details of the key interactions of 
the region boxed in (A) showing the extensive intradomain interactions between domains 
II/IV, responsible for holding the receptor in inactive form. The structure has been adapted 
from reference (Ferguson et al., 2003; Marmor et al., 2004). 
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1.7  EGFR signaling 
1.7.1  Receptor dimerization 
 Ligand mediated receptor dimerization is extremely crucial for EGFR activation and 
signaling. As mentioned in the earlier section, EGFR expressed on the cell surface exists in a 
continuous dynamic equilibrium, switching between the tethered/inactive/auto-inhibited state to 
the untethered/extended form which is able to adopt a wide range of conformations. Most of the 
receptors exist as monomers. The presence of ligand stabilizes the active form of the receptor and 
 
 
Figure 1.8  Schematic representation of conformation rearrangement of EGFR ectodomain. 
The EGFR ectodomain exists in a dynamic equilibrium between the high abundance of 
inactive conformations and the low abundance of active conformation. The -hairpin loop 
interaction between domains II and IV tethers the receptor in the auto-inhibited conformation. 
Disruption of the domain II/IV interface removes the receptor from the tethered state. These 
untethered receptors are able to adopt a wide range of extended conformations. EGF traps the 
receptor in the active conformation resulting in receptor activation and signaling. 
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exposes the dimerization arm. Following ligand binding, the receptor traverses along the cell 
membrane and either dimerizes with itself or with other members of the ErbB family. Recent 
studies reveal that the fate of receptor activation is mainly directed by the type of dimerization – 
homo or hetero (Pinkas-Kramarski et al., 1996; Riese et al., 1995). These reports strongly 
demonstrate that heterodimeric combinations of receptors are more mitogenic and transforming 
compared to homodimerization. In fact studies show that Her2 containing heterodimers are more 
potent than any other dimers of the ErbB family. Earp et al. in their review has provided a 
detailed summary on the importance of heterodimerization and has proposed few theories to 
explain the reason why nature has evolved with a more effective heterodimers (Earp et al., 1995). 
This review stated that “opposed to homodimerization, heterodimers are likely to: 
1. expand substrate selection and downstream signaling pathway activation 
2. promote interaction between sets of substrates in the mixed receptor complexes that 
would not ordinarily be physically juxtaposed 
3. alter the duration of receptor signaling by changing rates of receptor internalization, 
ligand loss, kinase inactivation, recycling, etc. 
4. alter rates of receptor and substrate dephosphorylation” 
 These studies have thus shed new light in our understanding of ligand dependent EGFR 
dimerization along with other factors that influence the triggering of the signaling events; 
transferring the binding event from the outside microenvironment of the cell to the inside of the 
cell. 
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1.7.2  EGFR tyrosine kinase activation 
 Though receptor dimerization is required for signaling, is it enough for receptor 
activation? Several reports suggest the presence of preformed dimers on the cell surface even in 
the absence of ligands (Moriki et al., 2001; Yu et al., 2002). Ligand independent dimerization has 
been observed on the surface of EGFR overexpressing tumor cells; possibly due to receptor 
crowding. So why are these receptor dimers not constitutively active? Taken together all these 
reports and pertaining curiosity to understand the mechanism of receptor activation resulted in the 
proposition that dimerization in itself is unable to trigger receptor activation and that the activity 
is modulated by certain conformational rearrangement in both ECD and ICD of receptor dimers. 
 For many years it was known that EGF binding to the ectodomain results in the activation 
of RTK that initiates receptor auto-phosphorylation. However, the role of RTK in receptor 
activation was poorly understood. Most of the RTKs require a low level of basal phosphorylation 
which increases exponentially following ligand binding. However, EGFR is one of the only 
known RTKs that do not require this initial phosphorylation of the kinase domain for its full 
catalytic activity. The ligand free and Tarceva bound structures of EGFR kinase domain 
crystallized by Stamos et al. (Stamos et al., 2002) showed that the kinase domain was not 
phosphorylated. Moreover, significant intermolecular contacts were formed between the kinase 
domains and the C-terminal was found to be in close proximity with the N-terminal of its binding 
partner. Surprisingly, the activation loop of kinase domain adopted a structure which was similar 
to the phosphorylated active form of insulin receptor kinase domain. Another structure of the 
kinase domain bound to the drug Lapatinib resolved by Wood et al. (Wood et al., 2004) showed 
an inactive form of the kinase domain and the structure was found to be similar to the inactive 
form of Src family of kinases (Jemal et al., 2008; Schindler et al., 1999) and cyclin dependent 
kinases (CDK) (De Bondt et al., 1993). But the actual mechanism of action for kinase activity 
was not well understood until the recent crystal structures published by Zhang et al. (Zhang et al., 
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2006). These structures provided a detailed insight on the mechanotransduction of conformational 
rearrangement of the ECD to the allosteric interaction of TK, required for EGFR activation. The 
study suggested that EGFR kinase domain exist in an auto-inhibited state, which can be activated 
by increasing its local concentration. It is known that following ligand binding, EGFR traverses 
laterally along the cell membrane and forms receptor dimers and oligomers. Such oligomerization 
would in turn increase the local concentration of the kinase domains, which is being hypothesized 
as the trigger for kinase activation. Thus it was proposed that EGFR is activated by asymmetric 
dimerization of the kinase domain, wherein the C-terminal lobe of one kinase domain interacts 
with the N-terminal lobe of another kinase domain. The schematic diagram of the proposed 
mechanism for the activation of EGFR kinase domain is shown in Figure 1.9. Since EGFR 
activation influences a wide range of key players responsible in regulating important cellular 
activities, the science community believes that nature might have evolved with EGFR kinase 
domain as a secondary control mechanism in order to avoid its dysregulated function. In the light 
of these structures, it is now proposed that the binding of EGF traps the receptor in the open 
conformation. This results in the shift in the equilibrium from the high abundance of auto-
inhibited towards the low abundance of activated form. This ligand mediated conformational 
rearrangement of ECD induces asymmetric receptor dimerization. Such conformational 
rearrangement of the ECD results in the mechanotransduction of the signal through the TM 
domain to the ICD. This triggers the allosteric interaction of kinase domain, exposing the cleft for 
ATP binding leading into auto- and trans-phosphorylation of the receptor and subsequent 
signaling cascade.  
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1.7.3  Tyrosine phosphorylation and signaling cascade 
 EGFR has six autophosphorylation tyrosine residues located at the carboxyl terminal of 
the receptor. Activation of tyrosine kinase domain is the precursor to catalyze the tyrosine 
residues of the auto-phosphorylation sites (Y – 992, 1045, 1068, 1086, 1148, 1173) (Downward 
et al., 1984a; Olayioye et al., 2000; Walton et al., 1990). These residues serve as docking sites 
for a wide range of intracellular signaling proteins containing SH2 and/or PTB binding domains, 
critically bridging the external stimuli to internal signal transduction. Figure 1.10 provides a 
schematic of all the phosphorylation sites located at the carboxyl tail of the ErbB family of 
receptors (Olayioye et al., 2000). Ligand induced phosphorylation of tyrosine residues of the 
EGFR results in the recruitment of several adaptor molecules such as Shc, Grb, Sos, PLC , 
SHP1, and PI3K; thereby modulating a wide range of signaling pathways, shown in Figure 1.11. 
Y1173 is the major tyrosine residue and is a major docking site for the binding of Shc, PLC- and 
protein tyrosine phosphatase Shp1. Among the six auto-phosphorylation sites, Y1068 and Y1173 
 
 
Figure 1.9  Schematic representation of the activation of EGFR tyrosine kinase. 
This figure has been adapted from reference (Zhang et al., 2006). 
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are considered as the most important autophosphorylation sites following EGF activation that 
provide docking sites for the adaptor proteins Grb2 and Shc respectively (Batzer et al., 1994; 
Downward et al., 1984a; Okutani et al., 1994). Y1068 phosphorylation has been indentified to 
modulate PI3K and STAT pathways (Coffer and Kruijer, 1995). Y845 is located within the 
conserved region of the activation loop of kinase domain and is considered to be responsible to 
stabilize and hold the loop in the active form to favor the binding of ATP and other substrates. 
Following EGF binding, c-Src is responsible for the phosphorylation of Y845 (Sato et al., 1995) 
and is also known to be involved in mitogenesis and tumorogenesis (Boerner et al., 2004; Tice et 
al., 1999). Thus EGFR activation directly and indirectly results in the downstream signaling 
cascade of different pathways. Figure 1.12 provides a schematic of the important signaling 
network that gets activated following receptor dimerization. 
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     ErbB1                ErbB2                 ErbB3                       ErbB4 
 
Figure 1.10  Phosphotyrosine residues and docking of signaling molecules to ErbB receptors. 
The autophosphorylation sites of the ErbB family that are identified are shown in yellow 
(Downward et al., 1984a; Hsuan et al., 1989; Margolis et al., 1989; Walton et al., 1990)  
while Src kinase docking sites are shown in black (Biscardi et al., 1999; Sato et al., 1995; 
Stover et al., 1995). Adaptor proteins that directly interact with specific tyrosine residues of 
the ErbB receptors are shown. This figure has been adapted from reference (Olayioye et al., 
2000). 
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Figure 1.12  EGFR induced signaling cascade. 
This figure has been adapted from reference (Marmor et al., 2004). 
 
Figure 1.11  A schematic view of EGFR showing the crucial signaling pathways regulated 
by the kinase activity. 
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1.8  Immunotherapy 
1.8.1  Antibodies – Body’s natural defense system 
 Antibodies also called as immunoglobulins (abbreviated as Ig) are large globular proteins 
that are present on the membrane of B-cells and are also secreted by plasma cells. Secreted Ig 
molecules circulate in the blood stream and other body fluids. These Ig molecules are the 
effectors of the humoral immunity and are responsible for the identification and neutralization of 
foreign bodies (also called as antigens). When any foreign material (pathogen) enters human 
body, the antigen presenting cells (APC) serve as the first line of defense. Once these pathogens 
are engulfed by APC, either by phagocytosis or receptor mediated endocytosis, they are digested 
and fragments of the antigen, bound to a class II MHC molecule are displayed on their 
membrane. Since antigens have complex structures, a number of different fragments of antigens 
are displayed. The T-cell recognizes and interacts with the antigen-class II MHC molecule 
complex on the APC membrane and gets activated. Activated T-cells release cytokines that 
activates specific B-cells. Activation of B-cells results in their proliferation and/or differentiation 
into plasma cells that produce antigen specific antibodies. Humoral response for pathogen 
requires activation of a number of different clones of B-cells, each clone producing antibodies 
that binds specifically to the displayed antigen fragment. Therefore, antibodies secreted in the 
serum in response to a particular antigen are heterogeneous. 
 In the human body there are five different antibody isotypes having specific biological 
functions – IgA, IgD, IgE, IgG and IgM. However, all the antibodies have similar basic structure 
of four peptide chains (Figure 1.13). They are Y-shaped molecules containing two identical light 
chains of about 25kD molecular weight and another two identical heavy chains of about 50kD or 
more, each composed of variable domains and constant domains. The light chain is bound to the 
heavy chain by a disulphide bridge and complemented with some additional non-covalent 
interactions such as salt bridges, hydrogen bonds and hydrophobic interactions. Similar non-
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covalent and disulphide bonds link the two heavy chains together. Apart from interchain 
disulphide bonds, there are two or more intrachain disulphide bonds within the light and heavy 
chains which provide stability to the antibody structure. Among different Ig molecules, the first 
120 amino acids or so of the amino terminal region of both the light and heavy chains are 
extremely variable. These regions are called the V-regions: VL and VH for light and heavy chains 
respectively. This region provides antibodies with their high specificity. Within this V-region lie 
the hypervariable (HV) regions that constitute the antigen binding site of the antibodies. This is a 
small region generally located at the very tip of the protein spanning around 7-10amino acids in 
length. This difference in the HV sequences provides the huge diversity in antibody recognition 
to a wide range of antigens with high specificity, keeping the structural framework the same. 
Since the antigen-binding site is complementary to the structure of the epitope of the target 
antigen, HV region is also termed as complementarity-determining regions (CDRs). There are 
three CDRs (CDR1, CDR2, and CDR3) on each variable chain. Regions apart from the variable 
region have fairly constant sequence and are called as the constant regions. The tail region of the 
antibody is called the Fc fragment (“fragment, crystallizable”) as it was found to crystallize 
during cold storage. The Fc region comprises of two heavy chains containing two or three 
constant domains depending on the class of the antibody, linked together by disulphide binds and 
other non-covalent interactions. The Fc region binds to the Fc receptors and other immune 
proteins such as complement molecules and plays a major role in the effector function of humoral 
immunity. The two antigen binding domains (also called as Fab fragments) are connected to the 
Fc region by a hinge region, except for the  and  heavy chain isotypes that contains an 
additional domain instead of hinge region (Figure 1.13). The hinge region is highly flexible and 
allows the antibodies to open and close; thereby enabling better binding between the antibody and 
antigenic determinants on the surface of an antigen. 
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Figure 1.13  Schematic diagram of the structure of immunoglobulin 
The schematic structure of immunoglobulins of isotype , ,  (a) and ,  (b) are shown. This 
figure has been adapted from Kuby, Immunology 
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1.8.2  Antibody therapy – “The Magic Bullet” 
 The term antibody was first used by the Nobel laureate Dr. Paul Ehrlich in his work 
“Experimental studies on immunity” published in Oct 1891 (Lindenmann, 1984). Since he 
exclusively worked with toxins, he used the term “Antikörper” which is the German word for 
 
 
Figure 1.14  General structures of five major classes of secreted antibodies. 
This figure has been adapted from Kuby, Immunology 
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antibodies. He had envisioned the creation of "Magic Bullets" – compounds that would have high 
affinity for the disease-causing microorganisms. These magic bullets would search for such 
organisms and destroy them; having no harmful effects on the bodies of patients. Ehrlich had 
written “If we picture an organism as infected by a certain species of bacterium, it will . . . be 
easy to effect a cure if substances have been discovered which have a specific affinity for 
these bacteria and act…on these alone . . . while they possess no affinity for the normal 
constituents of the body. . . such substances would then be . . . magic bullets.” Ehrlich was the 
first to propose the use of mAbs – the body’s natural magic bullet, to deliver toxins to cancer 
cells. Since then, the potential of targeted immunotherapy gathered attention of a number of 
investigators. However, this concept attained completion when the first hybridoma cell lines were 
developed to produce monoclonal antibodies by the Nobel laureates Köhler and Milstein, who 
developed hybridoma cell lines to produce monoclonal antibodies (Köhler and Milstein, 1975). 
In this pioneering work, they injected rodents with specific antigens. The B-cells secreting 
antibodies against the antigens were isolated from the spleen of the immunized rodents and were 
later fused with myeloma cells that had lost their ability to secrete antibodies. After successful 
selection of the fused cells in respective selective medium, the resulting fused cell lines were 
termed as “hybridomas”. These hybridomas were found to constantly produce large quantities of 
antibodies specific to the targeted antigen. Since then, there has been a tremendous improvement 
in the technology to develop mAbs which has high specificity and good homogeneity. Successful 
development of target specific mAbs played a pivotal role in the success of mAb therapy. Figure 
1.15 provides a schematic protocol recently used for the production of hybridomas secreting 
antigen specific mAbs.  
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1.8.3  EGFR targeted immunotherapy 
In the last 20 years, increased understanding of EGFR signaling, its role in 
tumorigenicity, combined with the success in developing EGFR specific novel antibodies that 
inhibit receptor activity and cell growth has led to significant progress in the field of EGFR 
targeted cancer immunotherapy. Since the development of recombinant techniques to produce 
target specific mAbs, a wide range of anti-EGF receptor mAbs having nanomolar and sub-
nanomolar affinities were produced (Aboud-Pirak et al., 1988; Kawamoto et al., 1983; 
Mendelsohn and Baselga, 2000; Rodeck et al., 1987). These mAbs were found to inhibit EGF 
binding and thus were able to block EGF mediated signal transduction and were also able to 
inhibit the growth of EGFR overexpressing cancer cells in-vitro. The inhibitory effects of these 
mAbs observed in-vitro were further validated in-vivo by tumor xenografts. Though inhibition of 
 
 
Figure 1.15  Monoclonal antibody production in the lab 
This figure has been adapted from  reference (2009). 
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ligand binding has always been the most important and commonly found mechanism of action in 
most of the anti-EGFR therapeutic antibodies, studies have shown that they exhibit different 
modes of action, which singly or in combination are responsible for their anti-tumor behavior. 
Since EGFR activity has direct implications on regulating diverse cellular functions, anti-EGFR 
antibodies display number of different mechanisms which directly or indirectly affect cellular 
machinery. Few of the most important mechanisms that have been identified and listed below: 
1. Inhibition of tyrosine kinase activity 
2.  Inhibition of cell cycle progression 
3. Increased receptor downregulation 
4. Inducing apoptosis 
5. Inhibition of angiogenesis 
6. Inhibition of metastasis 
7. Triggering the effector function through the Fc region of the mAb 
 Initial in-vitro and preclinical studies demonstrated good correlation between EGFR 
overexpression and tumor sensitivity to EGFR mAbs. However, from the results of the clinical 
trials it became evident that the sensitivity of tumor cells to these EGFR targeted drugs did not 
depend only on receptor expression levels (Glennie and Johnson, 2000).Murine mAbs that were 
tested for their therapeutic potentials failed terribly during the early stages of human clinical trials 
(Ross et al., 2005). The biggest challenge to the success was the development of human anti-
mouse antibody (HAMA) response by clinical subjects that significantly compromised the 
integrity of the EGFR mAbs and also resulting in hypersensitivity in patients (Tjandra et al., 
1990) . Researchers then realized that for the successful administration of mAbs and good 
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therapeutic efficacy required for FDA approval, efforts need to put in developing non-
immunogenic mAbs. Since then significant amount of work has concentrated in transforming 
murine mAbs into more human or human-like. However, making human mAbs was a challenge 
as the traditional method of immunization was not ethically feasible. This challenge turned out to 
be the key element for the break-through in antibody engineering in developing chimeric and 
human mAbs (Boulianne et al., 1984; Morrison et al., 1984; Vaswani and Hamilton, 1998; 
Winter and Harris, 1993). Chimeric antibodies were produced by replacing the constant region 
of murine mAb with that of human while the only murine part in the humanized mAbs is the 
complementarity-dependent regions (CDRs). C225 (Erbitux®/Cetuximab) by Imclone Inc. is one 
of the most successful chimeric mAb that has been FDA approved for treating patient diagnosed 
with colorectal cancer that overexpresses EGFR. Matuzumab (EMD72000) by Merck KGaA, 
Darmstadt is a 90% humanized IgG1 mAb targeting EGFR. This mAb was generated by grafting 
the mouse CDR of its precursor (mAb425/EMD59000) which was an IgG2b isotype into a human 
IgG1 framework (Kim, 2004). Though most of the sequences of chimeric and humanized mAbs 
are human, researchers were not ready to compromise any reduction in the anticipated efficacy 
caused due to the immunogenicity of the murine sequence. So with the goal to produce 100% 
human mAbs, transgenic mice were generated by replacing the murine immunoglobulin genes by 
human Ig genes. Such transgenic mice would thus have humoral immune system and would 
produce human mAbs. One of such mice that have been successfully used to generate high 
affinity, fully human mAbs is the Xenomouse system (Jakobovits et al., 2007). Xenomouse was 
successfully used to develop the first fully human mAb that targeted EGFR, Panitumumab 
(Vectibix®/ABX-EGF) and is now already FDA approved for the treatment of colorectal cancer 
as a single agent (Wainberg and Hecht, 2007). 
 The difference in the mAb framework between murine, chimeric, humanized and human 
mAbs is compared in Figure 1.16. These new generation of mAbs had human Fc region which 
ignited the wave of belief in the scientific community that apart from evading the HAMA 
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response, these molecules would also be able to trigger the effector functions making them 
therapeutically more efficacious. 
 
Though engineering human-like and human mAbs significantly reduced the HAMA 
response, it did not completely address all the other challenges observed during different phases 
of clinical trials. It was initially proposed that mAbs that bind to the target antigen with very high 
affinities, especially slower dissociation rates would be retained in tumor cells for prolonged 
period, thus showing improved efficacy. Based on this proposition, therapeutic mAbs were 
screened and sub-nanomolar affinity mAbs were selected and tested for their anti-cancer potency 
(Yang et al., 1999b). However during pre-clinical and clinical trials, it was found that high 
 
 
 
Figure 1.16  Difference between murine, chimeric, humanized and human mAbs 
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affinity mAbs preferentially bind to the antigens in the immediate proximity of the blood vessel, 
significantly decreasing the number of free, diffusible mAbs available for tumor penetration, a 
phenomenon called the “binding-site barrier” (Adams et al., 2001; Fujimori et al., 1990; Jain, 
1990; Juweid et al., 1992). This resulted in non-uniform distribution and limited penetration of 
mAbs in most tumors. So the presumed hypothesis that increased binding affinity would result in 
better sensitivity of tumor cell was contradicted. mAb degradation by the host immune system, 
increased hydrostatic pressure, heterogeneity of antigen expression in tumors, disordered 
vasculature in tumors (Adams et al., 2001; Juweid et al., 1992; von Mehren et al., 2003) further 
hindered the expected success of mAb therapy. Failure in the anticipated success of cancer 
immunotherapy has forced researchers and pharmaceutical companies to explore new modalities 
for effective treatment of cancer (Booy et al., 2006). 
1.8.4  New strategies in cancer immunotherapy 
 Clinicians and researchers together are trying to explore new approaches to improve 
therapeutic efficacy of immunotherapeutic drugs. It was observed that apart from the 
phenomenon of binding-site barrier, IgG molecules were unable to diffuse into the  interstitium of 
solid tumors due to their sheer-size (Jain, 1990). The emergence and advancement in antibody 
engineering has resulted in developing many innovative antibody moieties. Variant small sized 
antibody fragments - minibody, diabody, single-chain fragment (scFv), dimerized scFv are now 
developed to overcome such physiological barriers (Figure 1.17). Pharmacokinetic studies 
suggested that radiolabeled scFvs are more evenly distributed compared to IgGs and Fabs. 
However because of their smaller size, they are easily metabolized by the kidney leading to rapid 
blood and renal clearance resulting in insufficient tumor uptake (Colcher et al., 1990; Yokota et 
al., 1993). 
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Researchers are now exploring the therapeutic effect of combination therapy. Random 
cocktails of one antibody with chemotherapeutic drugs or with another mAb targeting different 
receptor are being trialed in hope of achieving improved efficacy (Carter, 2001). Combinations 
of mAbs with chemotherapeutic drugs such as doxorubicin (Baselga et al., 1993), paclitaxel 
(Johnson et al., 2004), gemcitabine (Xiong et al., 2004) has shown improvement in the 
therapeutic efficacy compared to single agents. The effector function of mAb is enhanced by 
triggering the antibody dependent cellular cytotoxicity (ADCC) through the Fc receptors 
expressed on the immune effector cells (Umana et al., 1999). Antibodies are also covalently 
 
 
Figure 1.17  Schematic diagram showing the structures of variety of engineered antibody 
molecules 
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linked to a range of other molecules to introduce different mode of action; such as cytotoxic 
drugs, toxins, or radionucleotides for killing cancer cells, enzymes for pro-drug therapy and 
cytokines to stimulate the antitumor immune response. The success of mAb linked to radioactive 
particles and toxins has resulted in the FDA approval of some conjugated mAbs. Bispecific mAb 
constructs with different effector functions have demonstrated superior antagonist effect in 
receptor signaling, achieving efficient reduction in cell proliferation and tumor growth (de Leij et 
al., 1998; Kontermann, 2005; Korn et al., 2004; Molema et al., 2000a; Molema et al., 2000b; 
Muller and Kontermann, 2007). Such rapid advancements in protein engineering and the 
observed success in producing antibodies with reduced immunogenicity, altered half-life, 
improved efficacy and increased tumor targeting assures tremendous potential in the field of 
cancer immunotherapy. Though these new generation, bispecific therapeutic antibodies are 
demonstrating great promises in the pre-clinical and early clinical trials; their mechanism of 
action is yet to be explored. Due to insufficient understanding of the actual mechanism of cancer 
immunotherapy, especially in the case of combinatorial therapy, tremendous amount of money, 
time and resources are spent in screening, developing and validating the anti-cancer effects of 
these mAbs and their derivatives; which provides the rationale of the current study.  
1.9  Aim of the study 
We believe that the use two EGFR targeting mAbs having distinct binding epitopes on 
the extracellular domain of EGFR would enhance the potency in inhibiting growth and ligand 
dependent signal transduction of EGFR overexpressing cancer cells. The goal of this research is 
(i) to screen for two non-competing EGFR targeting mAbs that synergizes when used in 
combination, (ii) understand the underlying mechanism of synergy and (iii) based on these 
results, develop a model which would assist in engineering novel biologics that would 
demonstrate improvement in cancer therapy. The outcome of the proposed research, would lead 
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to the development of a model to select multiple new combination therapies which would be too 
expensive to develop through clinical trials. More importantly, it would guide drug design for 
cancer therapy, developing novel antibodies or protein complexes in a variety of forms for 
improved therapy. The hypothesis, specific aims and rationale for current study are described 
below: 
Specific Aim 1: Select two EGFR targeting mAbs that have distinct binding epitopes on the 
extracellular domain of the receptor and demonstrate synergistic growth inhibition and enhanced 
inhibition of EGF dependent signal transduction. 
Hypothesis for Specific Aim 1: The use two non-competing EGFR targeting mAbs would 
simultaneously binding to the receptor and enhance their potency in inhibiting EGFR 
overexpressing cancer cells. 
Rationale for Specific Aim 1: Most of the therapeutic mAbs are screened for their potency in 
inhibiting ligand from binding to the receptor. However, every mAb has its characteristic mode of 
ligand binding inhibition. Some mAbs directly compete with the ligand (overlapping binding 
epitopes) while some mAbs allosterically inhibit ligand binding (non-overlapping binding 
epitopes). Apart from ligand binding inhibition, every mAb exhibits its characteristic secondary 
mode of action in inhibiting the growth of tumor cells such as, enhanced receptor downregulation, 
ADCC, activation of complement signaling, activation of immune cells and so on. The use of two 
non-competing mAbs in combination would harness the mechanisms of action demonstrated by 
both the mAbs; thus enhancing their potency in inhibiting the growth of cancer cells. 
Specific Aim 2: Explore the difference in the EGF binding in the presence of individual mAbs 
and in combination. Understand the difference in the mode of EGF binding inhibition for single 
mAbs and in combination. 
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Hypothesis for Specific Aim 2: Combined use of non-competing EGFR targeting mAbs more 
efficiently inhibits the binding of EGF compared to single mAb. Simultaneous binding of two 
non-competing mAbs stabilizes the trimolecular complex and locks the receptor in the inactive 
conformation, thus achieving complete blockage of EGF binding. 
Rationale for Specific Aim 2: The X-ray resolved crystal structures of liganded and unliganded 
EGFR suggest that EGF interacts at three distinct sites on the ectodomain of the receptor; two on 
domain III and one on domain I (Ferguson et al., 2003; Garrett et al., 2002; Ogiso et al., 2002). 
From these and other studies it is now postulated that EGFR should adopt the active conformation 
for EGF to bind with high affinity. This active receptor conformation allows EGF to simultaneous 
bind to domains I and III; thus trapping the receptor in the active conformation. Binding of EGF 
exposes the dimerization arm (-hair loop) located in domain II of the EGFR ectodomain, 
allowing its dimerization partner to interact, thereby initiating a plethora of signaling events. 
Inhibition of this EGF interaction leaves the receptor in its inactive conformation resulting in the 
blocking of signaling cascade – one of the most important mechanisms of EGFR targeted cancer 
immunotherapy. Generally, antibodies that are designed to efficiently inhibit EGF binding either 
exhibits a high EGFR binding affinity or induce a change in the receptor conformation which 
does not EGF to bind. The results of the western blot presented in Chapter 4 of this thesis clearly 
show that combined use of mAb425 and C225 significantly reduced EGF dependent downstream 
signaling of the receptor.  Since both the mAbs antagonize EGF binding, we believe that 
enhanced inhibition of ligand dependent signal transduction by mAb425/C225 combination is the 
result of more efficiently inhibition of EGF from binding to the receptor compared to individual 
mAbs. 
Specific Aim 3: Investigate EGFR downregulation by bivalent IgG molecules – single vs 
combination and compare it with monovalent Fab fragments. Investigate the effect of mAb 
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mediated receptor oligomerization (in the case of mAb425/C225 combination) on receptor 
trafficking. 
Hypothesis for Specific Aim 3: Receptor oligomerization by the use of two non-competing 
mAbs in combination is required for enhanced EGFR downregulation and synergistic growth 
inhibition. 
 Based on the results presented in this thesis, we have put forward two different modes of 
action demonstrated by mAb425/C225 combination – (i) Enhanced inhibition of EGF binding 
and (ii) Synergistic EGFR downregulation. The two models developed based on the observed 
distinct behavior by mAb425/C225 combination were later implemented to build the design 
criteria that would aid in engineering next generation biologics. We strongly believe that the new 
biologic drug generated based on the proposed design criteria would demonstrate significantly 
enhanced efficacy. The model that we proposed in this thesis for engineering next-generation 
drugs could help reduce the time spent in the traditional biologics development; thereby 
accelerating the translation of new biologics from bench to clinic. 
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CHAPTER 2 
EXPERIMENTAL PROCEDURES 
2.1 RESULTS I: KINETIC ANALYSIS AND MOLECULAR CHARACTERIZATION OF 
EGFR TARGETING MONOCLONAL ANTIBODIES – mAb425 & C225 
2.1.1  Materials and reagents 
 Unless specified all the enzymes were purchased from New England Biolabs (NEB). The 
extracellular domain of EGFR (sEGFR) was either purchased from R&D Systems or 
recombinantly expressed from stable Drosophila Schneider S2 cells. Amphiregulin and heparin-
binding EGF-like growth factor (HB-EGF) were bought from R&D Systems while epiregulin and 
TGF- were purchased from Peprotech. 
2.1.2  Generation of sEGFR construct 
 The pSecTag2B plasmid containing the sEGFR was generously provided by Dr. Greg 
Adams, Fox Chase Cancer Center, Philadelphia, PA. The plasmid was sequenced by Genewiz, 
Inc. and the sEGFR sequence was verified. The sequencing result showed a single point mutation 
(lysine to serine) at location 474. Xho1 and Kpn1 restriction sites of the Drosophila expression 
vector, pMT/BiP/V5-His-A plasmid (Invitrogen, Inc.) were selected for the ligation of the sEGFR 
fragment. For the sake of simplicity, this vector would be termed as V5-vector from now on. 
2.1.2.1  Transformation of E. coli 
 Unless specified, most of the transformation was done using Escherichia coli (E. coli) 
strain XL1-Blue cells. Around 40l of XL1-Blue cells was pipetted in a pre-chilled eppendorf 
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tube followed by the addition of 1l of DNA. After 30min incubation on ice, the transformation 
reaction was heat-pulsed for 45sec at 42ºC. The transformation reaction was then recovered for 
2min on ice and then 250l of pre-heated SOC medium was added. The recovered plasmid was 
then incubated at 37ºC for 1hr at ~200rpm and subsequently approximately 40-100l of the 
recovered plasmid was plated on a Luria Broth (LB) Agar plate containing ampicillin at 100g/ml 
concentration. The plate was incubated overnight at 30ºC for colony formation. Individual 
colonies were selected and grown overnight in LB base medium containing 100g/ml ampicillin 
and then the DNA was isolated using QIAprep spin miniprep kit. Depending on the purpose, the 
purified samples were either sent for DNA sequencing or stored at -20ºC for future work. 
2.1.2.2  Agarose gel electrophoresis 
 Routinely 1% agarose bead, diluted in Tris-acetate-EDTA (TAE) buffer (40mM Tris-
acetate, 1mM EDTA) was used in agarose gel electrophoresis. The agarose was first melted in the 
microwave and then allowed to cool down to ~55ºC. Ethidium bromide (EtBr) was added (to 
stain DNA fragments) and then the melted gel was poured into the gel bed. Once the gel settles, 
samples were loaded in the wells and the gels were electrophoresed in TAE buffer at room 
temperature till adequate separation was achieved. Electrophoresed DNA samples were 
visualized under long wavelength ultraviolet (UV) light and DNA was extracted using QIAquick 
gel extraction kit (QIAGEN Inc., Valencia, CA) using company’s protocol. 
2.1.2.3  Polymerase chain reaction 
 In order to amplify the sEGFR DNA fragment, the pSecTag2Bexpression vector was 
used as the PCR template. Pfu Turbo DNA polymerase (Stratagene) was used and the primers 
designed for the amplification are given below: 
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Forward Primer:  5’ – GCCGGTACCCGACTACAAAGACGAT – 3’ 
Reverse Primer:  5’ – TTCCTCGAGAGGCCCATTCTGTGG – 3’ 
 In a typical PCR protocol, the following reagents were added in a single PCR tube for a 
50l volume reaction: 
10X Pfu Buffer   = 5l 
DNA template (~100ng/ml) = 1l 
Forward primer (10pmol/l)  = 1.5l 
Reverse primer (10pmol/l) = 1.5l 
dNTP mix (20mM)  = 1l 
Nanopure water   = 37l 
2l of Pfu Turbo DNA polymerase enzyme was added last and after proper mixing of the 
cocktail, the reaction was allowed to proceed for around 16-20 cycles using the thermocycler 
program. 
 A typical PCR program consisted of an initial melt of 94ºC for 1min, followed by 25 
cycles of annealing at 55ºC for 1min, extension at 72ºC for 3min and denaturation at 94ºC for 
1min. After the final annealing step followed by 6min extension, the samples were allowed to 
cool to 4ºC. The reaction time and temperature were altered depending on the molecular weight 
of the DNA fragment to be amplified. Once the DNA amplification was verified using agarose 
gel electrophoresis, the products were purified either using QIAprep spin miniprep kit (QIAGEN 
Inc., Valencia, CA) or QIAquick gel extraction kit (QIAGEN Inc., Valencia, CA) prior to further 
manipulations. 
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2.1.2.4  Ligation of DNA fragments to expression vector 
 The amplified sEGFR DNA fragment was first digested using Kpn1 restriction 
endonuclease. A typical digestion reaction for a 20l volume reaction contains: 
Vector/Plasmid   = 250g/ml (5g in 20l) 
Restriction endonuclease = 1l 
10X Buffer   = 2l 
100X BSA   = 0.2l 
Nanopure water   = adjusted to 20l 
 Generally digestion reaction was performed for 2hr at room temperature. At the end of 
the reaction, 1l of SAP enzyme was added (to remove the phosphates from the reaction mix) and 
was further incubated for 30min at 37ºC. SAP enzyme was then inactivated by heat shock (65°C 
for 10min) and then the digested fragment was purified using by the QIAprep spin miniprep kit 
(QIAGEN Inc., Valencia, CA). The purified sample was again digested using Xho1 restriction 
endonuclease by following the same protocol. The final product containing double digested 
fragment was then separated using agarose gel electrophoresis. The gel was visualized under UV 
light and the segment of the agarose gel containing the desired DNA fragment to be isolated was 
cut and purified using QIAquick gel extraction kit (QIAGEN Inc., Valencia, CA). Similarly, the 
V5-vector was double-digested using Xho1 and Kpn1 restriction endonucleases and purified. 
 Double-digested and purified sEGFR fragment and V5-vector were ligated using T4 
DNA ligase at different vector:plasmid ratios – 1:1, 1:2 and 1:4. A typical ligation reaction is 
described as follows (for a 20l volume reaction): 
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Double digested vector   = 50fmol 
Double digested DNA fragment  = 50-200fmol 
10X T4 ligase buffer   = 2l 
Nanopure water    = Adjusted to 20l 
Ligation was generally performed overnight at 15ºC. T4 ligase was heat inactivated by 
incubation at 65ºC for 10min followed by the purification using QIAprep spin miniprep kit. The 
purified plasmid was then transformed into Escherichia coli strain XL1-Blue cells and the DNA 
was purified using QIAprep spin miniprep kit. The full length sequence was confirmed using 
DNA sequencing by Genewiz Inc. In the final construct, the C-terminal of sEGFR was linked to a 
V5 epitope followed by a hexahistidine sequence yielding pMT-sEGFR-V5-His construct. The 
amino acid sequence of the final construct was sEGFR1-620–
RGPFEGKPIPNPLLGLDSTRTGHHHHHH (the V5 epitope sequence is underlined). 
2.1.2.5  Site-directed mutagenesis 
 Site-directed mutagenesis was adopted to rectify the single point mutation at residue 474 
of the parent sEGFR DNA. The primers used to mutate the serine residue to its wild-type lysine 
residue (S474K) are given below: 
Forward Primer: 5’ – AACAGAGGTGAAAACAAGTGCAAGGCCACAGGC – 3’ 
Reverse Primer: 5’ – GCCTGTGGCCTTGCACTTGTTTTCACCTCTGTT – 3’ 
Using the above primers, site-directed mutagenesis was performed using PCR with the 
mutated parent sEGFR-V5 construct as the template. The PCR protocol mentioned above was 
followed and mutagenesis was allowed to proceed for 16 cycles in the thermocycler. At the end 
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of the cycle, 2l of Dpn1was added (to digest methylated parent template) and incubated for 4hr 
at 15ºC. The resulted mutagenesis product was later transformed into XL1-Blue cells and purified 
using Qiagen Maxi prep (QIAGEN Inc., Valencia, CA). The sequence was confirmed using DNA 
sequencing and once validated the plasmid was stored at -20ºC for subsequent protein expression. 
2.1.3  S2 cell transfection and development of stable cell lines 
 S2 cells were cultured at 25ºC in Insect-Xpress serum-free medium (Lonza). The cells 
were first transiently transfected with different amounts of DNA to determine transfection 
conditions yielding high levels of protein expression. For transient transfection, around 8x104 
cells were seeded in a 6-well plate with 2ml of medium and cultured overnight. Around 20l of 
Cellfectin® transfection reagent (Invitrogen, Inc.) was added in each eppendorf tube containing 
500l of medium with different amounts of pMT-sEGFR-V5-His expression vector. The cocktail 
was mixed gently and allowed to incubate for 1hr at room temperature. Around 800l of fresh 
medium was added in each tube (1.3ml final volume) and the medium from each well was 
replaced by 1.3ml of the transfection mixture. Cells were then incubated for 6hr and then after 2X 
washes, 3ml of fresh medium was added. After 48hr, protein expression was induced by adding 
copper sulphate (CuSO4) solution at 700M final concentration. Cell supernatants were collected 
every day for 4 days. Levels of protein expression were measured for both cell cultures and 
precipitants by Western blot using anti-histidine tag polyclonal antibody (Santa 
CruzBiotechnology). RIPA buffer (50 mM Tris-HCl, 150 mM NaCl, 1 mM PMSF, 1 mM EDTA, 
5μg/ml Aprotinin, 5g/ml Leupeptin, 1% Triton x-100, 1% Sodium deoxycholate, 0.1% SDS, pH 
7.4) was used to lyse the cells. Lysed cells were vortexed and then insoluble cell debris was 
pelleted by centrifugation at 13,000 X g for 15min at 4ºC and the supernatant was analyzed. 
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 Once the transfection conditions were optimized, stable S2 cell lines were generated by 
co-transfecting the expression vector with the blasticidin-resistant vector pCoBlast (Invitrogen). 
S2 cells were co-transfected with 1g of pCoBlast vector. After 48hr, fresh medium containing 
20g/ml of blasticidin was added and blasticidin-resistant S2 cells were selected after 3weeks. 
Resistant cells were then grown in the insect X-press serum free medium in the absence of any 
selection reagent and the stable cells were either stored in liquid nitrogen or used for subsequent 
protein production. 
2.1.4  Protein expression and purification 
 Less than 450ml of stable S2 cells were grown as suspension culture in 1lt shaker flask 
(to allow enough space for aeration) in Insect Xpress medium. Once the cells reached a density of 
approximately 8 x 106 cells/ml, protein expression was induced by adding CuSO4 at the final 
concentration of 700M. Suspension cultures were continued to grow for 72hr at 25ºC. Cell 
supernatant was separated by spinning the culture at 10,000xg and either purified immediately or 
stored at -20ºC. Cell supernatant was first diafiltered using 0.2 micron filter and then purified 
using affinity chromatography. sEGFR present in the supernatant was purified in two steps – His 
purification, using  HisTrap™ FF 5ml column (GE Healthcare Life Sciences) followed by affinity 
purification, using Matuzumab immobilized HiTrap NHS-activated HP 1ml column (GE 
Healthcare Life Sciences). Both the purifications were performed following company’s protocol. 
For His purification, supernatant was passed through the HisTrap column and the bound protein 
was eluted in buffer containing 50mM Tris, 150mM NaCl, 200mM Imidazole. HisTrap purified 
elution fraction was overnight dialyzed in phosphate buffer saline (PBS) buffer (1 mM KH2PO4, 
10 mM Na2HPO4, 137 mM NaCl, 2.7 mM KCl, pH 7.4) and then purified using Matuzumab 
immobilized affinity column. Matuzumab is the humanized form of mAb425 and was provided 
by Merck KgGA, Darmstadt, Germany. Immobilization of Matuzumab onto theHiTrap NHS-
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activated HP column was performed following company’s protocol. Around 10mg of Matuzumab 
was dialyzed in coupling buffer (0.2M NaHCO3, 0.5M NaCl, pH 8.3) overnight before 
immobilization onto the NHS-activated column. The binding efficiency was found to be ~72%. 
 His purified sEGFR sample was flowed through the Matuzumab immobilized column 
and bound protein was eluded using 10mM Glycine, pH 1.5. The eluded fraction was collected in 
a tube containing 1M Tris, pH 9.0. Purified sEGFR protein was dialyzed in PBS buffer and then 
concentrated to ~14M and stored at -20ºC. Purity of the protein was checked by SDS-PAGE and 
concentration was determined by measuring the absorbance at 280nm using extinction co-
efficient of 63830M-1cm-1. Expert Protein Analysis System (ExPASy) proteomics server was used 
to estimate the extinction co-efficient from the amino acid sequence of sEGFR protein. The final 
yield of the protein was approximately 2mg of protein per lt of culture. 
2.1.5  Production of Fab fragments by papain digestion of IgG 
 Fab fragments of IgG molecules were produced using immobilized papain slurry (Pierce). 
Before scaling the production of Fab fragments, experimental conditions were first optimized in 
order to improve the yield of digestion. Papain slurry was first washed five times with freshly 
prepared digestion buffer (PBS containing 20mM Cysteine, 30mM EDTA) in order to remove the 
excess glycerol present in the slurry. Immobilized papain was finally resuspended in original 
volume of slurry taken. Around 50l of homogeneous papain slurry was added in 100l of IgG 
solution at 2mg/ml. The digestion mixture was incubated for different times in a shaker at 25ºC 
and at 37ºC at high speed. At the end of each time period, the papain activity was quenched by 
adding 15l of freshly prepared 300mM iodoacetamide (30mM final concentration). The 
supernatant was separated from the resin and efficiency of papain digestion was checked on non-
reducing SDS-PAGE gel. After the determination of appropriate conditions, Fab fragments of 
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around 12mg of C225 and 15mg of Matuzumab were produced. After the addition of 
iodoacetamide, the supernatant containing digested IgG molecules was dialyzed overnight in 
PBS. Digested samples were diafiltered through 0.2 micron membrane before the purification 
using HiTrap™ Protein A HP, 1ml column (GE Healthcare Life Sciences) following company’s 
protocol. The purity of the Fab fragment was then checked using non-reducing SDS-PAGE gel. 
2.1.6  Surface plasmon resonance (SPR) studies 
 SPR studies were performed using BIAcore 3000 optical biosensor (Biacore Inc., 
Uppsala, Sweden). Unless specified, all the experiments were performed on a CM5 sensor chip at 
25°C in running buffer (20mM HEPES, 150mM NaCl, 3mM EDTA, 0.005% P20, pH 7.4). In 
order to achieve good signal to noise ratio and also minimize the undesirable spikes at the 
beginning and the ending of the association phase, running buffer was filtered and then degassed 
overnight using the in-line vacuum. The sensor chip was mostly derivatized with ligand by amine 
coupling. The sensor surface was first activated by injecting 35l of a 1:1 mixture of 400mM of 
N-ethyl-N-(3-dimethylaminopropyl)carbodiimide (EDC) and 100mM of N-hydroxysuccinimide 
(NHS). Ligand to be immobilized on the surface was diluted in 10mM acetate solution (pH 4.0) 
and injected onto a biosensor surface. Depending on the type of investigation, different RUs of 
ligands were immobilized. After achieving sufficient immobilization, injection of the ligand was 
stopped and the activated surface was quenched by flowing 40l of 1M ethanolamine, HCl (pH 
8.5). Throughout the immobilization process, the flow rate was maintained at 5l/min. During the 
entire SPR analysis, in order to reduce buffer effects, sample composition was maintained as 
close to the running buffer as possible. 
 For mAb binding kinetics using direct immobilization method, around 200RUs of 
mAb425 and C225 were immobilized on flow cells 3 and 4 respectively, while mAb17b (anti–
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human immunodeficiency virus gp120) was immobilized on flow cell 2 as a negative control for 
nonspecific interaction. Lower amounts of ligand immobilization (in this case mAb) on the sensor 
surface help in overcoming the problem of mass transport limitation. The real time interaction of 
mAb425 and C225 was measured by injecting different concentrations of sEGFR at a flow rate of 
50l/min. For direct binding studies like this, higher flow rate minimizes the effect of mass 
transport and receptor rebinding; thus providing more reliable interaction data. 
 Binding kinetics of IgG molecules and Fab fragments using the capture method were 
determined using anti-V5 mAb derivatized on a CM5 chip. In the capture method since we vary 
the amount of ligand capture, a high density chip (~3500 RUs) was produced. Anti-V5 mAb was 
immobilized on flow cell 3 while mAb17b was immobilized on flow cell 2. To evaluate the 
binding kinetics of bivalent IgG molecules it was empirically determined that capturing 5RUs of 
receptors overcomes the avidity effect generally observed in the case of bivalent molecules. 
Binding kinetics of Fab fragments was determined by capturing 45RUs of receptors. Following 
the receptor capture, different concentrations of IgGs and Fab fragments were injected and the 
after double reference subtraction was fit to a 1:1 binding model using BIAevaluation software. 
 The influence of temperature on mAb-sEGFR interaction was also investigated. The 
CM5 chip that was prepared for measuring the kinetics of binding was used for this study. The 
temperature of the flow cells was varied between 5°C to 37°C. Once the temperature reached the 
target temperature, the flow cells were injected with running buffer, 10-20 times in order to 
achieve a stable baseline. Once a stable baseline was achieved, the sEGFR sample was injected 
over the sensor surface and the real time sensorgrams were collected. 
 All the ligand binding inhibition studies were performed on sEGFR purchased from R&D 
Systems. mAb425, C225 and mAb17b were immobilized onto a CM5 chip as mentioned above. 
Since we were not measuring any kinetic parameters, a high density chip (5000RUs) was 
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prepared for this study. PBS containing 0.1mg/ml of BSA was used as the running buffer. sEGFR 
(10nM) was pre-incubated with increasing concentrations of ligand for at least 1hr before 
injecting the sample over the BIAcore chip for 2 minutes at 50l/min. An hour incubation time 
ensured that the binding of ligands to sEGFR reaches equilibrium. The entire process was 
repeated 3 times and the amount of sEGFR bound, just before the end of the association phase 
was normalized with the RUs obtained in the absence of ligands and plotted as percent binding. 
 
2.2 RESULTS II: ENHANCED EGFR INHIBITION AND DISTINCT EPITOPE 
RECOGNITION BY EGFR ANTAGONISTIC MONOCLONAL ANTIBODIES – mAb425 & 
C225 
2.2.1  Cell and reagents 
 Human epithelial breast cancer cells MDA-MB-468 (ATCC HTB-132) were purchased 
from American Type Culture Collection (ATCC), Rockville, MD, USA. NIH3T3 cells 
transfected with either full-length human EGFR (CO12) or mutated EGFR variant III (EGFRvIII; 
HC2) were a generous gift from Dr. Albert Wong (Moscatello et al., 1996). mAb425 was isolated 
from murine ascites by affinity purification using Protein A Sepharose columns followed by Ion 
Exchange columns (GE Health Sciences Q Sepharose 4, fast flow). Purified C225 was purchased 
from Bristol Myers Squibb, Princeton, NJ. The EGFR selective tyrosine kinase inhibitor, 
tyrphostin AG1478, was purchased from Calbiochem. For surface plasmon resonance 
experiments, the extracellular soluble domain of the human EGFR (sEGFR) was purchased from 
R&D Systems, Inc. WST-1 cell proliferation kit was purchased from Takara Bio Inc. HC2, 
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CO12, and MDA-MB-468 cells were cultured in DMEM supplemented with 1g/l glucose, 2mM 
L-glutamine, 10% FBS, 1% penicillin/streptomycin. 
2.2.2  Expression of recombinant EGFR fragments 
 Soluble EGFR (sEGFR) constructs, extracellular domain (residues 1–621), domain III, 
(residues 310–512) and the two point mutations, S460P/G461N introduced into sEGFR domain 
III were produced by our collaborator Dr. John C. Williams, Thomas Jefferson University 
following published methods (Ferguson, 2004). 
2.2.3  Papain digestion of mAb425 and C225 
 Fab fragments of mAb425 and C225/Cetuximab were prepared by our collaborator Dr. 
John C. Williams, Thomas Jefferson University using papain digestion and Protein A reverse 
purification (Pierce). Each protein was further purified using a HiLoad 16/60 Superdex 75 
column. 
2.2.4  Flow cytometry analysis 
 Flow cytometric analyses were carried out using mAb425 and C225 conjugated to 
Alexafluor488 through primary amines following the manufacturer’s protocol (Molecular 
Probes). Around 4–6 Alexaflour488 molecules were bound per antibody as estimated by 
measuring the optical density at 280nm and 494nm. For FACS analysis, cells were detached 
using a non-enzymatic cell dissociation solution (Cellgro), collected and resuspended in wash 
buffer (1X PBS containing 1% BSA). Approximately 500,000 cells were incubated at 4°C in 50l 
of labeled and unlabelled antibodies as indicated. After 30min of incubation, cells were washed 
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thrice with wash buffer and fixed using 1% freshly prepared paraformaldehyde. Samples were 
analyzed on a FACS Canto (BD Biosciences). 
2.2.5  Growth inhibition WST-1 assay 
 Effect of C225 and mAb425 on the metabolic activity of MDA-MB-468 was measured 
by assaying cleavage of the tetrazolium salt WST-1 to fluorescent formazan by cellular 
mitochondrial dehydrogenases; as quantified by measuring the absorbance of the dye solution at 
450nm. In 48-well plates, approximately 3000 cells/well suspended in 200l of DMEM 
containing 10% FCS were allowed to attach. After 24hr, 100l of antibody solutions diluted in 
DMEM were added to each well to achieve the desired concentrations. After 72hr, 30l of WST-
1 reagent was added and cells were further incubated for another 3hr. For analysis, 60l of culture 
medium was added to 200l of 1xPBS buffer and the absorbance was measured at 450nm using a 
Victor2 1420 Multilabel counter (Perkin Elmer). The absorbance at 550nm was used for 
background correction. The percent inhibition was calculated as, 
Growth Inhibition = 
AbsControl - AbsAntibody
AbsControl
 * 100 
2.2.6  Anchorage independent cell growth and survival 
 Cell survival in the anchorage-independent state was determined as previously described 
(Jost et al., 2001c) with minor modifications. Cell suspensions were prepared in DMEM 
containing 0.2% BSA in the presence and absence of 10% FBS, mAb425, C225 or their 
combination (10g/ml final antibody concentration), AG1478 (10M) and/or EGF (10ng/ml). 
After 48hr and 72hr, 500l of cell suspension was transferred to another 6-well plate with the 
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respective culture medium and allowed to attach and grow for 24hr. Attached cells were fixed in 
75% ethanol and stained with crystal violet. 
2.2.7  Immunoblot analysis 
 Cells were incubated in complete growth medium in 100 mm petri dishes (1 x 106 cells 
per dish) for 24hr. After overnight incubation in serum-free DMEM containing 0.2% BSA, 
antibodies (10g/ml final IgG concentration) or AG1478 (10M) were added. After 1hr, EGF 
(10ng/ml final concentration) was added to culture media and cells were lysed using Laemmli 
buffer. Differences in the phosphorylation of MAPK, AKT and EGFR were determined by 
immunoblot analysis. Antibody binding was detected using an enhanced chemiluminescence 
system (Pierce). 
2.2.7  BIAcore SPR Analysis 
 Molecular interactions were determined using a Biacore® 3000 optical biosensor 
(Biacore Inc.). Immobilization of EGFR specific mAbs to CM5 sensor chips were performed 
following the standard amine coupling procedure. Unless specified anti-HIV-1 gp120 antibody 
17b immobilized on CM5 chips was used as a reference flow cell (Thali et al., 1993). Ligand 
densities and flow rates were optimized to minimize mass transport and rebinding effects. 
Analysis of direct binding was achieved by passing different concentrations of sEGFR over mAb 
derivatized chip (200RUs) at a flow rate of 50l/min for 2min association and 6min dissociation 
at 25°C. Regeneration of the surfaces between injections was achieved by injecting three, six sec 
pulses of 10mM glycine, pH 2.0 at the flow rate of 100l/min. 
To evaluate binding competition between mAb425 and C225, a capture SPR format was 
employed. C225 immobilized on the chip was used to capture sEGFR which was then used as a 
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ligand to perform saturation analysis by injecting increasing concentrations of mAb425 (0–
512nM) at a flow rate of 50l/min until binding equilibrium (Req) was achieved. The amount of 
mAb425 bound was then plotted against mAb425 concentration and the value of maximum 
mAb425 binding was compared to theoretical maximum mAb425 binding for the respective 
ligand density. Binding competition studies were performed at 25°C and at 37°C. 
To evaluate the kinetics of mAb425 binding to sEGFR-C225 complex, around 20RUs of 
sEGFR was captured using a low density C225 surface (280 RUs) at 20l/min. The captured 
sEGFR was then used as ligand and increasing concentrations of mAb425 (0–512nM) were 
injected for 2min at a flow rate of 20l/min. Data were analyzed using BIAevaluation® 4.0 
software (Biacore Inc., NJ). The responses of buffer injection and responses from a reference 
flow cell were subtracted to account for nonspecific binding and instrument noise. Experimental 
data were fitted to a simple 1:1 binding model with a parameter included for mass transport. 
2.2.8  Sedimentation equilibrium analysis 
 A complex of full-length sEGFR, Fab425 and FabC225 was incubated for 30min, applied 
to a HiLoad 16/60 Superdex 200 prep grade column and loaded into a 6-well, analytical 
centrifugation cell at Abs280nm = 1.0. The samples were centrifuged using an An-50 Ti rotor at 
20°C in a Beckman ProteomeLab XL-I ultracentrifuge. Absorbance scans at 280nm were 
performed after 12hr and 14hr at 8000, 12000 and 16000 rpm. Equilibrium was assessed by 
comparison of scans at 12hr and 14hr. Analysis was performed using FastFitter (Arkin and Lear, 
2001) as implemented in Igor Pro (Wavemetrics, Lake Oswego, OR). The solvent density (	) was 
set at 1.0042g/ml and the specific volume (VBAR) was assumed to be 0.76ml/g. 
2.2.9  Size exclusion chromatography analysis 
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 Complexes comprised of different combinations of sEGFR domain III, the mutated 
(S460P/G461N) sEGFR domain III, Fab425 and FabC225 were prepared at 4M and incubated 
for 20min. Size exclusion chromatography was performed at 4°C using a Superdex 200 HR10/30 
column (GE Health Sciences) and monitored at 280nm. 
 
2.3 RESULTS III: SYNERGISTIC SUPPRESSION OF EGF BINDING BY THE 
COMBINED USE OF EGFR TARGETING MONOCLONAL ANTIBODIES – mAb425 & 
C225 
2.3.1  Cell and reagents 
 The cells and reagent details are provided in Section 2.2.1. 
2.3.2  S2 cell expression of sEGFR and mutagenesis 
 The pSecTagB plasmid containing the sEGFR (generously provided by Dr. Greg Adams, 
Fox Chase Cancer Center, Philadelphia, PA) was used as a polymerase chain reaction (PCR) 
template to amplify the sEGFR DNA fragment. PMT-sEGFR-V5-His construct was generated 
following experimental procedure provided in Section 2.1.2. For the construction of sEGFR514, 
PMT-sEGFR-V5-His plasmid was used as a template and the residues 1–514 of sEGFR were 
amplified using PCR. The PCR product was similarly ligated to yield the final sEGFR514 
construct with the sequence sEGFR1-514—LESRGPFEGKPIPNPLLGLDSTRTGHHHHHH (the 
V5 epitope sequence is underlined). The final construct was validated by DNA sequencing. The 
plasmids were amplified in XL1-blue cells and purified using Qiagen Maxi prep (Valencia, CA) 
for subsequent transient transfection. All the steps involved in transient transfection, developing 
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stable cell lines and protein expression was performed following the protocol provided in Section 
2.1.3. sEGFR was purified using Matuzumab immobilized affinity column, while Ni-NTA 
purified samples of sEGFR514 was used for binding studies. 
2.3.3  Flow cytometry 
 All the flow cytometry studies were performed by detaching the cells using non-
enzymatic cell dissociation solution (Cellgro, Manassas, VA) followed by the incubation of about 
500,000 cells for different experimental conditions. At the end of the experiment, all the samples 
were washed three times with phosphate-buffered saline and finally stored in 1% 
paraformaldehyde (PFA) at 4°C. Flow cytometry analysis was performed within 12 h using 
FACS Canto (fluorescence-activated cell sorting; BD Biosystems, San Diego, CA).  
 For studying the binding competition, cells were first incubated with different 
concentrations of mAbs or Fab fragments, single or in combination on ice for 1hr followed by the 
addition of 10nM (final concentration) fluorescein isothiocyanate (FITC)–EGF (Invitrogen). Cells 
were further incubated for 1hr either on ice or at 37°C and the amount of FITC-EGF bound was 
measured using flow cytometry. 
The effect of EGF concentration on mAb binding was studied by incubating cells with 
different concentrations of Alexafluor660–conjugated mAbs on ice followed by the addition of 0-
1-10-500nM of unlabeled EGF. Cells were further incubated for 1hr at 37°C and the amount of 
mAbs bound was measured using flow cytometry.  
 To understand EGF binding inhibition, cells fixed in 1% PFA were incubated with 
different concentrations of Alexafluor660 conjugated mAbs (single and in combination) or with 
unlabeled EGF (as a positive control) for 1hr on ice followed by the addition of 10nM FITC–
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EGF. After further incubation at 37°C for 1hr, amount of bound ligand were measured using flow 
cytometry. 
To study mAb recognition to different receptor conformations, various concentrations of 
Alexafluor660 conjugated mAbs (single and in combination) were incubated with either live cells 
or with cells fixed with freshly prepared 1% PFA for 1hr at 37°C. The amount of bound mAbs 
was then quantified using flow cytometry.  
2.3.4  SPR binding studies 
 About 3000 RUs of anti-V5 tag mAb were immobilized on flow cell 4, while similar 
amounts of mAb17b (anti–human immunodeficiency virus gp120 mAb) were immobilized on 
flow cell 3 as a negative control for nonspecific interaction.  
 In order to study the binding kinetics of mAbs, about 5RU of receptor (sEGFR or 
sEGFR514) from purified protein were captured on flow cell 4 using anti-V5 mAb. Amount of 
capture was empirically determined in order to avoid the avidity effect of bivalent IgG molecules. 
The real-time interaction of mAb with the anti-V5 captured receptor was studied by injecting 
different concentrations of mAbs at a flow rate of 50l/min for 3min followed by the dissociation 
for 6 min. At the end of each cycle, the chip was regenerated by removing both the captured 
receptor and bound mAb by injecting a 6sec pulse of 10mM glycine, pH 1.5, at a flow rate of 
100l/min. The entire procedure was automated to create repetitive cycles of receptor capture, 
mAb binding, and chip regeneration.  
 The real-time sensorgrams of at least four independent experiments were analyzed using 
BIAevaluation software. Sensorgrams from the reference flow cell and from the buffer injection 
were subtracted to account for nonspecific interaction and for buffer injection, respectively. The 
interaction curves thus obtained were then globally fit using the model for Langmuir 1:1 binding 
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with mass transfer limitation. The equilibrium dissociation constant KD was calculated as KD = 
koff/kon. 
2.3.5  Statistical analysis 
 Unless specified, all the experiments are performed in triplicates. The average values 
obtained from at least three independent experiments are presented with the experimental 
standard error of the mean (S.E.M.). Statistical significances of the differences were determined 
using the two-tailed, paired data Student’s t-test. 
 
2.4 RESULTS IV: SYNERGISTIC DOWNREGULATION BY mAb425/C225 COMBINATION 
2.4.1  Materials and reagents 
The Fab fragments were prepared by digesting Matuzumab and C225 using the protocol 
mentioned earlier in Section 2.1.5. 
2.4.2  Growth inhibition studies 
 In a 48-well plate, around 2500 A431 cells were seeded. After 24hr, the medium was 
replenished with 300l of fresh medium containing different concentrations of mAbs, single and 
in combination. During Fab vs IgG growth inhibition studies, monovalent Fab fragments were 
maintained at a concentration twice that of IgG molecules in order to compensate for the 
stoichiometry of the interaction. After 72hr, the metabolic activity of the cells was measured 
using WST-1 colorimetric assay. In each well, 30l of WST-1 reagent was added and the cells 
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were allowed to incubate for 2hr and the metabolic activity was quantified by measuring the 
absorbance at 450nm using ELISA plate leader. The absorbance value at 620nm was used as the 
reference wavelength and percent growth inhibition was calculated as 
Growth Inhibition = 
AbsControl - AbsAntibody
AbsControl
 * 100 
All growth inhibition studies were performed at least three times with a minimum of triplicate 
wells in each experiment. 
2.4.3  EGFR downregulation assay 
 In a 4-well rectangular chamber slide, around 800,000 MDA-MB-468 cells were 
incubated in 3ml of medium. Forty eight hours post-seeding, 100nM concentration of IgG 
molecules or 10ng/ml EGF was added. After incubating at 37ºC for different time points, cells 
were washed three times with cold PBS and membrane bound ligands were removed by two, 
3min washes of stripping buffer (10mM Glycine, 150mM NaCl, pH1.5). For EGFR 
downregulation studies using Fab fragments, cells were incubated with 200nM of Fab fragments 
for 6hr. Similar acid-stripping procedure was adopted at the end of treatment. Cells were further 
washed with cold PBS three times, detached using non-enzymatic cell dissociation buffer 
(Cellgro) and finally fixed using freshly prepared 1% PFA. All the washing and stripping 
procedures were performed on ice. Fixed cells were first washed with 3xPBS washes to remove 
PFA and then incubated with 100nM of Alexafluor488 conjugated C225 for 1hr on ice. After 
3xPBS washes, cell fluorescence was measured using flow cytometry and the percentage of cell 
surface receptors at different time points was plotted.  
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2.4.6  Western blot analysis 
 In a 4-well rectangular chamber slides, around 800,000 MDA-MB-468 cells were seeded 
and then allowed to grow for 48hr. After overnight serum starvation in medium containing 0.2% 
BSA, cells were incubated on ice for 1hr in medium containing 100nM mAb, single and in 
combination. EGF (10nM) was then added and at different time points, cells were lysed in RIPA 
buffer containing protease inhibitor cocktail (Sigma) and phosphatase inhibitor cocktail (Pierce).  
 To investigate the effect of Fab fragments on the inhibition of EGF dependent signal 
transduction, around 600,000 MDA-MB-468 cells were seeded in a 6-well plate and allowed to 
grow for 48 hr. After overnight serum starvation in medium containing 0.2% BSA, medium was 
replenished with fresh medium containing 200nM of Fab fragments (single and in combination). 
After 1hr, EGF was added (10ng/ml final concentration) and at different time points cells were 
lysed using Laemelli buffer.  
Lysed samples were then centrifuged for 15min at 4ºC at 14,000 rpm. The supernatant 
was collected and the protein concentration of the supernatant was determined using the BCA 
assay (Pierce, Rockford, IL). Equal amount of proteins were boiled in Laemelli buffer containing 
1% mercaptoethanol. Around 20-25g of protein was loaded in each lane and then separated by 
SDS-PAGE. Proteins from the gel were then transferred onto polyvinyldifluoridine membrane 
(Immobilon-P, Millipore, MA) by electroblotting and the membranes were probed for different 
proteins using specific mAbs. 
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CHAPTER 3 
RESULTS I: KINETIC ANALYSIS AND MOLECULAR 
CHARACTERIZATION OF EGFR TARGETING MONOCLONAL 
ANTIBODIES – mAb425 & C225 
3.1  INTRODUCTION 
 In this chapter we have performed biophysical characterization of mAb425 and C225. 
SPR based BIAcore 3000 system was used for characterization. To accomplish this, the 
ectodomain of EGFR (sEGFR) was expressed in stably transfected S2 cells. The results of EGFR 
cloning, expression and purification are provided in Appendix C. The kinetic parameters of 
mAb425 and C225 binding to sEGFR were evaluated using direct immobilization method and 
capture method.  The thermodynamics of interaction along with the ligand binding inhibition of 
mAb425 and C225 were also studied using BIAcore. 
3.2  RESULTS 
3.2.1  Kinetics of mAb binding to sEGFR 
 Characterization for specificity of therapeutic mAbs and evaluation of their binding 
kinetics are one of the major properties that are extremely essential for the success of therapeutic 
mAbs. In our study we have used SPR optical biosensor to evaluate mAb-sEGFR binding 
kinetics.  
3.2.1.1  Binding kinetics of mAbs using direct immobilization 
Chapter3
 
64 
 
 Direct immobilization of IgG molecules using the reactive amine groups is the most 
commonly used method for the characterization of mAb binding kinetics. The Fc region of IgG 
molecules is generally rich in lysine which contains reactive amines. So the widely used EDC-
NHS coupling reaction would most probably covalent link the mAbs through their Fc region, 
yielding a high degree of orientation. 
 Around 200 RUs of mAb425 and C225 were immobilized on flow cells 2 and 3 
respectively on a CM5 sensor chip. Lower amount of ligand density ensures that the observed 
interaction is not mass transport limited. Monoclonal antibody targeting the HIV viral envelope 
protein, gp120 – mAb17b was immobilized on the flow cell 1 and used as a reference flow cell to 
subtract any non-specific interaction and changes in the refractive index following the beginning 
and end of buffer injections. Flow rate of 50l/min used for the binding studies guarantees that 
dissociated analyte does not rebind to the ligand, thus avoiding any false-positive results. 
Different concentrations of sEGFR, diluted in running buffer were injected for 6min (association 
phase) followed by a 12min dissociation phase. The real time sensorgram shown in Figure 3.1 
(black line) was globally fit to a 1:1 binding model with mass transport limitation using 
BIAevaluation software and the resulted fits were plotted in red line. The values of the binding 
parameters calculated from at least three independent experiments are tabulated in Table 3.1.  
 More than 10-fold difference in the binding affinities between mAb425 and C225 was 
observed. The dissociation rate constants (KD) for mAb425 and C225 were found to be around 
13nM and 0.85nM respectively.  No significant difference in their association rates was observed. 
However, sEGFR bound to mAb425 dissociates almost ten times faster than its dissociation from 
C225, which is reflected on the binding affinities. 
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Figure 3.1  Direct binding kinetics of mAb425 and C225 
Different concentrations of sEGFR were injected over the sensor surface immobilized with 
mAb425 (A-C) and C225 (D-F). The real time sensorgrams are shown in black and the kinetic fits 
obtained by fitting the data using 1:1 binding model with mass transport limitation is shown in 
red. The values of calculated kinetic parameters are tabulated in Table 3.1. The sensorgram is a 
representative plot of at least three independent experiments.  
(A) (B) (C) 
(D) (E) (F) 
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Antibody (IgG) kon (1/Ms) koff (1/s) KD (nM) 
mAb425 (4.31 ± 0.47) E+05 (4.34 ± 0.86) E-03 11.87 ± 0.71 
C225 (11.0 ± 0.06) E+05 (8.02 ± 0.96) E-04 0.74 ± 0.08 
 
Table 3.2  Kinetic parameters of mAb-sEGFR interaction obtained by capture method. 
 
Antibody (IgG) kon (1/Ms) koff (1/s) KD (nM) 
mAb425 (6.05 ± 0.25) E+05 (7.93 ± 0.16) E-03 13.1 ± 0.04 
C225 (8.81 ± 0.31) E+05 (7.44 ± 0.09) E-04 0.85 ± 0.02 
 
Table 3.1  Kinetic parameters of mAb-sEGFR interaction obtained by direct method. 
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Figure 3.2  Kinetics of mAb425 and C225 binding to sEGFR captured on the surface of 
sensor chip. 
Around 6RUs of sEGFR were captured using anti-V5 mAb immobilized on the surface 
followed by the injection of different concentrations of mAb425 (A-C) and C225 (D-F). The 
real time sensorgram is shown in black and the kinetic fits obtained using 1:1 binding model 
with mass transport limitation are shown in red.  The values of calculated kinetic parameters 
are tabulated in Table 3.2.The sensorgram is a representative plot of at least four independent 
experiments.  
 
(A) (B) (C) 
(D) (E) (F) 
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3.2.1.2  Binding kinetics of mAbs using capture immobilization 
 There are a number of caveats in directly immobilizing the ligand onto the sensor surface 
to characterize protein-protein interactions. A detailed explanation on direct and capture 
immobilization methods is provided in Appendix A.2.2.3.2. Though the signal-to-noise ratio of 
the sensorgrams was very high and the 1:1 binding model used to fit the real time binding data 
yielded excellent fits with minimal residuals, we wanted to validate the reliability of the data 
using the capture method. 
Since sEGFR had a V5 tag at the C-terminal, an anti-V5 antibody was used to capture the 
receptor. Around 3500RUs of anti-V5 mAb was immobilized on the sensor chip using EDC-NHS 
chemistry. Anti-V5 mAb used in this analysis had a very high affinity for the V5 epitope and had 
been previously used to capture different proteins (Ishino et al., 2004). The dissociation of 
sEGFR bound to anti-V5 mAb is very slow and provides a very stable baseline. The binding 
interactions observed by mAbs, used as analytes are generally influenced by the binding avidity 
observed due to the bivalency of IgG molecules. Such avidity effects have a profound effect on 
the stability of the complex, thus yielding false-positive kinetic parameters. One way of reducing 
the avidity effect is by reducing the ligand density on the surface. At lower densities, ligands are 
sparsely separated and the mAb-sEGFR interaction would be driven more towards the 1:1 
interaction, with reduced effects of binding avidity. During the ligand density optimization 
experiment, it was empirically determined that capturing ~5RUs of sEGFR reduced the avidity 
effect and the stoichiometry of the interaction was found to be 1:1. Following the capture of 
~5RUs of sEGFR, different concentrations of mAbs were injected over the surface for 3min and 
the bound mAbs were allowed to dissociate for 5min. Before the end of each cycle, the chip was 
regenerated to remove both captured sEGFR and bound mAbs. The real time sensorgrams 
obtained after two reference subtractions (non-specific flow cell and buffer injection) are plotted 
in black while the kinetic fits obtained from 1:1 binding model with mass transport limitation 
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using BIAevaluation software are shown in red (Figure 3.2). The values of kinetic parameters 
calculated from at least four independent experiments are tabulated in Table 3.2. Binding 
affinities for mAbs binding to sEGFR obtained from direct method (Table 3.1) were found to be 
similar to that obtained using capture method (Table 3.2). The values of association and 
dissociation rates for both mAb425 and C225 calculated by these two different methods were also 
similar. Thus the kinetic values of mAb425 and C225 for binding to sEGFR were validated using 
two different methods by SPR. 
3.2.1.3  Fab binding kinetics by capture immobilization 
 In order to avoid any possible effect caused due to the avidity of bivalent IgG analyte, 
researchers have characterized the binding interactions using Fab fragments. Fab fragments are 
monovalent molecules as opposed to bivalent IgGs and contain the antigen binding region. 
Similar methodology was adopted as described in the Section 3.2.1.2 and the binding kinetics of 
Fab fragments was quantified. Since we had limited availability of mAb425, we made Fab 
fragments of Matuzumab, which is the humanized form of mAb425. Matuzumab was designed by 
grafting the CDR region of mAb425 onto a human IgG skeleton, thus keeping the same binding 
interface. Since the stoichiometry of Fab-sEGFR interaction is 1:1, around 45RUs of sEGFR was 
captured using the same anti-V5 immobilized CM5 chip. Different concentrations of Fab 
fragments of Matuzumab and C225 were injected at 50l/min for 3min followed by 5min 
dissociation. The real time sensorgrams and the fitted data are plotted as black and red 
respectively (Figure 3.3). Kinetic parameters obtained from four independent experiments are 
tabulated in Table 3.3. The binding affinity of the Fab fragments of C225 was found to be around 
2-fold higher than the IgG molecule. The observed difference is the result of increased 
association rate for the Fab fragment, while the dissociation rate barely changed. On the other 
hand, though mAb425 binding affinity remained unchanged for both Fab fragments and IgG 
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molecules, there is almost 4-fold increase in the rate of association and dissociation for the Fab 
fragments as compared to mAb425. There are a number of reasons that could be attributed to the 
observed differences in the calculated kinetic parameters for IgG molecules and Fab fragments.   
 The BIAcore 3000 instrument contains a flexible microfluidic chip that allows the flow 
of analytes. In these microfluidic channels analytes are transported by convection and diffusion, 
first on the hydrogel surface and then into the hydrogel, where they interact with the ligands. If 
the mass transfer is fast, the concentration of free analytes in the hydrogel equal the analyte 
concentration in the bulk solution and the interaction between the binding partners is governed by 
the intrinsic binding kinetics. It should be noted that apart from the flow rate and ligand density, 
this mass transfer also depends on the size of the analyte (Deen, 1987; Kusnezow et al., 2006; 
Yarmush et al., 1996). Diffusibility of large molecules is much lower than that of smaller 
molecules, resulting in non-uniform distribution of the analyte molecules in the hydrogel. The 
Fab fragments (~50kD) are almost one-third the size of intact IgG molecules. So there could be a 
possibility that the kinetic parameters obtained for the IgG molecules are diffusion limited.  
 The two different immobilization methods used to characterize the binding kinetics of the 
IgG molecules yielded similar values of ka and kd. In the direct method, IgGs were immobilized 
on the sensor surface and sEGFR (~76kD) was flown over the surface. If the interactions were 
diffusion limited, then the kinetic parameters of the IgGs obtained by the capture method should 
have been different from the direct method; which was not the case. So we think that the binding 
interaction of sEGFR and IgG molecules could possibly be sterically hindered due to the large 
size of the mAbs. In the capture technique, we believe that the monovalent Fab fragments might 
have easier accessibility to their binding epitopes compared to IgG molecules, thus interacting 
with sEGFR with their intrinsic kinetic parameters. 
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Figure 3.3  Kinetics of the Fab fragments of Matuzumab and C225 binding to sEGFR 
captured on the surface of sensor chip. 
sEGFR is captured using anti-V5 immobilized CM5 chip followed by the injection of different 
concentrations of Fab fragments of Matuzumab (A-C) and C225 (D-F). The real time 
sensorgram (black) was fit to a 1:1 binding model with mass transport limitation and the 
kinetic fitted data is shown in red. The values of calculated kinetic parameters of the 
interactions are tabulated in Table 3.3. The sensorgram is a representative plot of at least three 
independent experiments.  
 
(A) (B) (C) 
(D) (E) (F) 
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3.2.2  Effect of temperature on mAb binding characteristics 
 With the realization that high affinity mAbs generally have a tendency to demonstrate 
higher therapeutic efficacy, most of the mAb candidates are identified based on their binding 
affinities. Further binding studies revealed that improvement in efficacy was associated with the 
stabilization of the mAb-antigen complex and that mAbs which bind tightly to their targeted 
antigen and dissociate slowly are the best therapeutic candidates. All the binding kinetics 
experiments presented earlier were performed at 25ºC, which is most commonly used for 
characterizing protein-protein interactions in a typical SPR study. Temperature has been known 
to affect the binding properties of proteins. Depending on the type of interaction, at elevated 
temperatures, the affinities can either increase or decrease respectively for hydrophobic or 
hydrophilic interface. As both mAb425 and C225 are therapeutic mAbs, it would be important to 
understand the stability of sEGFR-mAb complex at physiological temperature (37ºC) and more 
importantly to identify how temperature alters the stability of the binding interaction of mAb and 
sEGFR. sEGFR solution at 100nM concentration was flowed over the low density mAb chip 
(~200RUs) and the real time sensorgrams collected at different temperatures for sEGFR binding 
to mAb425 (Figure 3.4 A) and C225 (Figure 3.4 B) are plotted. 
Antibody (Fab) kon (1/Ms) koff (1/s) KD (nM) 
Matuzumab (16.4 ± 2.54) E+05 (17.5 ± 1.56) E-03 11.07 ± 1.23 
C225 (32.1 ± 2.02) E+05 (10.1 ± 0.39) E-04 0.32 ± 0.02 
 
Table 3.3  Kinetic parameters of the interaction of Fab fragments of Matuzumab and C225. 
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 Both mAb425 and C225 were found to bind to sEGFR more tightly at lower 
temperatures. No appreciable difference in the profile of ka was observed between mAb425 and 
C225. Percent increase in dissociation rate was fairly similar for both the mAbs till 30ºC. At 
physiological temperature however, the stability of sEGFR-mAb425 complex was significantly 
reduced and sEGFR dissociated almost immediately following the end of injection. This sudden 
increase in the rate of dissociation was not observed in the case of C225 and that C225-sEGFR 
complex was found to be more stable than mAb425-sEGFR. 
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Figure 3.4  Effect of temperature on mAb-sEGFR interaction 
Real time sensorgram for sEGFR binding to mAb425 (A) and C225 (B) at different 
temperatures are shown. The percent increase in the values of kinetic parameters – kon (C), koff 
(D) and KD (E) at different temperatures obtained by fitting the sensorgram using 1:1 binding 
model are shown. 
(A) (B) 
(C) (D) 
(E) 
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3.2.3  Thermodynamic studies of mAb425 and C225 using van’t Hoff analysis 
Equilibrium dissociation constants determined at different temperatures were used to 
obtain the thermodynamic parameters by plotting ln(KD) versus 1/T (Figure 3.5 A). Within the 
temperature range relevant for this study, a linear relation between ln(KD) and 1/T was obtained 
for both mAb425 and C225. This suggests that both the changes in enthalpy and entropy are not 
affected by temperature. So the van’t Hoff analysis model was adopted to determine the values of 
enthalpy (H) and entropy (-TS) of the interaction. The plots were fit using the non- integrated 
form of the van’t Hoff equation and the values of G, H and S calculated are provided in 
Table 3.4 and plotted in Figure 3.5 B. There is no significant difference in the enthalpy of 
interaction for both the mAbs. However, the value of entropy of mAb425 binding to sEGFR is 
almost four times higher than C225. This suggests that during mAb425 binding to sEGFR, a 
significant amount of binding energy is used in ordering the receptor compared to C225 binding. 
These results demonstrate that C225 is more favorable for sEGFR binding compared to mAb425. 
 
 
Antibody G (kcal/mol) H (kcal/mol) -TS (kcal/mol)
mAb425 -9.66 -13.70 4.04 
C225 -11.33 -12.31 0.98 
 
Table 3.4  Values of thermodynamic parameters of mAb binding to sEGFR 
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Figure 3.5  Thermodynamic analysis of mAb425 and C225 
 
(A) 
(B) 
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3.2.3  Ligand binding inhibition studies 
 Ligand binding inhibition is one of the most commonly found traits of therapeutic mAbs.  
As mentioned earlier in Section 1.4 of this thesis, EGF, TGF-, AR and epigen specifically bind 
to EGFR while BTC, HB-EGF and ER bind to both EGFR and ErbB-4. In our study we selected 
EGF, TGF- and HB-EGF and studied their binding competition with mAb425 and C225. EGF, 
HB-EGF and TGF- are considered as one of the most important growth factors among the 
EGFR family of receptors. These ligands are found to be involved in regulating both autocrine 
and paracrine signaling and their over-expression is considered as a potent inducer of 
tumorogenesis and angiogenesis (Downing et al., 1997; Falls, 2003a, b; Fishman et al., 2002; 
Hantschmann et al., 2005; Harris et al., 2003; Ito et al., 2001; Jayne et al., 2000; Li et al., 
2000; Ongusaha et al., 2004; Ruck and Paulie, 1998; Schmitt and Soares, 1999; Schreiber et 
al., 1986; Smith et al., 1995; Soares et al., 2000). 
Different concentrations of ligands were pre-incubated with 10nM of sEGFR for at least 
1hr before injecting over the mAb425 and C225 immobilized high density (5000 RU) CM5 
sensor chip for 2min at 50l/min. The sensorgrams were normalized with the observed EGFR 
response in the absence of ligand. The average of the normalized response just before the end of 
sEGFR injection from three independent experiments is shown in Figure 3.6. The binding of 
EGF and TGF- to the receptor resulted in inhibition of mAb binding. No significant difference 
in the ligand inhibition profile between mAb425 and C225 was observed. In contrast, we 
observed completely different behavior in the case of HB-EGF. Binding of HB-EGF to the 
receptor inhibited C225 binding. On the other hand, mAb425 was able to recognize the HB-EGF-
EGFR complex in a concentration dependent manner. However, the results obtained using HB-
EGF would require further validation. 
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Figure 3.6  Ligand binding inhibition studies of mAb425 and C225 
A high density chip (5000RUs) immobilized with mAb425, C225 was used. sEGFR (10nM) 
was pre-incubated with increasing concentrations of EGF (A), TGF- (B) or HB-EGF (C, D) 
for at least 1hr before injecting the samples over the BIAcore chip for 2 minutes at 50l/min. 
An hour incubation time ensured that the binding of ligands to sEGFR reaches equilibrium. 
The entire process was repeated 3 times and the amount of sEGFR bound, just before the end 
of the association phase was normalized with the RUs obtained in the absence of ligands and 
plotted as percent sEGFR binding. 
 
(A) (B) 
(C) (D) 
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3.3  SUMMARY OF RESULTS 
 The kinetic parameters of mAb425 and C225 binding to sEGFR were evaluated using SPR 
analysis. Three different SPR methods were adopted to validate the obtained binding kinetics 
of mAb425 and C225. Binding affinity values from all the three methods were not 
significantly different. 
 The binding affinities of mAb425 and C225 were found to be around 12nM and 0.8nM 
respectively. 
 The stability of the mAb-sEGFR complex was studied at different temperatures. The C225-
sEGFR complex was found to be more stable at physiological temperatures than the 
mAb425-C225 complex.  
 The thermodynamic characterization of mAb425 and C225 revealed that the enthalpy of their 
binding interaction were comparable. However, the entropy of mAb425 binding to sEGFR 
was found to be higher than C225, suggesting that some amount of energy might be lost in 
ordering the mAb425-sEGFR complex. So C225 binding to the receptor is more favorable 
compared to mAb425 binding.  
 Both the mAbs inhibited the binding of EGF and TGF-. In contrast, a different behavior was 
observed when binding competition with HB-EGF was studied. C225 was unable to bind to 
sEGFR-HB-EGF complex. However, mAb425 displayed increased binding to the sEGFR-
HB-EGF complex in a concentration dependent manner. However further validation is 
required for this observation. 
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CHAPTER 4 
RESULTS II: ENHANCED EGFR INHIBITION AND DISTINCT EPITOPE 
RECOGNITION BY EGFR ANTAGONISTIC MONOCLONAL ANTIBODIES 
– C225 & mAb425 
4.1  INTRODUCTION 
 The use of mAbs, especially combining it with other therapeutic agents such as 
chemotherapy, radiation therapy, other small molecules or in fact another mAbs have always 
been the focus of the current investigation. In this chapter, we would demonstrate the biological 
importance on the combined use of EGFR targeting mAbs – mAb425 and C225. Since both the 
mAbs bind to domain III of EGFR and inhibit EGF binding, it was intriguing to see synergism 
with this particular combination of mAbs. In subsequent sections, we have characterized and 
compared the molecular interactions of both the mAbs for binding to EGFR. Our collaborative 
efforts with Dr. John C. Williams, Thomas Jefferson University helped us to shed some light on 
the binding epitope of mAb425. 
4.2  RESULTS 
4.2.1  Synergistic inhibition of growth and survival of MDA-MB-468 breast carcinoma cells by 
the combination of mAb425 and C225 
 In recent years, combinations of mAbs binding to different epitopes of the same antigen 
have proven to exert synergistic effects against tumor cells expressing their cognate antigens at 
the cell surface. For example, two antibodies to ErbB2 (i.e., Trastuzumab and Pertuzumab) inhibit 
survival of breast cancer cells more effectively than either antibody alone (Nahta et al., 2004). 
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Here we investigated whether two antibodies, i.e., mAb425 and C225, selected independently for 
the capacity to inhibit ligand binding to the EGFR would similarly affect breast tumor cell growth 
and survival. In earlier work, detailed characterization of the C225 binding epitope revealed 
direct competition with EGF/TGF- for binding to domain III of the extracellular portion of the 
EGFR (Fuh et al., 1992; Li, 2005).  mAb425 was similarly selected for interfering with ligand 
access to the EGFR (Murthy et al., 1987). However, the binding site for mAb425 is currently 
unknown. We compared the effects of either antibody alone with those of the combination of both 
antibodies on growth and survival of MDA-MB-468 breast carcinoma cells that express high 
levels of EGFR (Biscardi et al., 1998). To avoid effects due to differences in antibody 
concentration the total amount of IgG was kept constant for all experimental conditions. As 
shown in Figure 4.1 A, the combination of the two antibodies was superior to either antibody 
alone in inhibiting metabolic activity of actively growing, attached MDA-MB-468 cells. The 
synergistic effect of the antibody combination at 25% growth inhibition is demonstrated by 
isobologram which depicts equally effective dose pairs (isoboles; Figure 4.1 B). In this 
representation, the concentration of one drug required to produce a desired effect is plotted on the 
horizontal axis while the concentration of another drug producing the same effect is plotted on the 
vertical axis. A straight line joining these two points represents additive effects expected by the 
combination of two drugs. Figure 4.1 B shows that at 25% growth inhibition, the experimental 
value for the antibody combination lies well below the theoretical additive line consistent with 
drug synergism. These results demonstrate that the combination of the two antibodies is superior 
to either antibody alone in inhibiting metabolic activity of actively growing MDA-MB-468 cells. 
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Figure 4.1  Synergistic growth inhibition by mAb425/C225 combination 
(A) Dose-dependent effects of either antibody alone at 10g/ml and the antibody combination 
at 10 g/ml on metabolic activity as determined by WST-1assay; the experiment was 
performed three times and results shown as m ± SEM. (B) Isobolographic representation of 
synergistic antibody effects at 25% growth inhibition. (* p<0.05) 
(A) 
(B) 
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Figure 4.2  Synergistic inhibition of anchorage-independent growth by mAb425/C225 
combination 
Impaired survival of MDA-MB-468 cells in forced suspension culture in the presence of the 
425/C225 combination. In these experiments, the EGFR selective kinase inhibitior, AG1478, 
was used as a positive control. The capacity of cells to reattach and resume proliferation after 
two days of forced suspension culture in the presence or absence of 10% FCS was determined. 
Reattached cells were visualized by crystal violet staining 24 h after reseeding on cell culture-
treated plastic. 
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Next we assayed the capacity of the antibody combination to induce cell death in the 
anchorage-independent state (Figure 4.2). We demonstrated previously that EGFR inhibition 
with either mAb425 (10g/ml) or with small molecule tyrosine kinase inhibitors accelerates 
apoptosis of epithelial cells maintained in forced suspension culture which precludes extracellular 
matrix attachment (Jost et al., 2001a; Jost et al., 2001b). A simple method to assay cell survival 
in these conditions consists of reseeding cells on tissue culture-treated plastic after defined 
periods of suspension culture and the determination of cell reattachment after 12–24hr. This 
analysis revealed that treatment with either antibody at 10g/ml during suspension culture 
reduced the number of cells capable of matrix reattachment only marginally irrespective of the 
culture medium used in these experiments (Figure 4.2). In contrast, the combination of both 
antibodies where each antibody was used at 5g/ml markedly reduced levels of viable reattached 
cells similar to cultures treated with the small molecule EGFR inhibitor AG1478. This result 
indicates that the antibody combination accelerates death of MBA-MB-468 cells in the 
anchorage-independent state. Inhibitory effects of the mAb425/C225 antibody combination on 
signal transduction events triggered by EGFR activation.  
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Figure 4.3  Effects of mAb425 and C225 alone and in combination on signal transduction 
events upon EGF treatment of MDA-MB-468 cells. 
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4.2.2  Inhibitory effects of the C225/mAb425 antibody combination on signal transduction 
events triggered by EGFR activation 
 To account for combinatorial inhibitory effects of the antibody combination on EGFR-
dependent signal transduction events we determined the effects of the antibodies used either 
singly or in combination on short-term EGF-induced signal transduction events in serum-starved 
MDA-MB-468 cells. This analysis revealed more efficient inhibition of AKT and p42/44MAPK 
phosphorylation in serum-starved cells exposed to EGF and the antibody combination as 
compared to single antibody treatment (Figure 4.3). In fact, in MDA-MB-468 cells, mAb425 
treatment alone did not inhibit AKT and MAPK phosphorylation whereas it very effectively 
reduced EGF dependent phosphorylation of the EGFR on Y1068. As in the case of cell growth 
inhibition experiments the effects on signal transduction events occurred although either antibody 
was used at half the concentration (5g/ml) when combined as compared to single antibody 
treatments (10g/ml). Overall, the antibody combination effects were similar to those achieved by 
using AG1478 at very high concentration (10M). 
4.2.3  mAb425 and C225 have distinct binding epitopes on the extracellular domain of the 
EGFR 
 Cooperative growth inhibitory effects by the two antibodies under investigation here 
could be explained by binding of these antibodies to distinct EGFR populations thus providing 
more effective ligand binding competition. Alternatively, the two antibodies could simultaneously 
engage distinct epitopes of the EGFR domain III and inhibit EGFR-dependent signal transduction 
by independent mechanisms. To distinguish between these two possibilities we first addressed the 
question whether both antibodies could simultaneously bind to EGFR expressed on cell surfaces. 
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Figure 4.4  Independent binding of mAb425 and C225 to the human EGFR expressed on cell 
surfaces.  
Binding of Alexafluor488 labeled mAb425 (A, C) and C225 (B, D) was assessed by FACS in 
the presence of unlabeled C225 or mAb425 as indicated in the panels. This analysis was 
performed using NIH3T3 cells engineered to express wild-type human EGFR (CO12; A and 
B) or the tumor-specific EGFRvIII (HC2; C and D) as indicated. In both cases, either antibody 
competed with itself but not with the other antibody. A representative example of three 
experiments is shown. 
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To this end, we used NIH3T3 cells stably transfected with either full length wild-type human 
EGFR (CO12 cells) or a mutated EGFR characterized by intragenic deletion of most of domain II 
of the EGFR and prominently expressed in neoplasia (HC2 cells) (Moscatello et al., 1996). As 
both antibodies bind exclusively to domain III of the EGFR (Lax et al., 1991) we expected that 
they would not only bind to wild-type but also the tumor-specific EGFRvIII. To avoid 
confounding effects of endogenous EGFR expression we used transfected mouse 3T3 cells in 
these experiments rather than human cells. Since both antibodies under investigation do not 
recognize the murine EGFR (Murthy et al., 1987; Wen et al., 2001) no binding other than to the 
transfected human EGFR is measured. To assess direct binding competition between the two 
antibodies we determined by FACS analysis the capacity of mAb425 to replace C225 from the 
cell surface of CO12 and HC2 cells. This analysis revealed the expected result in that either 
antibody competed with itself for cell surface binding but not with the other (Figure 4.4). In 
addition and as expected both antibodies recognized both, human wild-type EGFR and EGFRvIII. 
Collectively, these results indicate simultaneous binding of the two antibodies under investigation 
to distinct epitopes on domain III of the extracellular portion of recombinant human EGFR and 
cell associated EGFR. 
 Since both mAb425 and C255 inhibit EGF binding; it was believed that both these mAbs 
competed for binding to EGFR. The flow cytometry results presented above clearly demonstrated 
that neither of these mAbs compete for EGFR binding. Since flow cytometry is a cell based assay 
where the results could be influenced by the dynamic movement of the surface receptors and 
deformability of the cell membrane, we performed SPR based assays to further investigate the 
competition between the mAbs. 
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Figure 4.5  Competition between mAb425 and C225 using BIAcore. 
 
(A) 
(B) 
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The traditional method of evaluating binding competition between two proteins was 
adopted in this study. To achieve this, sEGFR was captured using a C225 derivatized CM5 chip. 
Once the baseline of the sensorgram was stabilized, different concentrations of mAb425 (0-
512nM) were injected until binding equilibrium was reached. The responses at equilibrium were 
then plotted against respective concentrations to generate the saturation plot (Figure 4.5). Since 
both these mAbs are therapeutic agents, competition studies were performed at 25°C (Figure 4.5 
A) and at physiological temperature (Figure 4.5 B). The theoretical maximum equilibrium 
binding (Rmax) was calculated using the formula, 
Rmax =RUligand * S * 
MWanalyte
MWligand
 
Where, MW is the molecular weight and S is the stoichiometry of analyte binding to ligand i.e. 
1:2 in this study. At higher concentrations of mAb425, Req approached the theoretical for Rmax 
both the temperatures. These results clearly suggest that both of these mAbs are non-competing 
mAbs and simultaneously binding to sEGFR. If the two mAbs competed for sEGFR binding then 
Req would have never reached Rmax even at excessively high concentrations.  
 Knowing that mAb425 and C225 did not compete for binding to sEGFR, we wanted to 
investigate whether the binding of one mAb to sEGFR affected the kinetics of binding of another 
mAb to the captured sEGFR.  To achieve this, we first characterized kinetics of sEGFR binding 
to mAb425 and C225. 
Chapter4
 
91 
 
  
 
    
 
 
Figure 4.6  Simultaneous binding of mAb425 and C225 to sEGFR. 
Surface plasmon resonance analysis of sEGFR captured by mAb425 (A) and C225 (B) 
tethered on CM5 chips. The real time sensorgram is colored for different sEGFR 
concentrations and the calculated fit using the model of 1:1 Langmuir binding with mass 
transport limitation is shown in black. The residuals of the fit are provided under the 
sensorgram. For calculation of binding affinities please refer to Table 1. Binding of mAb425 
to sEGFR captured by C225 is shown in (C). Approximately 30 RUs of sEGFR were captured 
on a C225 immobilized CM5 chip and used as ligand to study the binding kinetics of 
mAb425. Increasing concentrations of mAb425 were injected at 20l/min for two minutes 
association time and two minutes dissociation time. All Biacore experiments shown were 
conducted at least three times with similar results. 
(A) (B) 
(C) 
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In these experiments, lower RUs (~200 RU) of mAbs were conjugated on a CM5 chip to 
avoid mass transport limitations. In order to overcome potential receptor rebinding effects, 
different concentrations of sEGFR were injected at a high flow rate of 50l/min over the chip 
derivatized with mAb425 (Figure 4.6 A) and with C225 (Figure 4.6 B) The resultant 
sensorgrams were then analyzed and the equilibrium rate constants were calculated. The real time 
sensorgrams were pseudo colored for different concentrations of injected sEGFR while the 
calculated kinetic fit of the interaction is represented in black. The values of the kinetic 
parameters obtained are tabulated in Table 4.1. It was observed that C225 binds to sEGFR with 
more than 10-fold higher affinity (2.7 ± 0.4 nM) compared to mAb425 (32.3 ± 6.75 nM). The 
value of the binding affinity of C225 as determined by these analyses was found to be very 
similar to that previously described (Li, 2005). 
 Once the binding kinetics of mAb425 and C225 were determined we studied whether the 
kinetic parameters were affected for the mAb binding to a pre-complex of sEGFR with another 
mAb. Capture method was adopted for this particular study. Since the dissociation rate of 
mAb425 was very high; we selected C225 to capture sEGFR and evaluated the affinity of 
mAb425 binding to sEGFR-C225 complex. To this end, sEGFR (5nM) was injected over a low 
Antibody (IgG) kon (1/Ms) koff (1/s) KD (nM) 
mAb425 (1.7 ± 0.66) E5 (5.18 ± 0.75) E-3 32.23 ± 6.75 
C225 (4.03 ± 0.42) E5 (1.09 ± 0.05) E-3 2.73 ± 0.41 
 
Table 4.1  Kinetic parameters of mAb-sEGFR interaction. 
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density C225 chip (280 RU) followed by the injection of different concentrations of mAb425 (0–
512nM) until binding equilibrium was reached. Lower amounts of sEGFR (20 RU) were captured 
in order to ensure that the calculated binding affinity is not influenced by the bivalency of 
mAb425 but is the result of the 1:1interaction between mAb425 and sEGFR. Moreover, in order 
to incorporate the possible weak interaction between mAb425 and C225, similar amounts of 
C225 immobilized on flow cell 3 was used as reference for the non-specific interaction. It should 
be noted that sEGFR was only injected over flow cell 4 during the entire experiment. It was 
empirical found that any flow rates above 20l/min resulted an artifact in the dissociation phase 
of mAb425-sEGFR interaction. So a flow rate of 20l/min was used in this study. The real time 
sensorgrams (pseudo colored) were fit to 1:1 binding model and the kinetic fit of the interaction is 
shown in black (Figure 4.6 C). The values of kinetic parameters obtained using the capture are 
provided in Table 3.1 and are compared with those obtained using the direct method. The kinetic 
parameters obtained using the two methods were similar and no significant change in the binding 
affinities were observed. It can thus be summarized that mAb425 and C225 do not compete with 
each other and the binding of C225 to sEGFR does not affect the kinetics of mAb425 binding to 
sEGFR-C225 complex; suggesting that mAb425 and C225 have distinct binding epitopes. 
 
mAb425 kon (1/Ms) koff (1/s) KD (nM) 
Direct (1.7 ± 0.66) E5 (5.18 ± 0.75) E-3 32.23 ± 6.75 
Capture (3.4 ± 0.97) E5 (7.91 ± 0.53) E-3 24.8 ± 7.14 
 
Table 4.2  Kinetic parameters of mAb425 binding using direct method and capture method. 
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To obtain independent confirmation for simultaneous binding of both antibodies to EGFR 
we performed sedimentation equilibrium analysis by analytical ultracentrifugation using an 
admixture of C225, mAb425 and the extracellular portion of the EGFR consisting of domains I to 
IV (sEGFR). This study was performed by our collaborator, Dr. John C. Williams from Thomas 
Jefferson University. This analysis indicated a single species with an apparent weight of 167kD, 
consistent with the existence of a 1:1:1 tripartite molecular complex (Figure 4.7). Note that total 
concentration was at 4.5M or >100-fold and >1000-fold the dissociation constant of mAb425 or 
C225 and EFGR, respectively. Together, these results strongly suggest that the binding epitopes 
of C225 and mAb425 are distinct albeit both are confined to domain III of the extracellular 
portion of the human EGFR (Lax et al., 1991). 
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Figure 4.7  Sedimentation equilibrium analysis of complexes formed by sEGFR and Fab 
fragments of mAb425 and C225. 
(A) The complex was formed by saturating sEGFR with Fab fragments of C225 and mAb425 
and isolated by size exclusion chromatography. (B) Radial scans at 280 nm were collected at 
8000 (red), 12000 (green) and 16000 (blue) RPM at 20°C. The data fit well to a single 
molecular species and afforded a calculated molecular weight of 167,100 +/- 1000 Da, 
consistent with a tripartite complex. These studies were performed by our collaborator Dr. 
John C. Williams, Thomas Jefferson University. 
(A) 
(B) 
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4.2.3  mAb425 recognizes an EGFR epitope distinct from the ligand binding domain 
 The results described above are consistent with independent and simultaneous 
engagement of the EGFR by both antibodies under investigation. C225 is known to directly 
compete with ligand binding to domain III of the EGFR (Li, 2005). In contrast, whereas mAb425 
is known to bind to domain III, its epitope has yet to be defined. In order to understand the 
phenomenon of simultaneous binding of mAb425 and C225, we investigated the binding epitope 
of mAb425. All the structural modeling studies and mutagenesis assay to investigate the mAb425 
binding epitope was performed by our collaborator, Dr. John C. Williams from Thomas Jefferson 
University. We inferred that the mAb425 binding site must encompass residues that are different 
in the human and murine EGFR sequences as mAb425 recognizes a conformationally defined 
epitope of the human but not the murine EGFR (Lax et al., 1991). Thus, residues that differ 
between the murine and human sequences and are present on the surface of the sEGFR domain III 
are likely candidates for the epitope defined by mAb425 binding. In addition, our data shows 
C225 and mAb425 bind simultaneously to the surface of EGFR domain III indicating that the 
mAb425 epitope must lie outside of the surface masked by C225. Mapping of the human EGFR 
using these constraints produced a handful of potential EGFR/mAb425 interaction sites (Figure 
4.8). Many of these sites are located near glycosylation sites and were considered unlikely targets 
for mAb425 binding because we previously showed that mAb425 recognizes a protein epitope on 
the deglycosylated EGFR (Murthy et al., 1987). After exclusion of residues occluded by either 
C225 or by putative carbohydrate side chains, two adjacent amino acids emerged as likely 
candidates for mAb425 docking (Ser460 and Gly461 highlighted in Figure 4.8). To investigate 
the role of these residues in mAb425 binding, we changed these two residues in human EGFR 
domain III to the corresponding murine sequence, (i.e., Pro460 and Asn461), expressed and  
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Figure 4.8  Modeling of the mAb425 binding site on the EGFR 
Surface representation of the extracellular portion of EGFR bound to C225 (ribbon 
representation) based on the structure 1YY9.16 Sequence differences between human and 
murine EGFR domain III are highlighted in red. Glycosylation of asparagines residues found 
in the structure of 1YY9 are shown as sticks (carbons yellow and oxygen red). The EGF-
EGFR interface based on the crystal structure 1IVO21 and limited to 5 Å cutoff is shown in 
orange. Note that S460 and G461 represent the only surface residues of interest on domain III 
that are either not occluded by C225 or likely to be affected by N-linked glycosylation. The 
figure was made in PyMol (DeLano, 2002). The modeling studies were performed by our 
collaborator, Dr. John C. Williams from Thomas Jefferson University. 
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Figure 4.9  mAb425 binds the EGFR at an epitope distinct from C225 as determined by size 
exclusion chromatography. 
mAb425 and C225 bind to domain III individually (cyan and orange traces) and as a 
combination (grey trace). Note that the complex of mAb425 with the EGFRdomIIIS460P/G461N 
elutes slightly earlier than the individual components (purple trace), but significantly later than 
the non-mutated domain III (cyan). The complex of C225 with the mutated EGFRdIII (red) 
eluted at the same volume as the non-mutated domainIII (orange) indicating that the point 
mutations do not interfere with the overall tertiary structure. Asterisks denote an impurity 
present in the C225 preparation. The concentration of each sample added to the column was 
4M (based on absorbance at 280 nM). These studies were performed by our collaborator Dr. 
John C. Williams, Thomas Jefferson University. 
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purified this domain, and used size exclusion chromatography to test whether mAb425 could bind 
sEGFR domain III encoding S460P and G461N mutations (Figure 4.9). The individual Fab 
fragments and sEGFR domain III proteins eluted at 15.6 ml. Co-incubation of sEGFR domain 
IIIS460P/G461N with Fab425 resulted in a slightly earlier elution, 15.2 ml, indicating weak 
association. Note that the concentration of the mixture added to the column is 4 M or 125-fold 
greater than the KD of the native EGFR/mAb425 interaction. Thus, some weak association is 
expected. As a point of reference, mutations that define the C225 epitope on EGFR-domain III 
reduced the affinity from 2.3 nM to 340 nM (Li, 2005) and complex of this mutant and C225 
would also show residual binding at concentrations 125 fold greater than the original KD (e.g., 
~290 nM). However, human sEGFR domain III at the same concentration formed a saturated 
complex that eluted at 13.9 ml. To demonstrate that the point mutations did not affect the tertiary 
structure of the sEFGR domain III, the S460P and G461N mutant was also mixed with C225 Fab 
and subjected to analysis by size exclusion chromatography. Its elution point at 14.0 ml is similar 
to the wild-type sEGFR domain III complexed with C225. Finally, when wild-type sEGFR 
domain III and both Fab fragments were mixed and applied to the column, a distinct peak eluting 
at 13.1ml emerged, consistent with a tripartite complex. Taken together, these data indicate that 
Ser460 and Gly461 significantly contribute to the overall affinity of the EGFR-mAb425 
interaction. These results raise the question of how mAb425 interferes with ligand binding to the 
EGFR as originally reported by us (Murthy et al., 1987). As it does not compete with C225 for 
binding and recognizes surface residues distinct from the ligand binding site, a different 
mechanism of action may account for its biological effects. Specifically, it is possible that 
interaction of mAb425 with the EGFR interferes with high affinity ligand binding by blocking a 
conformational change to bring domains I and III of the extracellular domain of the EGFR in 
close proximity. 
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4.3  SUMMARY OF RESULTS 
 Combined use of EGFR targeting mAbs – mAb425 and C225 synergistically inhibit growth 
and EGF dependent signal transduction in EGFR overexpressing MDA-MB-468 breast 
cancer cells. 
 mAb425 and C225 do not compete with each other and simultaneously binds to the domain 
III of the extracellular portion of the EGFR. 
 The mAb425 epitope on the human EGFR contains amino acid residues G460/S461 and is 
distinct from both, ligand binding site and C225 binding site. 
 Taken together, the results of this study suggest that the combination of humanized mAb425 
(Matuzumab) and Cetuximab may provide a more effective means to target tumor-associated 
EGFR in patients. 
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CHAPTER 5 
RESULTS III: SYNERGISTIC SUPPRESSION OF EGF BINDING BY THE 
COMBINED USE OF EGFR TARGETING MONOCLONAL ANTIBODIES – 
mAb425 & C225 
5.1  INTRODUCTION 
 Inhibition of ligand binding is the one of the most important mechanisms of 
immunotherapy. During the initial phases of drug development, most of the therapeutics mAbs 
are screened for their ability to bind to the target antigen/biomarker with high specificity and 
affinity. Moreover, their antagonism for ligand binding is also studied and mAbs exhibiting 
superior characteristics in both binding affinity and ligand binding inhibition are selected for pre-
clinical studies. In the previous Chapter 4, we demonstrated that mAb425/C225 combination 
synergistically inhibited growth and EGF dependent receptor signaling. Here, we shall delineate 
the molecular mechanism of synergy by measuring mAb binding and their EGF competition on 
cell surface receptors. Overall, the results presented in this chapter indicate that simultaneous 
binding of two non-competing mAbs, mAb425 and C225 stabilizes the inactive form of the 
receptor, which EGF binds with very low affinity; thus achieving efficient inhibition of EGF 
binding. 
5.2  RESULTS 
5.2.1  Binding competition studies on live cells 
 In order to understand the mechanism for the observed synergistic growth inhibition by 
the combined use of mAb425 and C225, we initially investigated the difference in their EGF 
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binding inhibition (single vs. combination). We have previously showed in Chapter 3 that the 
mAb–EGFR complex is more stable at lower temperatures. To ensure that most of the surface 
receptors are bound to mAbs, MDA-MB-468 cells were preincubated with different 
concentrations of mAbs, single and in combination, for 1hr on ice followed by the addition of 
FITC–EGF, 10nM final concentration. The cells were further incubated for 1hr at 37°C. The 
amount of bound FITC-EGF was measured using flow cytometry and the percent EGF binding 
inhibition by the mAbs was plotted as shown in Figure 5.1 A, Figure 5.1 B. We observed a 
concentration-dependent inhibition of EGF binding by the mAbs, consistent with the intended 
purpose of these mAbs to block the binding of EGF. In contrast to C225, which exhibited almost 
95% inhibition at 100nM, mAb425 was able to achieve only 90% inhibition even at a 
concentration of 400nM (Figure 5.1 B). The combination of mAb425 and C225, however, was 
observed to be a better EGF antagonist than individual mAbs. The values of 50% binding 
inhibition (IC50) for individual mAbs and combination were also calculated and the mean IC50 
values from four independent experiments were tabulated in Table 5.1. Although the IC50 value 
for the mAb combination was found to be relatively greater compared to individual mAbs, the 
slope of EGF binding inhibition profile is greater than for either of the individual mAbs.  
 The crystal structure of C225 bound to EGFR ectodomain revealed that its binding 
epitope partially overlaps with EGF (Li, 2005). However, Figure 5.1 A, Figure 5.1 B show that 
C225 was unable to completely block EGF from binding to cell surface receptors even at a 
concentration of 400nM. Because C225 competes directly with EGF, it is expected that it should 
completely inhibit EGF binding at higher mAb concentrations. The gradual decrease in EGF at 
higher concentrations of C225 suggests that C225 would be able to completely inhibit EGF 
binding at extremely high concentrations. Because we knew that the mAb–EGFR complex is 
more stable at lower temperatures and we wanted to confirm that the observed difference in the 
EGF antagonism (Figure 5.1 A, Figure 5.1 B) was not an artifact of the experimental protocol, 
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similar binding competition assay was repeated on ice. After incubation with mAbs on ice for 
1hr, cells were continued to incubate on ice following the addition of FITC–EGF, and percent 
EGF binding inhibition was measured and plotted as mentioned above. At this lower temperature, 
both C225 and the mAb combination achieved complete blockage of EGF binding (Figure 5.1 C, 
Figure 5.1 D). mAb425, however, continued to demonstrate partial inhibition of EGF binding, 
similar to the behavior exhibited at 37ºC. The amount of FITC-EGF binding inhibition observed 
at 100nM of mAb concentration for two different temperatures is listed in Table 5.2. 
 The studies presented so far in this chapter were performed using bivalent IgG molecules. 
There is a high possibility that binding of bivalent IgG to the cell surface receptors might induce 
receptor crosslinking and would influence the observed results. So in order to further understand 
the observed more efficient inhibition of FITC-EGF by mAb425/C225 combination and that 
binding/competition stoichiometry is 1:1, similar experiment were performed using monovalent 
Fab fragments of Matuzumab and C225. Experimental protocol similar to the results presented in 
Figure 5.1 A was followed. Figure 5.2 clearly shows that combination of Fab fragments of 
Matuzumab and C225 more efficiently inhibited the binding of EGF. Compared to IgG, a much 
higher concentration of Fab fragments were required to block EGF binding. However, even at 
800nM, Fab fragments (single and in combination) failed to completely abrogate EGF binding as 
observed in the case of bivalent IgG molecules (Figure 5.1 A). The values of the EGF binding 
inhibition for higher concentrations of Fab fragments are tabulated in Table 5.3. 
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Figure 5.1  Combination of mAb425 and C225 blocks EGF binding more efficiently 
compared to individual mAbs. 
MDA-MB-468 cells were first incubated with different concentration of mAbs for 1hr on ice. 
A total of 10nM of FITC–EGF was then added and cells were further incubated for another 
hour at 37°C (A) or at 4°C (C). The amount of FITC–EGF bound was measured using flow 
cytometry and then plotted as percent EGF binding. The magnified view of the rectangular 
box in (A) and (C) is shown in (B) and (D) respectively. The combination of mAb 
combination was found to be more efficient in EGF binding inhibition at physiological 
temperatures than individual mAbs. Data shows and average of at least three independent 
experiments, ± S.E.M. Values of binding inhibition studies performed at 4°C were not 
statistically significant between C225 and combination for concentrations greater than 50nM. 
But the values are statistically significant for mAb425. (* p<0.05) 
(A) (C) 
(B) (D) 
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 % EGF Binding Inhibition 
Antibody 37ºC 4ºC 
mAb425 13.2 ± 3.42 2.38 ± 0.13 
C225 4.66 ± 0.9 0.42 ± 0.44 
mAb425/C225 1.57 ± 0.78 0.17 ± 0.48 
 
Table 5.2  Comparison of EGF binding inhibition for mAb425, C225 and their combination. 
The mean values of EGF binding inhibition from at least three independent experiments at 
100nM mAb concentration are provided, ± S.E.M. 
 IC50 (nM) 
Antibody 37ºC 4ºC 
mAb425 17.5 ± 3.7 14.5 ± 2.3 
C225 13.3 ± 2.1 11.6 ± 2.0 
mAb425/C225 20.9 ± 4.2 15.6 ± 3.5 
 
Table 5.1  Values of IC50 (nM) for single mAbs and mAb combination 
The mean values of IC50 from at least three independent experiments are provided, ± S.E.M. 
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Figure 5.2  Combination of Fab fragments of Matuzumab and C225 blocks EGF binding 
more efficiently compared to individual Fab fragments. 
MDA-MB-468 cells were first incubated with different concentration of Fab fragments of 
Matuzumab and C225 for 1hr on ice. A total of 10nM of FITC–EGF was then added and cells 
were further incubated for another hour at 37°C. The amount of FITC–EGF bound was 
measured using flow cytometry and then plotted as percent EGF binding. The magnified view 
of the rectangular box in (A) is shown in (B). The combination of the Fab fragments was 
found to more efficiently inhibit EGF binding compared to individual Fab fragments. Data 
shows an average of three independent experiments, ± S.E.M. The values of binding inhibition 
between the Fab fragments of C225 and combination are not statistically significant at 100nM 
and 200nM. All the other values shown in (B) are statistically significant. (* p<0.05) 
(A) (B) 
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We further investigated whether EGF is able to influence the binding of mAbs, single vs 
combination. To achieve this, cells were first incubated for 1hr on ice with different 
concentrations of Alexafluor660 conjugated mAbs followed by the incubation with different 
concentrations of unlabeled EGF at 37ºC for another hour. The amount of bound mAb was 
measured using flow cytometry and plotted as the percent of maximum mAb bound to cell 
surface receptors in the absence of EGF (Figure 5.3). The presence of EGF resulted in reduced 
binding of mAb425 (Figure 5.3 A) and C225 (Figure 5.3 B). Although no significant difference 
in mAb binding was observed at EGF concentrations lower than 10nM, there was a significant 
decrease in the binding of mAb425 and C225 at 500nM EGF concentration. It was intriguing to 
find, however, that mAb binding in the case of mAb425/C225 combination was not significantly 
affected by EGF (Figure 5.3 C). Unlike individual mAbs, no significant reduction in mAb 
binding was observed in the case of combination even at the 500nM EGF concentration. These 
data show that simultaneous binding of mAb425 and C225 might alter the conformational state of  
 % EGF Binding Inhibition 
Antibody (Fab) 100nM 200nM 400nM 800nM 
Matuzumab 49.94 ± 4.66 37.43 ± 3.54 27.02 ± 3.32 19.93 ± 2.78 
C225 21.73 ± 2.31 14.67 ± 1.22 10.13 ± 1.56 6.63 ± 0.98 
Matuzumab /C225 25.10 ± 3.76 12.37 ± 2.37 4.82 ± 1.60 2.04 ± 0.81 
 
Table 5.3  Comparison of EGF binding inhibition for Fab fragments of Matuzumab, C225 and 
their combination. 
The mean values of EGF binding inhibition from at least three independent experiments at 
100nM mAb concentration are provided, ± S.E.M. 
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Figure 5.3  EGF disrupts mAb–EGFR complexes containing individual mAbs but not the 
complexes with mAb combination. 
MDA-MB-468 cells were incubated with different concentrations of Alexafluor660 conjugated 
mAb425 (A), C225 (B), or their combination (C) on ice for 1hr. Different concentrations of 
unlabeled EGF (0, 1, 10, 500nM) were added and cells were further incubated for 1hr at 37°C. 
Amount of bound mAbs was measured using flow cytometry and plotted as the percent of 
maximum binding in the absence of EGF. In the case of individual mAbs, EGF significantly 
disrupted mAb-EGFR complex, but failed to demonstrate such high levels of disruption in the 
case of mAb combination. Though the values of mAb binding at 10nM and 500nM of EGF 
concentration are statistically significant for both individual mAbs and combination, no 
significant inhibition of mAb binding was observed in the case of mAb425/C225 combination. 
This strongly suggests that the mode of EGF binding inhibition demonstrated by the combined 
use of mAb425 and C225 is different from that in the case of single mAbs. Data shows an 
average of three independent experiments, ± S.E.M.
(A) (B) 
(C) 
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EGFR that is not conducive for EGF binding and that mAb combination might exhibit a different 
mode of EGF binding inhibition compared to individual mAbs. 
5.2.2  EGF binding inhibition studies on fixed cells 
 Because unliganded EGFR exists in a dynamic equilibrium on the cell surface, we 
investigated EGF–mAb binding competition in the absence of this equilibrium by fixing the cells 
using freshly prepared 1% PFA. Fixed cells were first incubated for 1hr on ice with different 
concentrations of Alexafluor660 conjugated mAbs or with unlabeled EGF followed by the 
incubation with FITC–EGF (10nM) at 37ºC for another hour. The median fluorescent intensities 
of the FITC channel from three independent experiments were plotted as percent FITC–EGF 
bound (Figure 5.4). Incubation with unlabeled EGF exhibited a concentration-dependent binding 
inhibition of FITC–EGF. Neither individual mAbs nor their combination blocked EGF binding 
even at saturating mAb concentrations. Both the mAbs and their combination were able to 
recognize receptors on the surface of fixed cells in a concentration-dependent manner (Figure 5.4 
B). One-site binding model was unable to fit the binding curve and so a two-site binding model 
was used because it gave the best fit to the experimental data. The values of the mean binding 
affinities obtained from three independent experiments are provided in Table 5.4. 
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Antibody KD1 (nM) KD2 (nM) 
mAb425 3.68 ± 0.54 568.66 ± 89.91 
C225 3.38 ± 0.23 595.57 ± 31.87 
mAb425/C225 6.7 ± 1.07 770.8 ± 185.76 
 
Table 5.4  Binding affinity values of mAb binding to EGFR present on the surface of fixed 
cells in the presence of EGF. 
The mean values of binding affinities obtained from at least three independent are provided, ± 
S.E.M. 
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Figure 5.4  mAbs fail to inhibit EGF binding on fixed cells. 
Fixed cells were incubated with different concentrations of Alexafluor660 conjugated mAbs, 
singly and in combination or with unlabeled EGF for 1hr on ice. FITC–EGF 10nM was added 
and cells were further incubated for an hour at 37°C and the amount of EGF bound was 
measured using flow cytometry (A). Labeled mAbs were able to bind to cell surface receptors 
in a concentration dependent manner (B). The experimental results were fit to a two-site 
binding model and the calculated values of binding affinities are tabulated in Table 5.4. 
Though the presence of unlabeled EGF resulted in reduced FITC–EGF binding, no significant 
reduction in EGF binding was observed in the presence of mAbs, either singly or in 
combination. This clearly demonstrates that both the mAbs are not able to recognize the active 
receptor isoform that EGF binds with high affinity. The mean values of EGF binding 
inhibition from at least three independent experiments at 100nM mAb concentration are 
provided, ± S.E.M. 
 
(A) (B) 
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5.2.3  Ligand binding studies on fixed and live cells 
 On the cell surface, EGFR exists in a dynamic equilibrium between high and low affinity 
receptor conformations. EGF preferentially binds to the high-affinity receptor conformation, as it 
can make simultaneous contacts on domains I and III. EGF binding traps the receptor in the 
active form and drives the equilibrium from the high abundance, inactive receptor conformation 
to its preferred high-affinity, active conformation (Ferguson et al., 2003). However, such a shift 
in equilibrium has not yet been studied for mAb425 and C225. Because the combined use of 
mAbs almost completely blocked EGF binding (Figure 5.1, Figure 5.2) and the presence of EGF 
did not significantly disrupt mAb-EGFR complex in the case of mAb combination (Figure 5.3), 
we sought to study the difference in this dynamic behavior for individual mAbs and for the mAb 
combination. Different concentrations of Alexafluor660 conjugated mAbs were incubated either 
with live cells or with fixed cells. Unlike live cells, receptors on the surface of fixed cells would 
be locked in one of its isomeric states and the binding of mAbs would not induce any 
conformational rearrangement of surface receptors or influence any shift in the equilibrium. To 
ensure that we measured the kinetics of ligand binding at conditions that represent the in vivo 
environment, cells were incubated with ligands at 37ºC. After incubation for 1hr, the fluorescence 
intensity of labeled cells (live and fixed) was measured using flow cytometry. The histogram of 
labeled cells incubated with 50nM of mAb (single and combination) or 10nM is shown in Figure 
5.5. All the ligands were able to bind to the surface receptors of fixed cells. The fluorescence of 
live cells was always greater than that of fixed cells. A 100-fold increase in the binding of EGF to 
live cells was observed. In contrast, there was a less than two-fold increase in mAb binding to 
live cells. 
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Figure 5.5  Comparison of ligand binding to live and fixed cells. 
A total of 50nM Alexafluor660 conjugated mAb425, C225, their combination, or 10nM 
FITC–EGF was incubated with either live or fixed cells. The histogram of fluorescence of 
bound ligands measured using flow cytometry is shown. An almost 100-fold increase was 
observed in the binding of FITC–EGF to live cells, demonstrating that few high-affinity 
receptors are expressed on the surface of cells and that the binding of EGF traps the receptor 
in the active conformation, shifting the equilibrium from the autoinhibited to the activated 
state. Similar to EGF, mAb also demonstrated increased binding to live cells vs fixed cells. 
These data indicate that like EGF, binding of mAb425 and C225 shifts the equilibrium 
towards their respective preferred conformation. 
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Figure 5.6  Comparison of mAb binding to live and fixed cells. 
Fixed or live MDA-MB-468 cells were incubated with different concentrations of 
Alexafluor660 conjugated mAb425, C225 or their combination for 1hr at 37°C and the 
amount of bound mAb was measured using flow cytometry. Fluorescent intensities were 
normalized with respect to maximum mAb binding to the live cells and the data were fitted to 
calculate the binding affinities. A two-site binding model was adopted to fit the experimental 
data and the respective binding affinities are listed in Table 5.5. The fitted data suggest that 
both the mAbs, singly and in combination, recognize two distinct classes of receptors on the 
surface of fixed cells. The calculated affinities for the binding of mAbs to the subclass of high-
affinity conformations were found to be similar to those for live cells. Also, the observed less 
than two-fold increase in mAb binding to live cells suggests that both mAb425 and C225 were 
able to recognize a greater population of EGFR conformations expressed on the surface of 
cells. 
(A) (B) 
(C) 
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The fluorescent intensities measured at different concentrations of mAb binding to fixed 
and live cells were normalized with respect to maximum mAb binding to live cells, and the dose 
responses was plotted as shown in Figure 5.6. Dashed lines represent the fitted data, and the 
mean binding affinities obtained from three independent experiments of the fitted data were 
calculated (Table 5.5). Binding of mAbs to live cells was fit to a one-site direct binding model 
using Origin 7.0 (OriginLab, Northampton, MA). The same model, however, was unable to fit 
mAb binding to fixed cells. A two-site binding model was used because it gave the best fit to the 
experimental data. The fitting of the two-site binding model indicated that PFA fixation might 
have resulted in dividing the cell surface receptors into two distinct populations: a mAb-preferred, 
high-affinity conformation (KD1) and a less preferred low-affinity conformation (KD2). Although 
the calculated affinities for the binding of mAbs to the observed subclass of high-affinity receptor 
conformations on the surface of fixed cells were found to be slightly higher than those calculated 
for live cells, these values are not significantly different. To determine whether mAb binding to 
 Live Cells Fixed Cells 
Antibody KD1 (nM) KD2 (nM) KD1 (nM) KD2 (nM) 
mAb425 9.69 ± 0.69 - 5.33 ± 0.93 810.78 ± 123.28 
C225 11.3 ± 1.1 - 4.2 ± 0.32 947.36 ± 171.08 
mAb425/C225 15.27 ± 0.76 - 9.49 ± 0.68 874.90 ± 195.4 
 
Table 5.5  Comparison of affinity values of mAb binding to EGFR expressed on the surface of 
live and fixed cells. 
The mean values of the binding affinities from three independent experiments are provided, ± 
S.E.M. 
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live cells similarly demonstrated two distinct receptor subclasses, similar two-site binding model 
was used to fit live cell binding data. The values of calculated affinities, KD1 and KD2, were found 
to be the same, confirming that on the surface of live cells both the mAbs recognize receptors as a 
single population, unlike fixed cells. These data argue that, unlike EGF, both of the mAbs are 
able to recognize the majority of receptor conformations expressed on the surface of fixed cells. 
5.2.4  BIAcore binding studies to tethered and untethered receptors 
 To further validate mAb recognition to most of the receptor isoforms, a domain IV 
truncated mutant was expressed that would represent the untethered receptor conformation. This 
particular mutant, containing residues 1–514 (sEGFR514), lacks the -hairpin loop of domain IV 
which is responsible for receptor tethering. In the absence of this tether, sEGFR514 would be able 
to adopt a wide range of extended conformations. Both of the receptors expressed, namely the 
wild-type sEGFR (sEGFR-wt) and sEGFR514, had a V5 tag at the C-terminal. The anti-V5 mAb 
immobilized on the CM5 sensor chip was used to capture V5-tagged receptors, thereby achieving 
receptor orientation that closely mimics the cell surface receptor. It was empirically determined 
that capturing ~5RUs of receptors would neutralize the avidity effect observed due to bivalent 
IgG analyte. Different concentrations of mAbs were injected at 50l/min for 3min, followed by a 
6min dissociation phase. The real-time sensorgrams of mAb425 (Figure 5.7 A, Figure 5.7 B) or 
C225 (Figure 5.7 C, Figure 5.7 D) binding to sEGFR-wt (Figure 5.7 A, Figure 5.7 C) and 
sEGFR514 (Figure 5.7 B, Figure 5.7 D) were obtained.  The corrected sensorgrams resulting 
from double reference subtraction (buffer injection and nonspecific flow cell) are shown in 
Figure 5.7 (black line). The sensorgrams were fit to a 1:1 binding model with mass transport 
limitation (red line).  The average values of the association rate (ka), dissociation rate (kd), and 
binding affinity (KD) from at least four independent experiments are listed in Table 5.6. There 
was no difference in the affinities of C225 for binding to sEGFR-wt and sEGFR514 and similar 
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values were obtained for the association and dissociation rates. In contrast, the association rate for 
mAb425 binding to sEGFR514 was reduced by almost two-fold compared with sEGFR-wt. No 
significant change in the dissociation rate was observed. To verify that the observed difference in 
the association rates is real and not the result of any inconsistency in sample preparation, six 
independent experiments were performed to characterize mAb425 binding to sEGFR-wt and 
sEGFR514. Apart from the two-fold decrease in the association rate for mAb425-sEGFR514 
interaction, no significant differences in the kinetics of mAb425 and C225 for binding to sEGFR-
wt and untethered receptor (sEGFR514) was observed. Thus, both mAb425 and C225 are able to 
recognize different EGFR isomers with similar affinities and is in agreement with the data 
presented in Figure 5.6, showing that both mAbs can bind a large and likely mixed population of 
receptor isoforms in live cells. 
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Figure 5.7  mAbs recognize different EGFR conformations with similar affinities. 
sEGFR-wt and domain IV truncated mutant lacking the -hairpin loop (sEGFR514) were 
expressed in stable S2 cells with a V5 tag at the C-terminal. Around 6RU of sEGFR-wt (A, C) 
or sEGFR514 (B, D) were captured using an anti-V5 antibody, immobilized on a CM5 sensor 
chip followed by the injection of different concentrations of mAb425 (A, B) or C225 (C, D) at 
50μl/min. Capture method was adopted to ensure that the orientation of captured receptors 
closely resembled membrane receptors expressed on the cell surface. The real-time 
sensorgrams were fitted to a 1:1 binding model with mass transport limitation using 
BIAevaluation software. The calculated affinities of at least four independent experiments are 
shown in Table 1. The fact that there were no significant differences in the kinetics of mAb 
binding to sEGFR-wt and sEGFR514 suggests that mAb425 and C225 are able to recognize 
different EGFR isomers with similar affinities. 
(A) 
(B) 
(C) 
(D) 
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5.3  SUMMARY OF RESULTS 
The underlying mechanism of action of immunotherapeutic drugs has always been the 
biggest challenge in designing therapeutic mAbs. Inhibition of ligand binding has been the most 
successful mechanism of blocking RTK activity. In this chapter we demonstrate that: 
 Combination of non-competing IgGs targeting EGFR - mAb425 and C225 completely blocks 
EGF binding unlike individual mAbs. 
 
Antibody Receptor ka (1/Ms) kd (1/s) KD (nM) 
mAb425 
sEGFR-wt (4.31 ± 0.47) E+05 (4.34 ± 0.86) E-03 11.87 ± 0.71
sEGFR514 (2.49 ± 0.88) E+05 (5.18 ± 0.62) E-03 20.80 ± 2.41
C225 
sEGFR-wt (11.0 ± 0.06) E+05 (8.02 ± 0.96) E-04 0.74 ± 0.08
sEGFR514 (8.54 ± 0.43) E+05 (8.35 ± 0.43) E-04 0.99 ± 0.06
 
Table 5.6  SPR based characterization of mAb binding to sEGFR-wt and sEGFR514 
The mean values of mAb kinetic parameters from at least four independent experiments are 
provided, ± S.E.M. 
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 Though Fab fragments of Matuzumab (humanized mAb425) and C225 achieves EGF binding 
inhibition, it fails to completely abrogate EGF binding, as observed in the case of 
combination of Fab fragments. 
 In the case of individual mAbs, EGF is able to disrupt mAb-EGFR complex. However, it fails 
to dissociate the trimolecular complex of mAb425, C225 and EGFR. 
 Both mAb425 and C225 failed to inhibit EGF binding to fixed cells. 
 Almost 100-fold increase in EGF binding to live cells is observed compared to fixed cells. On 
the other hand, mAb binding to live cells demonstrate only 2-fold increase. 
 Using surface plasmon resonance, both the mAbs bound to the sEGFR-wt and sEGFR514 
(receptor lacking the -hair pin loop of domain IV which is involved in receptor tethering) 
with similar affinities suggesting that both mAb425 and C225 are able to recognize the 
tethered and untethered receptor isoforms. 
 Based on these results, a model is developed in Chapter 7 explaining the mechanism how 
mAb425/C225 more efficiently blocks EGF binding.  
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CHAPTER 6 
RESULTS IV: SYNERGISTIC DOWNREGULATION OF EGFR BY 
mAb425/C225 COMBINATION 
6.1  INTRODUCTION 
A number of different mechanisms have been presented till date to explain the 
mechanism of immunotherapy. Apart from ligand binding inhibition, receptor downregulation is 
another mode of action that therapeutic mAbs generally exhibit to inhibit growth of tumor cells 
(Foon et al., 2004; Friedman et al., 2005; Mendelsohn and Baselga, 2000; Sarup et al., 1991). 
Binding of mAb to cell surface receptors results in receptor internalization. However, the rate of 
receptor internalization and its sorting to recycling endosomes or lysosomes vary with different 
mAbs. Certain mAbs demonstrate faster receptor uptake, while some fail to mediate endocytosis. 
In this chapter, we will shed some light on EGFR endocytosis, compartmentalization and 
downregulation mediated by mAb425, C225 and their combination. 
6.2  RESULTS 
6.2.1  Growth inhibition studies on A431 cells using Matuzumab, C225 and their combination 
 In Chapter 3, we had demonstrated synergistic growth inhibition by the combined use of 
mAb425 and C225 on MDA-MB-468 metastatic breast cancer cells. We however wanted to 
extend our observation and validate such synergistic behavior on a different cell line. For this 
study we selected A431 cells which is the human epidermoid carcinoma cell line derived from the 
vulvar region of a 85 year old female patient. A431 cells express similar levels of EGFR as 
MDA-MB-468 cells and are a well established model cell line to test the efficacy of EGFR 
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targeting immunotherapeutics (Fan et al., 1993; Fan et al., 1994; Gill et al., 1984; Goldstein et 
al., 1995; Kawamoto et al., 1984; Li et al., 2006; Masui et al., 1984; Michel et al., 2004; Saleh 
et al., 1999; Shimada et al., 1993). Optimization of initial cell seeding density revealed that 
plating 2,500 cells per well in a 48 well-plate would keep the cells in exponentially growing 
phase at the end of the experiment. After 24hr of post-seeding, medium was replenished with 
fresh medium containing different concentration of Matuzumab, C225 or their 1:1 combination. 
Metabolic activity was measured after 72hr and the average of the percent growth inhibition of 
A431 cells from five independent experiments is shown in Figure 6.1. 
Both Matuzumab and C225 were able to inhibit the growth of A431 cells. Treating the 
cells with the combination of Matuzumab and C225 on the other hand, resulted in enhanced 
growth inhibition; a behavior that was previously observed in the case of metastatic breast cells 
(Figure 4.1). C225 was found to be a better inhibitor than Matuzumab as reported in the growth 
inhibition of MDA-MB-468 cells. Around 10nM of mAb combination was sufficient for ~16% 
growth inhibition; while more than 100nM of C225 was required to achieve similar growth 
inhibition. Even at 10nM concentration, Matuzumab failed to achieve 10% growth inhibition. 
Since we did not have the growth inhibition profile for a wide range of mAb concentrations, we 
were not able to plot the isobologram as done previously. However, the results highlight that 
more than 10-fold lower concentration of mAb combination is sufficient to reach the growth 
inhibition for individual mAbs. This indicates synergism in growth suppression for A431 cells 
incubated with the combination of Matuzumab and C225; but in order to further validate synergy 
a wide range of mAb concentrations need to be screened. 
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6.2.2  Enhanced EGFR downregulation by mAb425/C225 combination 
 Cancer cells overexpressing EGFR rely predominantly on the receptor activity for their 
migration, proliferation, survival and growth of the cells. Receptor internalization and its sorting 
to lysosomal compartments have been shown to reduce the overall expression of cell surface 
receptors, a phenomenon called as receptor downregulation. Such decrease in receptor expression 
immediately reciprocated into reduced cellular activity. Therefore, EGFR downregulation and 
 
Figure 6.1  Enhanced growth inhibition of A431 by the combined use of Matuzumab and 
Cetuximab. 
Data represents the average of five independent experiments with at least triplicates in each 
experiment ± SEM. (* p<0.05) 
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degradation has become one of the successful mechanisms for attenuating receptor signaling and 
cell growth (Albanell et al., 2003; Baselga and Albanell, 2001; Foon et al., 2004; Ye et al., 
1999). Recently, Friedman et al. reported that the use of two non-competing mAbs targeting Her-
2 receptor results in increased inhibition of tumor growth in animal models (Friedman et al., 
2005). The mechanism of action for such enhancement in growth inhibition was attributed to 
synergistic internalization and degradation of Her-2. A working model to explain the 
improvement in mAb efficacy was developed. This model proposed that the rate of internalization 
and endocytotic clearance of surface receptors depends on the size of the receptor-mAb 
complexes formed on the cell surface. We had previously characterized that mAb425 and C225 
are non-competing mAb, having distinct binding epitopes. Therefore in order to elucidate the 
other possible mechanism for the observed synergistic growth inhibition by the combined use of 
mAb425 and C225 and check whether Friedman’s model holds true for our mAb combination, 
we measured the rate of EGFR downregulation for single mAb and in combination. 
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 MDA-MB-468 cells were incubated with 100nM of mAbs (single and in combination) or 
10nM of EGF. At indicated time points (Figure 6.2), surface bound ligands (mAb or EGF) were 
acid stripped and the cells were detached using non-enzymatic cell dissociation buffer. After 
fixing the cells in freshly prepared 1% PFA, surface EGFR was stained using Alexafluor488 
conjugated C225 (100nM). Labeled cells were then analyzed using flow cytometry and the 
amount of fluorescence measured from three independent experiments was plotted as shown in 
Figure 6.2. Cells incubated without any ligands were used as control to calculate the total surface 
EGFR at any particular time point. Incubation of cells with the combination resulted in much 
faster and higher EGFR downregulation compared to individual mAbs. After 10hr, the mAb 
 
Figure 6.2  Kinetics of mAb mediated EGFR downregulation. 
Data represents an average of three independent experiments ± SEM. 
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combination induced internalization of almost 60% of the total surface receptors as opposed to 
only 24% and 14% internalization for C225 and mAb425 respectively. In contrast, EGF exhibited 
a completely different downregulation profile. Almost 25% of the surface receptors were 
internalized in less than 30min and no further internalization was observed till 4hr. However at 
the end of 10hr, cells were able to recover EGFR back to normal levels of expression. mAbs on 
the other hand showed continuous internalization profile, faster for mAb combination and slower 
for individual mAbs. It should be noted that the initial rate of EGFR downregulation (first 30min) 
for C225 and mAb combination was not significantly different. However, cell surface receptors 
were continuously internalized with almost the same rate for mAb combination, but the rate of 
internalization was significantly reduced in the case of C225.  
 Faster internalization of cell surface receptors caused due to the result of larger ligand-
receptor complexes is a well studied phenomenon commonly observed during viral entry and 
other polyvalent antibody interactions such as IgM. In the case of RTKs, EGFR oligomerization 
and clustering following ligand binding has been shown to be extremely important to initiate 
receptor endocytosis (Barriere et al., 2006; Iwamoto and Mekada, 2000; Madshus, 2006).  Fan 
et al. showed that EGFR crosslinking by bivalent IgG is essential to induce receptor 
downregulation (Fan et al., 1994). Unlike IgG and F(ab’)2 molecules of mAb 225 (murine form 
of C225), monovalent Fab’ fragments of mAb225 (Fab’225) failed to downregulate EGFR, but 
indirect crosslinking if Fab’225 using anti-mouse IgG initiated receptor 
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internalizati
 
Knowing that the Fab fragments fail to induce receptor internalization, we wanted to 
check whether the incubation with the combination of Fab fragments result in EGFR endocytosis. 
Fab fragments of Matuzumab and C225 were generated by papain digestion of IgG molecules and 
their activity was validated using SPR analysis. In this study, MDA-MB-468 cells were incubated 
with the Fab fragments of Matuzumab, C225 and their combination (200nM final concentration) 
 
Figure 6.3  EGFR downregulation by Fab fragments of Matuzumab, C225 and their 
combination. 
Data presented is the average of three independent experiments ± S.E.M. * p<0.05, ** p>0.05 
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for 6hr followed by acid-stripping of surface bound Fabs and staining the surface receptors with 
Alexa488 conjugated C225. As expected, no internalization of EGFR was observed in the case of 
individual Fab fragments (Figure 6.3). Even the combination of Fab fragments did not induce 
EGFR downregulation. These results suggest that crosslinking of surface receptors using bivalent 
IgGs is required for EGFR internalization, which is also in complete agreement with previously 
published results (Fan et al., 1994). 
6.2.3  Comparison of growth inhibition of A431 cells between IgG and Fab fragments 
 After validating that the Fab fragments (single and in combination) did not induce EGFR 
internalization, we wanted to check whether the combined use of Fab fragments would exhibit 
any inhibitory effect on the growth of A431 cells. Growth inhibition assay was performed 
following the procedure mentioned above and the average value of the growth inhibition obtained 
from three independent experiments is shown in Figure 6.4. In order to maintain similar amounts 
of interacting surfaces, monovalent Fab fragments were kept at a concentration twice that of 
bivalent IgG molecules. As observed earlier (Figure 6.1), mAb combination showed enhanced 
inhibition of cell growth compared to individual mAbs. In contrast to the observed growth 
inhibition by IgGs, it was intriguing to observe negative growth inhibition of the cells treated with 
Fab fragments, both singly or in combination. Based on these results, it looks like Fab fragments 
might possibly act as a proliferative factor resulting in an increase in the metabolic activity 
compared to the control cells. The average values of growth inhibition for Fab combination were 
found to be higher than individual mAbs. Student t-test was used to compare the statistical 
significance between the data sets. Apart from the values at 10nM Fab concentration, our analysis 
did not show any statistical significant difference between individual Fab fragments and their 
combination.  
Chapter6
 
129 
 
 
6.2.4 Inhibition of EGF dependent receptor signaling 
  Results presented until now clearly demonstrate that there are two mechanisms of 
synergy – (i) Efficient inhibition of EGF binding and (ii) Faster EGFR downregulation. During 
the western blot analysis, previously reported Figure 4.3, we were unaware of these mechanisms. 
During that study, cells were incubated with mAb for 1hr before the addition of EGF. The 
receptor downregulation data presented above (Figure 6.2) clearly show that in 1hr, almost 25% 
 
Figure 6.4  Comparison of growth inhibition of A431 cells between IgG and Fab fragments. 
Data presented is the average of three independent experiments ± S.E.M. 
(* p<0.05) 
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of cell surface receptors are already internalization in the case of mAb combination as opposed to 
~12% and ~1% for C225 and mAb425 respectively. So during the addition of EGF, there was 
already a significant difference in the amount of EGFR on cell surface which might have 
influenced the outcome of the experiment. So we wanted to examine if the western blot data 
reported previously is being influenced by EGFR downregulation. 
 Similar experiment was performed with a slight change in the mAb incubation step. 
MDA-MB-468 cells were treated with 100nM of mAb, single and in combination on ice for 1hr 
followed by the addition of EGF. Incubation on ice would not internalize cell surface receptors so 
that the amount of EGFR would remain the same when EGF was added. Cells were lysed at 
different time points and the cell lysates were used to study EGFR phosphorylation and its 
downstream signaling. EGFR activation was studied by probing the cell lysate to check the 
activity at tyrosine residues Y1068, Y1173 and Y1045. The auto-phosphorylation sites of EGFR, 
Y1173 and Y1068 are considered as the most important tyrosine residues and have shown to play 
a major role in regulating downstream signaling (Keilhack et al., 1998). EGFR phosphorylation 
at Y1045, required for the activation of Cbl (ubiquitin ligase) results in sorting of EGFR from 
early endosomes to lysosomal compartment for degradation (de Melker et al., 2004; Duan et al., 
2003; Ettenberg et al., 2001).  
 As observed previously (Figure 4.3), mAb425 was found to be a poor inhibitor of EGF 
dependent signaling (Figure 6.5). In contrast to the minimal decrease in EGFR activity by 
mAb425; both C225 and mAb425/C225 combination significantly suppressed EGFR 
phosphorylation at Y1173, Y1045 and Y1068 to as low as the basal level. No significant 
difference in EGFR activity at Y1068 and Y1173 was found for C225 and mAb combination. 
However, EGFR phosphorylation at Y1045 was observed to be lower for mAb combination than 
C225. 
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 EGF dependent receptor signaling is transduced through two main pathways –PI3K, Akt 
pathway and Ras, Raf, Erk1/2 pathway. We wanted to check if the difference in EGFR activity by 
single mAb and combination is reflected on the downstream receptor signaling. So cell lysates 
were probed for measuring the activity of Erk1/2 and AKT. There was no noteworthy difference 
in Erk1/2 phosphorylation in the presence or absence of mAb425 (as previously observed in 
Figure 4.3). In contrast to previous results, C225 was unable to suppress the phosphorylation of 
Erk1/2. But, mAb combination showed similar behavior of almost complete abrogation of Erk1/2 
activity. Within 15min of incubation with EGF in the presence of mAb (single and combination), 
phosphorylation of Erk1/2 was observed. But only mAb425/C225 combination was able to 
achieve rapid suppression of Erk activity close to the basal level. Moreover, mAb combination 
was able to maintain basal levels of AKT activity and neither mAb425 nor C225 blocked AKT 
phosphorylation.  
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Figure 6.5  Western blot analysis – mAb425/C225 combination reduces EGFR activation and 
downstream signaling. 
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Figure 6.6  Western blot analysis – Use of Fab fragments of Matuzumab and C225 fails to 
antagonize EGF activity. 
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We also investigated inhibition of EGF dependent signaling using the Fab fragments of 
Matuzumab and C225 – single and in combination. Knowing that Fab fragments did not induce 
EGFR downregulation (Figure 6.3) and that their combination more efficiently inhibited EGF 
binding (Figure 5.2) similar to that observed in the case of IgG molecules (Figure 5.1); we 
wanted to test whether efficient inhibition of EGF binding is sufficient to block ligand dependent 
signaling cascade. To achieve this, MDA-MB-468 cells were first incubated with Fab fragments 
of Matuzumab, C225 or their combination (130nM concentration) for 1hr at 37°C followed by the 
addition of EGF (10ng/ml final concentration). Cells were further incubated and then lysed at 
indicated time points (Figure 6.6). There is a slight decrease in the phosphorylation of EGFR at 
Y1068 site but it is not significantly reduced as observed in the case of bivalent IgG molecules 
(Figure 4.3, Figure 6.5). But most importantly, none of the Fab fragments blocked the 
downstream signaling pathways; as similar amounts of phosphorylation were observed for Erk1/2 
and AKT in the presence or absence of Fab fragments. Though the use of combination of Fab 
fragments more efficiently inhibited EGF binding, they failed to antagonize EGF activity. 
Collectively these results suggest that bivalency of IgG molecules plays a pivotal role in 
inhibiting growth and EGF dependent signaling and that efficient inhibition of EGF binding 
inhibition might work co-operatively with enhanced EGFR downregulation observed in the case 
of mAb425/C225 combination.. 
6.3  SUMMARY OF RESULTS 
 Synergistic behavior of mAb425/C225 combination is not cell line specific. 
Matuzumab/C225 combination also synergizes with A431 squamous cell carcinoma that 
overexpresses EGFR to levels similar to MDA-MB-468 cells. 
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 Combination of mAb425 and C225 showed increased EGFR internalization compared to 
individual mAbs. However monovalent Fab fragments failed to induce receptor 
internalization. 
 The use of Fab fragments; single and in combination did not inhibit growth of A431 cells 
suggesting that receptor crosslinking by bivalent IgG molecules is required for growth 
inhibition. 
 Western blot analysis showed that bivalent IgG molecules are required to antagonize EGF 
activity and the use of Fab fragments failed to block downstream signal transduction of 
EGFR.  
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CHAPTER 7 
DISCUSSION & CONCLUSION 
7.1  OVERVIEW 
Advancement in the field of biologics and the ever increasing need to design novel 
therapeutic mAbs has significantly accelerated the need to develop new modalities of mAb 
therapy. In view of this, different strategies have been adopted to improve the therapeutic efficacy 
of mAbs. People have combined immunotherapy with radiation therapy, chemotherapeutics with 
a hope to observe an improvement in the efficacy. Even mAbs targeting different receptors were 
administered simultaneously. Though all these strategies showed improvement in the treatment; 
the underlying mechanism of action still remains a mystery.  
In Chapter 3, the interactions of mAb425 and C225 binding to sEGFR were 
characterized using SPR optical biosensor. Different strategies were adopted to calculate kinetic 
parameters. The values of the association and dissociation rates along with the binding affinities 
were consistent with all the strategies. C225 has a higher binding affinity than mAb425. The 
association rates for both the mAbs are similar; but the dissociation rate of mAb425 is around 10-
fold higher than C225. 
In Chapter 4, we observed that mAb425/C225 combination synergistically inhibits EGF 
dependent signal transduction (Figure 4.3). In light of this observation, in Chapter 5, we aimed 
to elucidate the mechanism of synergy by comparing the difference in EGF binding inhibition for 
mAb425, C225 and their combination. Using binding competition studies we demonstrate that the 
combined use of mAb425 and C225 more efficiently blocks EGF binding compared to individual 
mAbs (Figure 5.1). Similar increased inhibition of EGF binding was observed in the case of 
combination of Fab fragments of Matuzumab and C225 (Figure 5.2).  While the EGF antagonism 
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by C225 was observed to be more potent at lower temperatures, mAb425 never achieved 100% 
inhibition. This difference in the binding inhibition of the two mAbs could be attributed to the 
difference in their mode of EGF binding inhibition. Antibody bound crystal structures of sEGFR 
showed that C225 directly competes with EGF (overlapping binding epitopes). However, the 
binding epitope of mAb425 is distinct from EGF binding interface. Binding of mAb425 sterically 
inhibits EGF binding by preventing the receptor from adopting the active receptor conformation, 
which is required for EGF binding with high affinity (Li, 2005; Schmiedel et al., 2008). Thus, the 
incomplete inhibitory behavior of mAb425 is visualized to be the result of its allosteric mode of 
EGF binding inhibition, unlike C225. This difference in the mode of EGF binding inhibition is 
evident when we investigated the effect of EGF concentration on mAb binding (Figure 5.3). The 
amount of C225 binding to cell surface receptors gradually decreased with increasing EGF 
concentrations, a characteristic of a direct inhibitor. Unlike C225, however, mAb425 binding 
abruptly decreased at 500nM EGF concentration and did not demonstrate gradual decrease at 
lower EGF concentrations. The most enticing finding of this study was that even at 500nM 
concentration EGF was unable to disrupt the pre-complex of EGFR with the mAb combination 
(Figure 5.3 C). This observation strongly argued that there was a distinct difference in the mode 
of EGF binding inhibition for the mAb combination compared to individual mAbs. So it was 
extremely important for us to understand whether these mAbs in combination bind to cell surface 
receptors in a manner similar to individual mAbs or whether their simultaneous binding induces 
subtle structural alterations, modifying the manner in which they inhibit EGF binding. 
 Knowing that membrane receptors are always in a state of dynamic equilibrium, we 
wanted to understand the EGF binding competition results taking into consideration the 
phenomenon of receptor switching between tethered and untethered isoforms. Untethered 
receptors are flexible and are able to adopt a wide range of conformations during their probable 
130° rotation along the axis close to the R310 carbon atom (Ferguson et al., 2003). Among the 
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different untethered conformations, EGF binds to the active receptor conformation with high 
affinity. So in order to enhance our understanding on the mode of EGF binding inhibition, we 
investigated EGF binding competition in the absence of such receptor switching. Fixation of cells 
and tissues using a mild fixative such as PFA is the most commonly used method to preserve 
samples in their native environment. Fixing the surface receptors in their native conformation 
would help in understanding the manner in which these mAbs inhibit EGF binding (single vs 
combination). EGF binding competition studies on fixed cells (Figure 5.4) revealed that none of 
the mAbs singly or in combination were able to inhibit EGF binding. Though most of the 
receptors on the surface of fixed cells would be in the inactive conformation, we believe that a 
small population of receptors could still be in the active form; to which EGF would bind with 
high affinity. Previously reported SPR binding studies showed that the binding affinity for EGF 
to the untethered receptor is about 7.8nM, whereas the wild-type receptor binding affinity is about 
175nM (Dawson et al., 2005). With the FITC–EGF concentration of 10nM used in this study, we 
believe that most of FITC–EGF would bind to the active receptor conformation. Inhibition of 
FITC–EGF binding observed in the presence of unlabeled EGF further supports this hypothesis. 
These results strongly suggest that none of the mAbs are able to recognize the active form of 
EGFR that is required for EGF binding with high affinity. Further support for this interpretation 
comes from the structural studies previously reported indicating that neither mAb425 nor C225 
would bind to the active EGFR conformation (Li, 2005; Schmiedel et al., 2008). Although the 
binding epitopes of both the mAbs are located on domain III and are mostly exposed, none of the 
mAbs would be able to reach to their respective epitopes due to direct clashes with domains I and 
II for mAb425 binding (Schmiedel et al., 2008) and with domain I for C225 binding (Li, 2005). 
Combined with the structural analysis previously reported, our results showing that neither 
mAb425 nor C225 inhibits EGF binding to fixed cells support our hypothesis that none of the 
mAbs are able to recognize activated form of EGFR. 
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 X-ray crystallography studies suggested that the binding of mAb425 and C225 would 
prevent the receptor from adopting the active extended conformation (Li, 2005; Schmiedel et al., 
2008).  It has been hypothesized that although binding of C225 or mAb425 does not alter 
intradomain structure of the receptor, it might influence the distribution of EGFR isoforms by 
stabilizing the mAb–EGFR complex and restraining the untethered receptors to adopt the wide 
range of extended conformations. It is well known phenomenon that the binding of EGF traps the 
receptor in its preferred high-affinity, active conformation and shifts the conformational 
equilibrium of EGFR from the high abundance of inactive receptors to the low abundance of 
active receptors. We sought to understand whether similar shifts are observed following mAb 
binding. To achieve this, the amount of ligand binding to fixed and live cells was compared. The 
histographic representation of flow cytometry data (Figure 5.5) showed increased ligand binding 
to live cells compared to fixed cells. The observed significantly reduced binding of FITC–EGF to 
fixed cells, where most of the surface receptors are in the low-affinity conformations, could be 
attributed to the inability of EGF to shift the equilibrium of the surface receptors towards the 
high-affinity conformation. Conversely, in the case of live cells, where EGF binding can induce a 
significant conformational rearrangement of the receptor, ~100-fold increase in the fluorescence 
of FITC–EGF was observed, a finding which is in agreement with previous reports. In contrast to 
EGF, both mAb425 and C225 recognized most of the receptors on the surface of fixed cells. 
However, they are unable to bind to all the surface receptors (Figure 5.6). A possible explanation 
for this incomplete recognition is that certain conformational states of EGFR might sterically 
occlude mAb binding. The binding epitopes of mAb425 and C225 are located on domain III and 
are mostly water accessible. Due to the sheer size of the mAb-sEGFR binding interface, however, 
there is a high possibility that these mAbs could not reach to their respective epitopes. The two-
site binding model used to fit the mAb binding data to fixed cells indicates that cell fixation 
results in dividing the cell surface receptors into two subclasses: high-affinity and low-affinity 
receptors. mAb-preferred receptor conformations correspond to the high affinity population of 
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receptors. On the other hand, the low-affinity receptors could be attributed to the weak 
interactions between mAb–EGFR. The binding interfaces of mAbs involve complex interactions 
from the three CDR loops of each light and heavy chain with the antigen surface. Exposure of any 
interface would result in the weak interaction and the observed low-affinity binding could be the 
result of such interactions. SPR binding studies (Figure 5.7) complemented the flow cytometry 
data and validated our conclusion that both mAb425 and C225 are able to recognize both tethered 
and untethered receptors with similar affinities. Taken into account all the above results, it could 
be inferred that binding of mAb425 and/or C225 shifts the equilibrium by trapping the receptors 
in their respective preferred conformational states, similar to that observed following EGF 
binding. 
 It is possible that the results obtained using fixed cells may have been influenced by some 
alterations of the cell membrane and also the proteins embedded in the membrane due to PFA 
fixation. Freshly prepared 1% PFA is a very mild fixative and it has been previously reported that 
PFA fixation does not affect the secondary structure of proteins (Mason and O'Leary, 1991). 
Moreover, it does not alter the antigenicity of the proteins compared with other harsh fixatives 
such as methanol and glutaraldehyde (Cashman et al., 2003; Van Ewijk et al., 1980). Though the 
mAb binding studies suggest that on the surface of fixed cells, both mAb425 and C225 recognize 
receptors as two subclasses, the KD for the high-affinity receptors was not significantly different 
from the values obtained from direct mAb binding to live cells. Based on these evidences we 
strongly believe that PFA fixation would only “lock” surface receptors in their native 
conformational state without inducing unexpected modification of membrane proteins. It was 
intriguing to see that there was no significant change in the affinities of mAb binding to the 
receptors on the surface of fixed cells, in the presence or absence of EGF. The values of the 
affinities for mAb binding to fixed cells in the presence of EGF (Table 5.4) were found to be 
similar to those calculated in the absence of EGF (Table 5.5). Even a weak interaction of mAb  
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Figure 7.1  Crystal structure of sEGFR showing simultaneous binding of the Fab fragments of 
C225 and Matuzumab. 
Crystal structure of receptor bound Fab fragments of C225 and humanized mAb425 
(Matuzumab) aligned using PyMOL (DeLano Scientific LLC, Palo Alto, CA) is shown (A). 
The above structural evidence along with our previously reported data (Kamat et al., 2008) 
clearly shows that both the mAbs have distinct binding epitopes and are able to 
simultaneously bind to EGFR without affecting their binding properties. 
60º
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Figure 7.2  Proposed model on efficient EGF binding inhibition by mAb425/C225 
combination. 
Schematic diagram representing the proposed model on the more efficient inhibition of EGF 
binding by the combined use of mAb425 and C225.  
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with the active receptor conformation would result in its competition with EGF. Such competition 
would reduce mAb binding affinity, which was not observed in our studies. This validates our 
understanding that none of the mAbs binds to the active EGFR conformation. 
The results presented so forth lead us to hypothesize that simultaneous binding of 
mAb425 and C225 is essential for stabilizing the conformational state of EGFR, which is not 
recognized by EGF. Such a high degree of stabilization could not be achieved using single mAbs. 
Crystal structure of Fab fragments of C225 and Matuzumab (humanized mAb425), aligned using 
PyMOL (Figure 7.1) clearly shows that the binding epitopes of mAb425 and C225 are distinct. 
No steric clashes between the Fab fragments observed in the structure matches our results 
showing that binding of sEGFR to C225 does not affect the binding characteristics of mAb425 
(Figure 4.6). Based on the above results, we have developed a model to explain the observed 
phenomenon of efficient inhibition of EGF binding by mAb425/C225 combination (Figure 7.2). 
The unliganded form of EGFR exists in a dynamic equilibrium between the activated 
state and wide range of inactive conformations. Binding of single mAb would stabilize the 
inactive form of the receptor, sterically restraining the freedom of movement of the receptor to 
adopt the active form. Such behavior is also expected to occur in the case of monovalent Fab 
fragments. EGF binding inhibition for individual IgGs and Fab fragments will be preferentially 
governed by the dissociation rates of the respective antibodies. In the case of the mAb425/C225 
combination, however, EGF binding will be modulated by the dissociation rates of both the 
antibodies. Knowing that both mAb425 and C225 could simultaneously bind to EGFR without 
affecting their binding properties, one would assume that the amount of free energy G required 
to dissociate both the mAbs for EGF binding would be greater than the binding energy required to 
dissociate individual mAbs. Moreover, double occupancy of EGFR by mAb425 and C225 would 
result in EGF inhibition in a two-fold manner: (i) direct competition, in which the binding 
epitope of C225 on EGFR partially overlaps with EGF, and (ii) steric restriction of the 
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conformational freedom of EGFR by mAb425 as it prevents the receptor from forming the open 
conformation that is required for high-affinity ligand binding. Steric restriction could also be 
envisioned for C225. Moreover, the trimolecular complex of two mAbs plus a receptor would 
probably become so big that the receptor would completely lose its freedom to adopt the active 
conformation. Some of our data are consistent with the view described above. The combination of 
mAb425 and C225 used as bivalent IgG molecules and as monovalent Fab fragments more 
efficiently blocks EGF binding (Figure 5.1, Figure 5.2), and that mAb-EGFR complex is not 
significantly disrupted in the case of combination even at very high EGF concentrations (Figure 
5.3 C) as observed in the case of mAb425 (Figure 5.3 A) and C225 (Figure 5.3 B). None of the 
mAbs are able to recognize the active conformational state of EGFR, and similar to EGF, binding 
of mAbs drives the equilibrium of EGFR towards their respective mAb-preferred conformation. 
All these results indicate one mechanism whereby simultaneous binding of mAb425 and C225 
might lock the receptor in the inactive state, which is not favorable for EGF binding, thus 
achieving more efficient inhibition compared to individual mAbs. Thus, efficient EGF blockade 
could be attributed as one of the possible mechanisms for the synergistic activity observed by the 
combined use of mAb425 and C225 reported previously (Kamat et al., 2008). 
The results showing synergistic growth inhibition using mAb425/C225 combination 
presented in Chapter 4 (Figure 4.1, Figure 4.2) were obtained using EGFR overexpressing 
MDA-MB-468 breast cancer cells. So we wanted to evaluate the specificity of synergy and 
understand whether the observed synergy is cell line specific. To achieve this, we selected the 
human vulva epidermoid carcinoma A431 cells which are the model cell line, used for a cancer 
research. A431 cells overexpress EGFR to the levels comparable to those expressed on the 
surface of MDA-MB-468 cells. Similar to the results observed for MDA-MB-468 (Figure 4.1 A), 
Matuzumab/C225 combination demonstrated enhanced inhibition of the growth of A431 cells 
(Figure 6.1). Matuzumab showed poor inhibition compared to C225. Though the growth 
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inhibition profiles for MDA-MB-468 and A431 cells were similar, the amount of growth 
inhibition was observed to be lower for A431. The observed difference in the level of growth 
inhibition could be the result of a number of different factors. The WST-1 assay measures the 
metabolic activity of the cells and the change in the metabolic activity is plotted as the amount of 
growth inhibition. So treating the cells with the mAbs quite possibly did not reduce the metabolic 
activity of A431 cells to the levels observed in the case of MDA-MB-468 cells. Another 
explanation could be due to the very fact that these two cell lines are derived from different 
tissues and are phenotypically different from each other and thus would respond differently when 
treated with any anti-cancer drugs. Every drug exhibits its own mechanism of action to inhibit the 
growth of cancer cells. Depending on the mode of action, phenotypically distinct cell lines would 
respond differently resulting in a varied inhibition profile. Such differences between MDA-MB-
468 and A431 cell lines are also reported previously during the screening of various cancer drugs 
(Beuttler et al., 2009; Bhatia et al., 1999; Bos et al., 1997; LI et al., 2008; Pedersen et al., 2009 
; Wels et al., 2000; Yang et al., 1999a). So we believe that though the levels of growth inhibition 
for MDA-MB-468 and A431 are different, the inhibition profile follow similar trend and are 
comparable. Most importantly, it should be noted that the observed synergistic inhibition by 
mAb425/C225 combination is the common feature between the two cell lines and that the 
synergistic behavior is not simply cell line specific. 
In Chapter 6, we investigated the difference in mAb mediated EGFR downregulation in 
order to study the mechanism of action that governs the synergistic growth inhibition by 
mAb425/C225 combination. It was previously reported that synergistic inhibition of tumor 
growth by the combined use of two non-competing mAbs targeting Her-2 (another receptor from 
EGFR family of receptors) is the result of faster receptor downregulation (Friedman et al., 2005). 
In light of this report and the observed synergistic growth inhibition by the combination of non-
competing EGFR targeting mAbs – mAb425 and C225, we studied the difference between mAb 
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mediated EGFR trafficking for mAb425, C225 and their combination. It was observed that 
incubation of MDA-MB-468 cells with mAb425/C225 combination resulted in a significant 
increase in EGFR internalization compared to individual mAbs (Figure 6.2). Monovalent Fab 
fragments of Matuzumab and C225 used as single agents and in combination did not 
downregulate EGFR (Figure 6.3). Further comparison of growth inhibition by monovalent Fab 
fragments and bivalent IgGs showed that monovalent Fab fragments failed to inhibit growth of 
A431 cells. We understand that most of the results presented in the thesis were obtained on 
MDA-MB-468 cells. However as discussed above, the growth inhibition profile for both A431 
and MDA-MB-468 cell lines were comparable and similar synergistic inhibition of growth was 
observed for mAb425/C225 combination. So we strongly believe that similar behavior of Fab 
fragments (no growth inhibition) on MDA-MB-468 cells would be observed and that bivalent 
IgGs were required for growth inhibition (Figure 6.4). Moreover, it has been previously 
demonstrated that receptor crosslinking by the use of bivalent IgG and (Fab’)2 molecules is 
required to achieve growth inhibition (Fan et al., 1994), an observation that further supports our 
hypothesis.  
We further looked at the potency of the Fab fragments to inhibit EGF dependent signal 
transduction. The use of Fab fragments (single and in combination) failed to antagonize EGF 
activity (Figure 6.6). As presented earlier, both IgG and Fab fragments were found to be a better 
inhibitor of EGF binding when used in combination (Figure 5.1, Figure 5.2). However, it should 
be noted that a much higher concentration of Fab fragments (combination) was required to 
achieve almost complete inhibition of EGF binding (Table 5.2, Table 5.3). Our SPR binding 
studies showed that the binding affinities of IgG and Fab fragments are similar (Figure 3.1, 
Figure 3.2, Figure 3.3). There is no difference in the binding specificity for IgG and Fab 
fragments and that they bind to the same epitope on the receptor. However, a significant 
difference in their rates of association and dissociation was observed. Fab fragments were found 
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to dissociate faster than the IgG molecules (Table 3.1, Table 3.2, Table 3.3). Moreover, SPR 
experiments were tailored so that the binding stoichiometry even for bivalent IgG molecules was 
1:1. Experimental conditions were optimized so that the avidity effect, which is expected to occur 
in the case of bivalent IgG molecules, did not influence the values of the binding kinetics. 
However, in the case of cellular assays, the binding avidity is anticipated to influence the results 
and the affinities of IgG binding to cell surface receptor would probably be higher than those 
calculated using SPR. The need of a much higher concentration of Fab fragments to completely 
block EGF binding (in case of Fab combination) further supports our proposition. So, we believe 
that the observed higher level of EGF binding inhibition by IgG molecules at lower 
concentrations is the result of the binding avidity present in such cellular assays. Taking all these 
arguments into consideration, (higher dissociation rates of Fab fragments and binding avidity of 
IgG molecules), there would be a greater chance that the Fab fragments might leave a small 
subpopulation of cell surface receptors unoccupied. Binding of EGF to this small sub-population 
of unbound receptors would then trigger the signaling cascade as observed in Figure 6.6. It has 
been previously demonstrated that EGF binding to a small sub-population of receptors is enough 
to induce signal transduction (Defize and de Laat, 1989). This report further supports our 
hypothesis. Collectively, these results suggest that bivalency of IgG molecules are extremely 
important for mAbs to behave as an effective antitumor agent. Receptor dimerization mediated by 
IgG molecules is required for receptor downregulation and for the inhibition of cell growth and 
EGF dependent signal transduction. 
The results of receptor downregulation presented in Figure 6.2 measured the amount of 
EGFR expressed on the cell surface. These measurements are influenced by the difference in 
receptor trafficking – internalization and recycling. Live cell confocal imaging showed significant 
amount of EGFR recycling in the case of mAb425 and C225 (Figure D.3, Figure D.4, Figure 
D.5, Figure D.6, Figure D.7). The kinetics of EGFR recycling was found to be much faster for 
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mAb425 compared to C225. However, mAb425/C225 combination showed significantly reduced 
recycling. In fact, continuous fusion of endosomal vesicles to form larger multivesicular bodies 
was observed for mAb425/C225 combination. 
Ligand mediated EGFR endocytosis is a very dynamic process and the sorting of the 
internalized receptors is regulated by the stability of receptor-ligand complex. Dissociation of the 
ligand from its complex with the receptor triggers the signal for directing the endosomal vesicles 
towards recycling endosomes. However stable receptor-ligand complex, as observed in the case 
of EGF results in trafficking of the early endosomes towards late endosomes and lysosomes for 
proteolytic degradation. 
The model elucidating the mechanism of efficient inhibition of EGF binding by 
mAb425/C225 combination presented in Figure 7.2 proposes that simultaneous binding of 
mAb425 and C225 to cell surface receptors results in improved stabilization of the trimolecular 
complex, compared to individual mAbs. So, in the case of the mAb425/C225 combination, we 
believe that the two mAbs might continue to stay bound to the receptor even in early endosomes 
and multivesicular bodies. The observed high degree of colocalization of both the mAbs and 
EGFR in the multivesicular bodies shown in Figure D.7 validates our hypothesis. However such 
stable complexes are less likely to occur in the case of individual mAbs. SPR based binding 
studies showed that C225-sEGFR complex is more stable than mAb425-sEGFR complex, 
especially at physiological temperature (Figure 3.4). Rapid recycling of EGFR observed during 
live imaging of cells treated with mAb425 could be attributed to the characteristic rapid 
dissociation of mAb425 from EGFR at 37°C. However, slower recycling of EGFR from the 
multivesicular bodies for C225 could be the result of its slower dissociation rate.   
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Figure 7.3  Proposed model on synergistic downregulation by mAb425/C225 combination 
Fab Fragment – No Dimerization 
No Growth Inhibition 
Single IgG – Receptor Dimerization 
Growth Inhibition 
mAb425/C225 Combination – Receptor 
Oligomerization – Synergistic Growth Inhibition 
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The model proposed in Figure 7.3 explains the mechanism of synergistic EGFR 
downregulation by the combination of mAb425 and C225. The rate of EGFR internalization is 
directly proportional to the size of the mAb-EGFR complex. Binding of two non-competing 
mAbs – mAb425 and C225 would result in oligomerization of EGFR, in contrast to simple 
dimerization by single mAbs. This model is similar to the one presented earlier (Friedman et al., 
2005). However, we further validated the model by evaluating the efficacy of the Fab fragments 
of mAb425 and C225 (single vs combination) on EGFR downregulation and inhibition of cell 
growth. These results suggest that dimerization and oligomerization of EGFR is essential for the 
growth inhibition of cells. The demonstration of the Fab fragments (single and combination) as 
poor inhibitors of growth, could be attributed to their inability to crosslink the receptors on the 
cell surface. This observation is also consistent with previous reports (Fan et al., 1994). Apart 
from receptor oligomerization, we also propose that enhanced receptor downregulation is the 
result of higher stability of trimolecular complex formed by two mAbs and the receptor. Such 
stable complexes present in the early endosomes are responsible for directing the receptors 
towards late endosomes and lysosomes for degradation, thus significantly reducing the recycling 
of internalized receptors as observed in the case of individual mAbs. 
Based on the results presented in this thesis, we believe that: 
1. Combined use of mAb425 and C225 more efficiently inhibits EGF from binding to the 
receptor compared to individual mAbs. Simultaneous binding of both the mAbs (both 
bivalent IgG molecules and Fab fragments) stabilizes the trimolecular complex and locks the 
receptor in the inactive conformation, thus achieving complete blockage of EGF binding. 
2. mAb425/C225 combination efficiently inhibits growth and EGF dependent signal 
transduction of EGFR overexpressing cancer cells. Though mAb425/C225 combination used 
as bivalent IgG molecules and as monovalent Fab fragments more efficiently blocks EGF 
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binding; only IgG molecules (single and in combination) inhibit cell growth and EGF 
activity. Bivalency of IgG molecules is extremely crucial for anti-cancer activity. Higher 
order receptor oligomerization, that is expected to occur by the combined use of two non-
competing mAbs – mAb425 and C225, results in the observed synergistic activity. 
7.2  FUTURE IMPLICATIONS ON THE DESIGN OF NOVEL BIOLOGICS 
 Biologics, a class of engineered drugs developed from natural proteins, are emerging as 
one of the most promising treatments for a wide range of diseases from primary and metastatic 
cancers to inflammatory bowel diseases, Crohn’s disease, arthritis, auto-immune disorders 
(Adams and Weiner, 2005; D'Haens, 2007; Fuh et al., 1992; McCann and Woo, 2007; Miles, 
2007; Nicolaides et al., 2006; Panes et al., 2007; Papachristou and Plevy, 2004; Pascher and 
Klupp, 2005; Pivot, 2007; Scott, 2007; Strand et al., 2007; Wilkinson et al., 2003; William et 
al., 2009; Zhao et al., 2008). The field of biologics emerged with the development of mAbs 
targeting specific biomarkers. Over the past decade however, with the advancements in protein 
engineering the field has grown by leaps and bounds. Initial failures of first–generation biologics 
set the critical path forward for the development of new strategies to improve the therapeutic 
efficacy of the drug candidates. Biotech companies are now trying to overcome the limitations of 
existing targeted therapies by either administering the combination of already approved therapies 
or investigating complementary treatments to synergize their effects. In pursuit of synergy, 
significant amount of time, money and resources are spent to develop next–generation biologics; 
designing novel mAbs, fusion proteins and other modified recombinant growth hormones (2006; 
Hagiwara et al., 2006; Haurum, 2006; Mitchell, 2005; Walsh, 2000, 2003, 2006). But without a 
validated working model on the design aspects of these biologics, the question remains whether it 
is the right strategy for advancing the field of biologics. The development costs for drugs have 
increased to an estimated average of $800 million per approved drug (Caskey, 2007). Second 
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generation biologics are now entering into the market with a capitalized cost per approved new 
molecule of approximately $1.2 billion (DiMasi, 2007; DiMasi and Grabowski, 2007). The 
primary reason for these high costs is failed drug initiatives (Caskey, 2007) with only a few 
candidates managing to enter the pipeline. Moreover, the lack of proper understanding on the 
actual mechanism of synergy and the large number of failures in preclinical and clinical trials, has 
limited the translation of drug candidates into clinic. 
 
 In this study, based on the EGF binding inhibition and receptor downregulation, we have 
presented two different models elucidating the mechanism of action exhibited by the combined 
use of two EGFR targeting non-competing mAbs – mAb425 (or Matuzumab) and C225. Based 
on these models, we propose that the bispecific mAb containing one arm directed towards 
mAb425 epitope and another arm targeting the C225 epitope would exhibit similar behavior as 
observed by mixing these two IgG molecules together (Figure 7.4). Such bispecific mAb can also 
 
Figure 7.4  Model proposing the synergistic behavior by the new bispecific mAb 
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be developed by crosslinking the Fab fragments of mAb425 and C225 at the hinge region. 
Though optimization of crosslinker length would be helpful in modulating the level of synergy, it 
might not be essential. We believe that this new molecule would be able to fit into both the 
models presented above.  
The two epitopes of this bispecific IgG molecule which are derivatized from the epitopes 
of mAb425 and C225 have been characterized to be distinct. The bispecificity of the new 
molecule would lead to the simultaneous binding of two molecules to single EGFR. The 
trimolecular complex formed by the simultaneous binding of two molecules would be similar to 
that expected to occur by using the combination of mAb425 and C225. It can thus be anticipated 
that this new bispecific IgG molecule would lock the receptor in the inactive conformation and 
thus would block EGF binding more efficiently than both mAb425 and C225, as proposed in the 
model shown in Figure 7.2. Moreover, due to the bispecific nature of the molecule, EGFR 
oligomerization and enhanced receptor downregulation is also expected to occur. Thus the second 
mechanism of synergy as presented in Figure 7.3 would also be demonstrated by this new 
molecule. 
 We thus expect that the model presented above would be extremely helpful for the design 
of the next–generation biologics. This novel molecule would be a better drug candidate than both 
mAb425 and C225. Most importantly the results presented in this study could change the 
paradigm of molecular targeted therapy by providing some insights for optimizing drug 
combination therapies or designing novel biologics. This will result in lowering the costs of drug 
development and speed-up the translation of drugs to the clinic. These findings can result in 
immediate translation to the clinic where combinations of antibodies can be identified and used at 
an optimal dosage. At the drug design level, more effective antibodies can be assembled, which 
target changes in the receptor conformation and mimic such structural rearrangements to produce 
the most efficacious drug candidates. 
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APPENDIX A 
PROTEIN-PROTEIN INTERACTION TECHNIQUES 
A.1  INTRODUCTION 
Monoclonal antibodies have become one of the most promising and innovative 
therapeutic agents in the last 20 years. The global market for therapeutics is expected to reach 
around $26 billion by 2010. With an increasing demand for the development of therapeutics 
mAbs, there is an ever-increasing need to characterize these mAbs in order to proceed towards 
testing their efficacy in pre-clinical and clinical trials. mAb obtained from a large pool of 
antibody-producing cell lines are screened and lead candidates are selected for future efficacy 
studies. Screening of mAbs is a pivotal stage and a number of different characterization 
techniques have been adopted and are in use during this phase of mAb development. Among 
different techniques, characterization of the molecular interaction of mAbs and understanding 
mAb specificity, binding kinetics and ligand binding inhibition are some of the preliminary stages 
for selecting the best lead mAb candidates. Since molecular interaction studies play a central role 
in mAb screening, a detailed understanding of such interactions at the macroscopic level is 
extremely critical. This chapter details some of the methods used for the characterization of 
protein-protein interactions. The working principles of three methods – Surface Plasmon 
Resonance, Analytical Ultracentrifugation and Isothermal Titration Calorimetry are provided 
along with their respective advantages/limitations.   
A.2  METHODS FOR PROTEIN-PROTEIN INTERACTIONS 
 Cellular activities are very tightly modulated by a number of different interactions. Each 
interaction has a specific purpose of recognizing its target molecules and activating them. Such 
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interactions form a part of the complex, interdependent multi-component system of interactions. 
Most of these interactions occur inside the cells; in the cytoplasm or in different vesicular 
compartments. Cells sense their surrounding microenvironment through transmembrane proteins 
which interact with their specific growth factors and cytokines leading to signal transduction from 
the outside to the inside of the cell. These covalent and non-covalent interactions are coordinated 
and regulated both in time and space. 
 Proteins play a pivotal role in regulating these myriad of biological functions. Proteins 
are the major building blocks existing in nature that function like mechanical transducers and are 
responsible for the regulation and modulation of all the signaling cascades. Several covalent and 
non-covalent interactions hold the proteins in their native conformation. These protein molecules 
exist in a dynamic equilibrium and their activity mainly depends on their binding to another 
molecule. This binding event acts as a trigger to induce either subtle or significant changes in 
protein conformation, thereby initiating subsequent signaling events. Most of the proteins are 
activated by the reversible binding to their binding partner called the ligand. Different protein 
molecules existing in nature are able to recognize their binding partners with high specificity and 
can thus achieve their intended purpose of triggering downstream signaling. Such ligand-protein 
interaction allows an organism to respond spontaneously and reversibly to the changing 
microenvironment and so is extremely crucial for the proper control of cellular signaling. 
 Since protein-ligand interactions play a central role in regulating various cellular 
activities, detailed understanding of such interactions at the macroscopic level is extremely 
critical. Understanding such protein-protein interactions and characterizing them in terms of 
binding kinetics and possible conformational rearrangement following ligand binding is 
extremely essential. There are a number of different methods used for the characterization of 
protein-protein interactions, few of them are listed below: 
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1. Analytical Ultracentrifugation (AUC) 
2. Isothermal Titration Calorimetry (ITC) 
3. Surface Plasmon Resonance (SPR) 
4. Co-immunoprecipitation 
5. Bimolecular Fluorescence Complementation (BiFC) 
6. Circular Dichroism (CD) 
7. Florescence Resonance Energy Transfer (FRET) 
8. Yeast two-hybrid Screen 
9. Chemical crosslinking 
10. Tandem Affinity Purification (TAP) 
11. Dual Polarisation Interferometry 
12. Static Light Scattering (SLC) 
13. Mass spectrometry (MS) 
14. Fluorescence correlation spectroscopy 
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Figure A.1  Different techniques used for studying molecular interactions 
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Figure A.1 provides a schematic representation of different techniques that are adapted 
depending on the type of characterization. During the current study, the laboratory at Thomas 
Jefferson University has performed an experiment using AUC. So the working principle and 
limitations of the method would be presented in this chapter. The major part of the molecular 
interaction studies for this thesis were performed using a BIAcore® SPR system. So a detailed 
explanation on the BIAcore working principle is presented in this chapter. I have also included a 
brief explanation on ITC which is a standard technique used to study the thermodynamics of 
protein-protein interactions and could also be used to measure change in conformation following 
ligand binding. 
A.2.1  Analytical ultracentrifugation (AUC) 
 During the early age of biochemistry, researchers observed that proteins have high 
molecular weights and exhibit a tendency to be retained in cellulose membranes and scatter light; 
this latter was one of the most commonly observed phenomenon with colloidal dispersions of 
inorganic solutes. With an increase in our understanding of the importance of macromolecules in 
nature, there was an increasing need to develop new tools to study proteins. Discovery of AUC 
has been one of the pioneering findings that significantly progressed our understanding of protein 
science (Pedersen, 1976; Rawson et al., 1940). 
 AUC was first developed in 1920’s and has become one of the most powerful techniques 
to study the interaction between proteins in solution. It is still the most versatile, rigorous and 
accurate method to determine the molecular weight and hydrodynamic-thermodynamic properties 
of a macromolecules. There are two types of experiments that can be performed using AUC – 
sedimentation equilibrium and sedimentation velocity. Since all the parameters that describe 
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sedimentation behavior are experimentally determined, AUC is the only method till date that 
provides data with high levels of precision and accuracy (Hensley, 1996).  
A.2.1.1  Working principle 
 The working principle of AUC considers proteins as particles suspended in solution 
which are subjected to the gravitational force. Each particle would experience three forces as 
shown in the free body diagram (Figure A.2). The sedimentation or the gravitational force (Fs) 
experienced by a single particle is given by,  
Fs = m
2r = 



2r 
Where, 
m = mass of the single particle in grams 
M = Molar weight of the solute in g/mole 
N = Avogadro’s number 
 
The buoyant force, Fb, from Archimedes’ principle is equal to the weight of the fluid displaced: 
Fb = -m0
2r  
Where, m0 is the mass of fluid displaced by the particle. 
m0 = m = 


 
Fb = 



2r  
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Here,  
 = Volume in ml 
	 = Density of the solvent in gm/ml 
 
The particle will sediment provided the density of the particle is greater than that of the 
solvent.  As the particle begins to move along the radius towards the bottom of the cell, its 
velocity (u) will increase due to increasing radial resistance.  During its motion, the particle will 
experience a frictional drag (Ff) since it is moving through a viscous fluid. Ff is directly 
proportional to the velocity and is given by, 
Ff = -fu 
Where, f is called the co-efficient of friction and is dependent on the size and shape of the 
particle. In an infinitesimally small time (in the order of sec) all the forces balance out. 
Fs + Fb+ Ff = 0 
 
 
 
Figure A.2  Working principle of AUC. 
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


2r + 


	
2r - 	 = 0 
Rearranging the above equations, we get 

  	)

= 
	

2r
 = s 
The term 


2r
 provides information regarding the velocity of the particle per unit gravitational 
acceleration and is called the sedimentation co-efficient (s). This sedimentation coefficient is a 
function of the properties of the particle. Thus, molecules having different molecular weights, 
shapes, sizes would have different sedimentation co-efficient and thus in a given centrifugal force 
would move in the cell with different velocities. 
A.2.1.2  Modes of measurement 
Sedimentation equilibrium 
 Sedimentation equilibrium is the most frequently used AUC technique. This mode is used 
to measure the molecular weight of proteins or protein complexes. Protein samples are allowed to 
sediment at lower rotor speed. The centrifugal force acting upon the protein molecules is opposed 
by the diffusive force. Once these forces are equal and opposite, they cancel out each other and 
the system reaches equilibrium. At equilibrium, the gradient of protein concentration developed 
in the cell is measured by the 280nm absorbance. Analysis of the measured protein concentration 
gradient enables quantification of the molecular weight of protein samples. 
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Sedimentation velocity 
 This mode provides information regarding the molecular weight and shape of the protein. 
In this mode, the rate of movement of protein molecules in response to a centrifugal force is 
measured. High rotor speeds used in this mode rapidly pellet the protein to the bottom of the 
sample cell. As the protein pellets to the bottom, a boundary is formed between the pure solvent 
and the solution containing the protein. The movement of this boundary is measured by repetitive 
scanning of the absorbance of the sample cell. Based on the movement of this boundary, the 
sedimentation coefficient parameter is obtained which could then be used to calculate the 
diffusion coefficient and molecular weight. In addition, data obtained from the sedimentation 
velocity experiments can also be used to get information about protein conformation and/or 
heterogeneity. 
A.2.2  Isothermal titration calorimetry (ITC) 
 Similar to AUC, ITC also characterizes protein-protein interaction in the solution phase. 
It is one of the most quantitative methods to study the thermodynamic properties of molecular 
interactions. ITC has been most effectively used to determine the heat involved when a protein 
interacts with its partner. This technique is most widely used to measure the binding constants 
(K), the stoichiometry of interaction (n) and the enthalpy of binding (H) of the interactions 
between two or more molecules. The Gibb’s free energy (G) and the entropy of binding (S) 
can be calculated from the equilibrium association constants using the equation,  
G = -RTln(K) = H - TS 
 The schematic diagram depicting the working principle of ITC is shown in Figure A.3. 
The instrument contains two identical cells surrounded by an adiabatic jacket. The sample cell 
contains the selected proteins and the reference cell contains the buffer where the protein is 
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diluted in. It is important that both the reference and sample cells have equal volumes of solution 
and care should be taken that the reference cells do not contain any protein. The interacting 
molecule is placed in a syringe, also referred as titrant. The titrant is injected in the sample cell in 
small fractions. Addition of each fraction results in the absorption or release of heat, depending 
on the type of interaction – endothermic or exothermic reaction. This heat exchange is 
proportional to the amount of bound fraction. For characterizing molecular interactions, ~25-30 
repetitive injection cycles are performed. As the concentration of the titrant increases, the 
interaction reaches saturation resulting in reduced heat exchange. 
 ITC has been successfully used to characterize a number of different protein-protein 
interactions. In fact, extensive ITC studies performed by Lemmon et al. (Lemmon et al., 1997) 
demonstrated that that the stoichiometry of EGFR:EGF in a dimer is 2:2. This was the first 
evidence that demonstrated that EGF first binds to EGFR monomer and two EGF-EGFR 
monomers subsequently form dimers. Further studies revealed that the binding interaction of EGF 
with sEGFR is biphasic as opposed to that observed in the case of EGF interacting with the 
recombinant expressed domain III of the receptor. Based on the structural studies (Ferguson et 
al., 2003; Garrett et al., 2002; Ogiso et al., 2002) it is now understood that the observed biphasic 
response could possibly be the result of the 130º counterclockwise rotation of the domain I/II 
rigid body of the tethered receptor about an axis close to the -carbon of R310. 
ITC is a label-free technique to study protein-protein interactions. It does not require any 
chromophores or fluorophores, nor does it require an enzymatic assay. Though ITC is a robust 
method, it requires large volumes (~1.7ml) of high concentrations of proteins, generally greater 
than 2M for each experiment in the sample cell. A very stable baseline is required to obtain 
reliable data and air bubbles can often generate unexpected heat signals which could lead to error 
in measurements. Moreover, the lower limit of detection for protein-protein interaction is usually 
~10nM and hence it is difficult to study tight protein binders with ITC. 
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A.2.3  BIAcore surface plasmon resonance (SPR) 
 With the advancement in the field of molecular therapeutics and biologics, there has been 
an ever increasing need to devise tools for label-free detection and measuring protein interactions 
with high sensitivity and reliability. Since the development of SPR based biosensor in 1990’s, the 
use of this technique to characterize the molecular interaction between two or more proteins has 
exponentially increased. Though there are a number of SPR based systems currently in the 
market, the BIAcore™ system developed by BIAcore Life Sciences has by far ruled the market 
for almost 2 decades. BIAcore biosensor technology is a versatile, highly sensitive, label-free, 
 
Figure A.3  Schematic diagram of ITC. 
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and easy-to-use technique to study a number of different aspects of protein-protein interactions. 
Though the system is most widely used in either a quantitative mode such as determining binding 
kinetics and equilibrium affinities (~70% of the time) or in a qualitative mode to identify and/or 
compare binding partners (~25% of the time), it could also be used to investigate the 
thermodynamics of the interaction, mode of binding inhibition, optimization of protein 
production/purification, effect of buffer conditions on interaction, epitope mapping, and so on. In 
2007, there were around 1179 papers published suggesting the wide spread use of optical 
biosensors technology (Rich and Myszka, 2008). Despite a significant increase in the usage of 
SPR based optical biosensors, especially BIAcore systems, the data existing in the literature 
suggests that only 10% of the SPR data published in 2005 was estimated to be reliable (Rich and 
Myszka, 2006). So it is very important to understand the technology and the possible pitfalls that 
may result in unreliable data. In the subsequent section, I shall provide the working principle of 
BIAcore biosensor technology and also address all the possible steps necessary for reliable 
binding data. 
A.2.3.1  Working principle 
 BIAcore biosensor works on the principle of surface plasmon resonance. At the interface 
of two transparent media having different refractive indices, the incident light gets reflected and 
refracted. If the angle of incidence is greater than a certain angle, called the critical angle, no light 
is refracted and the incident light undergoes total internal reflection (TIR). At this critical angle, 
the electromagnetic (EM) field penetrates a very short distance into the medium, developing an 
exponentially decreasing evanescent field. If the interface between the media is coated with a 
very thin layer (~ 10-100nm) of metal like gold or silver and a polarized monochromatic light of 
certain wavelength is incident, at the critical angle, surface plasmon resonance occurs resulting in 
resonance energy transfer between the evanescent field and the surface plasmons. These surface 
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plasmons, also termed as surface plasmon polaritons, are surface EM waves that propagate in a 
direction parallel to the metal/dielectric interface. So most of the incident light traverses along the 
metal surface and the intensity of the reflected light is significantly reduced. Since surface 
plasmon resonance is a surface phenomenon, observed within ~100-200nM distance from the 
surface, these oscillations are extremely sensitive to any change in the surface properties of gold, 
such as the adsorption of molecules. Binding of proteins onto the sensor surface changes the local 
refractive index near the dextran hydrogen layer, which is coated on the gold film. This alters the 
critical angle which is measured by the optical detector. The schematic working principle of SPR 
biosensor has been depicted in Figure A.4. The SPR signal obtained from a BIAcore sensor is 
expressed in terms of resonance units (RUs). The SPR signal is directly proportional to the total 
mass of protein accumulated in the hydrogel and is given by, 
1 RU = 1pg/mm2 
 The BIAcore sensor chip has a dextran layer on top of the gold surface that allows 
immobilization of the binding partners involved in the study (called the ligand). The other partner 
(called the analyte) is then injected over the ligand immobilized sensor surface at different 
concentrations and the real time sensorgram is measured. Since SPR response is related to the 
change in surface mass concentration, the observed sensorgram is dependent on the molecular 
weights of analyte and ligand. The maximum binding capacity of the ligand can be calculated as, 
Rmax = 
[MW]analyte
MW]ligand
 * RU * S 
Where, 
MW is the molecular weight in kD 
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RU is the amount of ligand immobilized on the sensor chip, 
S is the stoichiometry of the analyte:ligand binding 
 
 
 
 
Figure A.4  Schematic representation showing the working principle of SPR biosensor 
The glass sensor surface is coated with a thin layer of gold. The dextran layer attached onto 
the gold surface allows immobilization of the ligand. The change in the critical angle 
following analyte binding to the immobilized ligand is measured by the detector.  
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 The BIAcore instrument provides superior control over the selection of flow rate, flow 
cells and temperature. The surface properties of the sensor chip can be easily modified depending 
on the requirements. It is thus a very versatile tool that can be used to study a wide range of 
molecular interactions involving anything from low molecular mass analytes to cells (Figure 
A.5). Depending on the type of interaction under investigation, experimental parameters such as 
the amount of immobilized ligand, flow rate, injection time and number of detection areas can be 
varied and the range of data collected could be used to evaluate the molecular interaction. 
 
Figure A.5  Molecular interactions studied using BIAcore 
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A.2.3.2 Methods for ligand immobilization 
 Depending on the type of study, there are two different immobilization methods used to 
characterize binding interactions – Direct method and Capture method (Figure A.6). 
Direct immobilization method 
 In the direct method, the ligand is covalently attached onto the sensor surface by 
chemical modification of the amine, carbohydrate, aldehyde or thiol groups. It is a well accepted 
technique to immobilize mAbs on the sensor surface and study antigen-antibody interactions. 
Though direct immobilization is the most commonly used technique to characterize binding 
properties of a wide range of binding partners, there are a number of drawbacks in using this 
technique: 
1. The immobilized ligands need to be extremely stable and not denature/unfold when subjected 
to harsh conditions during the regeneration of the surface at the end of each cycle. 
2. The conjugation reaction is non-specific and cannot be directed to any reactive groups on the 
ligand. 
3. Non-specific conjugation reaction would result in random, multi-oriented immobilization of 
the ligand, thereby affecting the activity of the ligand and reproducibility of the results. 
4. Since the dextran layer is negatively charged, it is difficult to immobilize acidic ligands (pI < 
6) due to charge repulsion. 
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Capture immobilization method 
 The Capture method provides an alternative to the covalent immobilization. In this 
method, a molecule is first immobilized on the surface which is used to capture the ligand of 
interest. The ligands used in the capture method generally have a tag to which the immobilized 
molecule can bind. The Capture method has added advantages over the direct method, namely: 
1. Ligand is properly oriented on the sensor surface. 
2. Since the ligand is captured in every cycle, we need not have to worry about the denaturation 
of ligand caused during chip regeneration and the data is reproducible. 
 
Figure A.6  Schematic showing different methods of ligand immobilization 
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3. Using just one sensor chip, the ligand density can be changed depending on the type of 
interaction under investigation.  
A.2.3.3 Thermodynamic studies using SPR BIAcore system 
 A detailed understanding of any protein-protein interaction requires accurate structural, 
thermodynamic and binding kinetics information. Characterization of the thermodynamics of the 
interaction provides a more complete understanding of the forces involved to form protein 
complexes; thus complimenting the structural information. Although ITC is the standard method 
for measuring the binding thermodynamics; the method requires a significantly larger amount of 
samples. Recently, SPR based optical biosensor system like BIAcore system has been used to 
determine the thermodynamics of protein-protein interaction. The values of the binding constants 
measured at different temperatures were used to determine thermodynamics with significantly 
reduced sample requirements.  
The Gibb’s free energy change (G) for an interaction is related to the equilibrium 
dissociation constant by, 
G = RTln(KD) 
 The non-calorimetric van’t Hoff analysis is used for determining the enthalpy change for 
a binding interaction. However, in this model; it is assumed that the binding reaction reaches a 
single equilibrium throughout the temperature range under investigation. So, it is applicable only 
to proteins that do not aggregate or change conformation over the temperature range studied. 
For a simple equilibrium reaction, the van’t Hoff enthalpy change (H) is calculated 
from the temperature dependence of equilibrium dissociation constant (KD). 
G = RTln(KD) = H – TS 
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ln (KD) = H/R (1/T) – S/R 
If the van’t Hoff plot (ln KD versus 1/T) is linear; i.e. if H and S were independent of 
temperature; the values of binding enthalpy and binding entropy could be determined from the 
slope and the y-intercept of the line, respectively.  
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APPENDIX B 
LIGAND MEDIATED EGFR TRAFFICKING 
The cell surface consists of a wide range of membrane components that can be 
dynamically altered in order to regulate normal cellular functions. Membrane receptors are 
considered the most important cellular components. Such membrane receptors are the key players 
that continually sense the cell microenvironment and convert the external message into a 
biochemical signature inside the cells, thus modulating cellular activity. Figure B.1 provides a 
schematic representation of receptor mediated endocytotic pathways. Binding of ligands, 
hormones, cytokines and other proteins to cell surface receptors activates the receptors and 
triggers a number of different complex, cascaded downstream signaling. Activated membrane 
receptors, mostly get internalized and are transported inside the cell through endocytotic 
pathways. The dynamics of receptor trafficking are tightly regulated by the binding of different 
proteins at the cytoplasmic tail of the receptors. The rate of receptor internalization and its sorting 
to recycling endosomes or lysosomes determines the fate of receptor mediated downstream 
signaling. In this chapter, we will shed some light and describe ligand dependent EGFR 
activation, endocytosis, compartmentalization and downregulation. Based on our results on mAb 
mediated EGFR downregulation presented in this chapter, we have developed a model suggesting 
that EGFR oligomerization by the simultaneous binding of two non-competing bivalent IgG 
molecules – mAb425 and C225 is required for synergistic receptor downregulation. 
 Since the discovery of EGFR as the first RTK (Carpenter et al., 1978), ligand mediated 
activation and its subsequent trafficking was most comprehensively studied for EGFR (Baass et 
al., 1995; Le Roy and Wrana, 2005; Mayor and Pagano, 2007; Pike, 2003; Schlessinger, 2000; 
Sigismund et al., 2005; Simons and Toomre, 2000; Sorkin and Von Zastrow, 2002). Binding of 
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ligand to EGFR results in rapid clustering of ligand-receptor complexes and trans-auto-
phosphorylation of multiple Tyr residues located at the cytoplasmic tail of the receptor. 
Phosphorylated Tyr residues serve as binding sites for different cytosolic signaling proteins 
containing SH2 and PTB domains. Activated receptors are then internalized from the cell 
membrane into endocytotic compartments which are later directed to either recycling endosomes 
or to lysosomal compartments for degradation. Vesicular trafficking of activated EGFR is divided 
into two main pathways – the classical clathrin dependent endocytotic pathway and the non-
classical clathrin independent, lipid raft dependent pathway. 
 A detailed schematic diagram of EGF mediated receptor trafficking is shown in Figure 
B.2. Clathrin mediated endocytosis is the most well characterized endocytotic pathway which is 
responsible for the internalization of nutrients, pathogens, growth factors, receptors and other 
molecules inside the cell. Clathrin mediated endocytosis is the most common route of 
internalization following the binding of ligand to cell surface receptors. On the cell surface, 
unliganded EGFR has been shown to be mostly located in caveolae and GM1 containing lipid 
rafts (Mineo et al., 1999; Roepstorff et al., 2002). Following EGF binding, EGFR either 
homodimerizes or heterodimerizes with other members of the Erb family. Receptor dimers then 
migrate out of the lipid rafts towards the clathrin-coated pits. Activated receptors recruit E3 
ubiquitin ligase Cbl. Binding of Cbl results in EGFR multiubiquitylation and binding to Cbl-
interacting protein of 85 kDa (CIN85) and endophilins. Assembly of endocytotic cargos is 
regulated by EGFR-dependent phosphorylation of EGFR-pathway substrate-15 (EPS15) and 
ligand-dependent monoubiquitylation of Epsin and EPS15. Epsin also interacts with adaptor 
protein-2 (AP2), clathrin and phosphatidylinositol-4,5-bisphosphate in bending the phospholipid 
bilayer, thus facilitating the formation of vesicles at the cell membrane. Finally these clathrin-
coated vesicles are pinched off from the cell membrane by a GTPase, dynamin and the vesicles 
formed get internalized to form early endosomes.  
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Figure B.1  Classification of endocytotic pathways 
This figure has been reproduced from reference (Mayor and Pagano, 2007).  
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Figure B.2  Schematic of ligand dependent EGFR trafficking 
This figure has been reproduced from reference (Le Roy and Wrana, 2005).  
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Figure B.3  Schematic diagram showing the dynamics of EGF mediated receptor trafficking 
This figure has been adapted from reference (Sorkin and Von Zastrow, 2002). 
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 Though most of the receptors are endocytosed through the classical pathway, it was 
recently observed that the route of endocytosis depends significantly on the amount of EGF used 
to stimulate the receptor (Sigismund et al., 2005; Woelk et al., 2007). At lower doses of EGF, the 
receptor follows clathrin dependent internalization and ubiquitination of the receptor is not 
required for endocytosis. Though EGFR follows the clathrin dependent pathway at higher EGF 
concentrations, a significant amount of receptors get endocytosed through clathrin-independent 
pathways.  However, the exact mechanism of EGFR trafficking through this alternative pathway 
is still controversial. Since EGFR internalization through lipid rafts requires ubiquitination of the 
receptor, it is believed that Eps15 and epsin play a major role in directing the receptor to clathrin 
dependent or clathrin independent pathways.  
 Once the receptors are endocytosed and enter into early endosomes, they are either 
recycled back to the cell membrane or are sorted towards the multivesicular endosomes and 
eventually to late endosomes/lysosomes for degradation (Figure B.3). Two separate mechanisms 
have been observed that route these early endosomes into Rab11 positive recycling vesicles – (i) 
dissociation of the ligands from their receptor complexes in early endosomes (French et al., 
1995), and (ii) protein kinase C (PKC) dependent phosphorylation of EGFR at Thr654 (Bao et 
al., 2000). For example, compared to EGF, TGF- dissociates from its complex at a higher pH 
present in the early endosomal vesicles, leading into efficient recycling of intact receptor back to 
the cell membrane (Ebner and Derynck, 1991). Internalized receptors can either undergo rapid 
recycling (t1/2 ~ 5-7min) or slow recycling (t1/2 ~ 20min), depending on the type of ligand. During 
recycling, EGFR does not get ubiquitinated. Studies show that sustained multiubiquitylation of 
EGFR in the endosome is the key signal that directs internalized receptors into the intralumenal 
vesicles of multivesicular bodies (Barriere et al., 2006; de Melker et al., 2004; Duan et al., 
2003; Levkowitz et al., 1998; Yokouchi et al., 1999). It is also observed that EGFR located in 
endosomal compartments is able to regulate certain cellular signaling (Vieira et al., 1996; Wang 
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et al., 2002). But once the endosomal vesicles fuse with the lysosomes, these receptors get 
degraded leading into the termination of cellular signaling. 
 It is thus evident that ligand mediated EGFR internalization and trafficking are regulated 
by a very complex network of protein-protein and protein-lipid interactions. The route of EGFR 
trafficking and sorting depends on the type of ligand and the amount of dosage that activates the 
receptor. Various components of the endocytotic pathway are responsible for proper regulation of 
receptor dependent phosphorylation and ubiquitylation. Different adaptor proteins and 
phospholipids that control endocytosis play an important role in sorting early endosomes and 
eventually link endocytotic machinery to cell signaling. 
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APPENDIX C 
EGFR CLONING, EXPRESSION AND PURIFICATION 
C.1 INTRODUCTION 
 In this appendix, the results of cloning, expression and purification are presented. The 
results of optimization of papain digestion of IgG molecules are also provided.  
C.2 RESULTS 
C.2.1  Cloning of sEGFR gene fragment into the pMT/V5-HisA expression vector 
 The base pair sequence corresponding to sEGFR (1-618) was amplified from the 
pSecTag2B vector (expression vector generously provided by Dr. Adams, Fox Chase Cancer 
Center) using PCR.  Both pSecTag2B and pMT/V5-HisA vectors had Xho1 and Kpn1 restriction 
sites in their multiple cloning regions (Figure C.1) and so were selected for the ligation of 
sEGFR fragment. To determine optimum ligation conditions, different ratios of empty vector to 
sEGFR fragment were mixed during the ligation reaction. The ligated products were then 
electrophoresed vector on 1% agarose gel and visualized under UV. Ligation reaction performed 
at 1:4 ratio showed lower yields compared to that observed for 1:1 and 1:2 ratios. Since there was 
no significant difference in the ligation efficiency between 1:1 and 1:2 ratios, ligation product 
obtained from 1:2 ratio was used for further DNA transformation followed by DNA purification. 
Once the DNA sequence was verified, this expression vector was used as a template for site-
directed mutagenesis to rectify the single point mutation located at the residue 474. The observed 
lysine to serine mutation at this location was corrected and validated by DNA sequencing. 
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Validated expression was transformed into larger cultures and later purified using QIAGEN 
Plasmid Plus Maxi Kit and stored at -20ºC for future transfections and protein expression. 
  
 
 
 
 
Figure C.1  Vector map of pSecTag2 and pMT/V5-His 
Figure shows the vector maps of pSecTag2 (A) and pMT/V5-His (B) along with their different 
multiple cloning sites, promoter regions, region of antibiotic resistance and origin of 
replication site. The sEGFR fragment was excised from pSecTag2b vector and cloned into 
pMT/V5-HisA vector between Kpn1 and Xho1 restriction sites to facilitate protein expression. 
These figures were reproduced from Invitrogen, Inc. 
(A) 
(B) 
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C.2.2  Protein expression and purification 
 S2 cells were first transiently transfected with sEGFR-V5 expression vector in order to 
optimize the transfection efficiency and to select condition that yielded high levels of protein 
expression. S2 cells were also transfected with empty V5-vector as a positive control. Around 
100l from 3ml of culture medium was sampled every day and the amount of protein present in 
culture medium and in the cells was analyzed using western blot by probing the membrane with 
anti-His antibody (Figure C.3). The western blot showed a single thick band near the 80kD 
weight marker and matches the 76kD molecular weight of sEGFR-V5 (Figure C.3 A).  No other 
 
 
Figure C.2  Ligation of sEGFR fragment into pMT/V5-HisA expression vector. 
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bands were developed from the culture medium suggesting that the protein is intact and did not 
degrade over time. Irrespective of the amount of DNA used during transfection, no significant 
difference in the expression of sEGFR-V5 was observed. Though the blot shows a slightly higher 
protein expression on day 3 compared to day 2, the difference in not statistically significantly 
different. Western analysis of the culture medium of the cells transfected with empty V-vector 
showed no bands (data not shown). In contrast, a number of different molecular weight bands 
were seen from the lysates of the cells transfected sEGFR-V5 which also matched with control 
cell lysates. This could be due to the anti-His antibody used to probe the membrane. Anti-His 
antibody recognizes the His repeat sequence which is very commonly found in a number of 
different organisms. The activity of proteins present in the culture medium was validated by 
evaluating the binding kinetics of mAb425 and C225 using SPR analysis and stable cell lines 
were produced following the procedure mentioned in the experimental procedures. Around 450ml 
of stable cultures were allowed to proliferate in a shaker flask at 25ºC. Once the cells reached a 
density of ~8 x 106 cells/ml, protein expression was induced by adding CuSO4 (700M final 
concentration). After 3 days of induction, cells were pelleted by centrifugation at 10,000 x g and 
supernatant was purified using HisTrap column followed by the affinity purification using 
Matuzumab immobilized column. Figure C.4 shows the chromatograms of different purification 
steps of sEGFR purification. Purified samples were later analyzed for purity using SDS-PAGE. 
Figure C.5 shows the SDS-PAGE of purified protein samples from two different batches. 
Purified sEGFR was more than 95% pure. Protein concentrations were calculated by measuring 
the absorbance at 280nm and stock solutions of around 14M was stored in the freezer (-20ºC) 
for further studies. The protein yields from two different batches were around 2mg/lt of cell 
culture. 
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Figure C.3  Western blot analysis to study levels of protein expression by transfecting cells 
with different amounts of DNA. 
S2 cells were transfected with different amounts of DNA followed by induction of protein 
expression. After 48hr of induction, small volumes of culture medium were collected every 
day and the levels of protein expression was analyzed using western blot (A). After 4 days of 
induction, cells were lysed and protein levels inside the cells were also evaluated using 
western blot (B). Transfection with empty V5-vector was used as control. No expression of 
protein was observed from the cells transfected with empty V5-vector.  
(B) 
(A) 
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Figure C.4  Chromatograms of sEGFR purification 
Cell supernatant was first His purified using HisTrap™ FF column (A) followed by affinity 
purification using Matuzumab immobilized column (B, C) 
(A) 
(B) 
(C) 
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Figure C.5  SDS-PAGE showing purified sEGFR samples 
The purified samples obtained from the chromatograms shown in Figure C.4 (B, C) were run 
in gel (A). SDS-PAGE of purified protein sample shows a single thick band near 80kD 
molecular weight suggesting that sEGFR-V5 protein (MW = ~76kD) is more than 95% pure. 
Figure shows purified sEGFR samples obtained from two different batches of protein 
production (A) and (B).  
(A) 
(B) 
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C.2.2  Papain digestion of IgG molecules 
 Papain is a nonspecific, thiol-endopeptidase isolated from papaya latex. It has sulfhydryl 
group in the active site that needs to be reduced for its activity. When IgG molecules are 
incubated with papain in the presence of cysteine, peptide bonds near the hinge region gets 
broken, resulting in three fragments of similar molecular weight – two Fab fragments and one Fc 
fragment. In order to avoid protease contamination, ease of separation, and controlled digestion of 
IgG molecules, use of papain has been replaced by papain immobilized to agarose beads. But 
since papain non-specifically digests IgG molecules, optimization of experimental conditions is 
extremely critical to digest mAbs with high yield. In order to achieve this, a pilot experiment was 
performed wherein 100l of mAbs (2mg/ml) were incubated with 50l of immobilized papain 
that has been pre-washed with the digestion buffer. Digestion reaction was allowed to continue at 
two different temperatures – 37ºC and 25ºC for different time periods. Since we had limited 
resources of mAb425, we had to restrain the pilot study to only few conditions, unlike the 
extensive study performed for C225. Tubes were vigorously shaken during the entire incubation 
period. Digestion efficiency was then studied by running a SDS-PAGE (Figure C.6). Papain 
digestion was found to be more efficient at higher temperatures compared to 25ºC. However 
incubation of both mAb425 and C225 for 24hr at 25ºC was able to achieve almost complete 
digestion, as observed at 37ºC. In order to avoid the possible inactivity of protein caused due to 
longer incubation time at elevated temperatures (37ºC), 24hr digestion at 25ºC was selected to 
produce Fab fragments of mAb425 and C225. 
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Figure C.6  SDS-PAGE analysis to check Papain digestion of C225 and mAb425 
Immobilized papain was incubated with C225 (A) or mAb425 (B) for different time points 
and the digestion was analyzed on SDS-PAGE. 
(A) 
(B) 
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Matuzumab (EMD72000) is a humanized mAb derived from its murine pre-cursor mAb425 
(Kim, 2004) and was obtained from Merck, KgGA, Darmstadt, Germany. Since mAb425 is a 
murine mAb, clinical trials showed that administration of mAb425 resulted in high levels of 
human anti-mouse antibody (HAMA) response. So in order to improve safety and efficacy of this 
drug candidate, Matuzumab was developed by grafting the CDR region of mAb425 into a human 
IgG1 framework. Since the CDR region gives specificity to IgG molecules, such grafting would 
not affect the antigenic properties of the mAb. As the framework of the constant region of C225 
is also human, similar to Matuzumab, especially at the site of papain digestion, it was assumed 
that the kinetics of Matuzumab digestion would be similar to those observed for C225. mAbs at 
2mg/ml concentration were allowed to shake vigorously by mixing them with immobilized 
papain for 24hr at 25ºC. Immobilized papain was separated by pushing the digested mix through 
0.2m filter. After 24hr dialysis of digested mix in PBS, Fab fragments were separated using a 
protein A column. Figure C.7 represents the chromatograms of the purification of Fab fragments 
of C225 (Figure C.7 A) and Matuzumab (Figure C.7 B). Since the Fc region of the IgG molecule 
binds to protein A with very high affinity, the desired Fab fragments would be present in the 
flow-through fraction. The partially digested or undigested protein bound to the column was then 
eluded in 0.2M citric acid-NaOH, pH 3. The purity of the Fab fragments was checked by running 
a SDS-PAGE (Figure C.7 C). A thick protein band at molecular weight of around 160 kD was 
observed in the elution fraction, suggesting that significant amount of protein was not digested. 
Though the digestion reaction was optimized for C225, the efficiency of papain digestion of 
larger amounts of proteins was significantly reduced. There could possibly be a number of 
reasons for such discrepancy. One of the possible reasons could be larger reaction volumes. 
Optimization of papain digestion was performed in smaller volumes of 150 l as opposed to ~10 
ml volume for larger scale production. It is known that for higher papain activity, immobilized 
beads need to continuously interact with IgG molecules. Such interaction- would be greater in 
lower volumes, since there are reduced water currents in the sample compared to larger sample 
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volumes. Also, at the end of the digestion, it was observed that lots of agarose beads settled on 
the walls of the tube. This would result in reduced immobilized papain in the reaction mix, 
leading to decreased digestion efficiency. After running the flow-through sample into the SDS-
PAGE, the gel showed higher molecular weight bands of Matuzumab and C225. These bands 
could possibly be the undigested or partially digested IgG molecules that did not bind to the 
protein A column. Though this band corresponded to only a small percentage of total proteins, the 
flow-through sample was re-purified as we wanted Fab samples with very high purity (>95%). 
Therefore, the flow-through samples were again passed through the protein A column and purity 
was validated again using SDS-PAGE (Figure C.7 D). This second purification step yielded Fab 
fragments with more than 95% purity. The Fab fragments were either kept in the refrigerator (for 
immediate use) or stored at -20ºC for future studies. 
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Figure C.7  Purification of Fab fragments of C225 and Matuzumab using protein A column 
Chromatograms of purification of papain digested Matuzumab (A) and C225 (B). SDS-PAGE 
shows that the flow through fraction containing Fab fragments of Matuzumab has some higher 
molecular weight proteins (C). The purified Fab fragments were re-purified using protein A 
column and the SDS-PAGE (D) demonstrates that the Fab fragments are more than 95% pure.  
(B)
(C) 
(A) 
(D)
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APPENDIX D 
EGFR TRAFFICKING MEDIATED BY mAb425, C225 AND THEIR 
COMBINATION 
D.1  INTRODUCTION 
 Ligand mediated EGFR trafficking is now a well studied phenomenon. It is known that 
binding of EGF or TGF- to EGFR results in rapid internalization of cell surface receptors via 
endocytosis. However it was observed that there is a difference in EGFR trafficking following the 
binding of TGF- and EGF (Decker, 1990; Ebner and Derynck, 1991; Masui et al., 1993). 
Binding of TGF- to the cell surface receptors results in receptor recycling whereas EGF binding 
directs the receptor towards late endosomes and lysosomes for degradation. It was later found that 
unlike EGF, TGF- dissociates from TGF--EGFR complex at the pH present in early endosomal 
compartments. This dissociation results in the fusion of the early endosomal vesicles into the 
recycling vesicles and directs it towards the cell membrane, thus escaping from the EGFR 
degradation pathway. It is now believed that the fate of the endocytotic EGFR depends on the 
stability of ligand-receptor complex. In this appendix, we would demonstrate that treating the 
cells with mAb425, C225 or their combination results in distinct trafficking of EGFR in cells. 
Confocal images of fixed cells and live cells are presented here to demonstrate the difference in 
sorting of internalized receptors from the endosomal compartments. 
D.2  MATERIALS AND METHODS 
D.2.1  Cells and reagents 
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Stably transfected A431 cells expressing EGFR-EGFP were generously provided by Dr. 
Donna Arndt-Jovin, Max Planck Institute for Biophysical Chemistry, Germany. Alexafluor 
conjugation kits were purchased from Invitrogen and mAbs were labeled following the 
company’s protocol. 
D.2.2  Immunofluorescence and confocal imaging 
 In a 4-well chamber microslide, around 20,000 MDA-MB-468 cells were seeded (400l) 
and the cells were allowed to grow for 48hr. After overnight incubation in starvation medium 
(DMEM containing 0.2% BSA), cells were pulsed by incubating with labeled mAbs on ice for 
1hr. After 3xPBS washes, fresh warm medium without any mAb was added and the cells were 
incubated at 37ºC for different time periods. During the pulse and chase incubations, starvation 
medium was supplemented with 10mM HEPES buffer. After fixing the cells with freshly 
prepared 1% PFA, surface receptors were stained with Alexafluor488 conjugated EGF. The 
samples were mounted in the VectaShield mounting medium with DAPI (Vector Inc) and then 
imaged using TCS SP2 Leica Laser Scanning Spectral Confocal Microscope.  
D.2.3  Live cell confocal imaging 
 In a 35 mm, glass-bottomed Petri dish (Matek), around 10,000 A431 cells expressing 
EGFR-EGFP were seeded and grown for 48hr. After three washes with Tyrode buffer (10mM 
Hepes, 12mM NaHCO3, 137mM NaCl, 2.7mM KCl, 5 mM glucose, pH 7.4), ice-cold solution 
containing 100nM of labeled mAb (single and in combination) was added and cells were 
incubated on ice for 1hr. Excess of unbound mAb was removed by 3x washes of ice-cold Tyrode 
buffer. Fresh warm Tyrode buffer was added and the cells were imaged. Temperature was 
maintained at around 30ºC during the entire experiment. 
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 Confocal laser scanning microscopy was performed with Olympus FluoView™ FV1000 
inverted microscope using 100x 1.2 NA oil immersion objective. The excitation lasers used for 
GFP, Alexafluor594 and Alexafluor660 were 488nm, 543nm and 635nm respectively. To 
eliminate crosstalk between different channels, images were collected by exciting individual 
fluorophores and sequentially scanning individual channels using the filter sets BA505-525, 
BA560-620 and BA655-755 for GFP, Alexafluor594 and Alexafluor660 respectively. The gain, 
offset, and accumulation time for individual channels were varied depending on the sample to 
obtain optimal fluorescent images with high signal to noise ratio. 
D.3  RESULTS AND DISCUSSION 
D.3.1  Distinct EGFR trafficking in cells treated with mAb425/C225 combination 
  The results of EGFR downregulation showed that mAb425/C225 combination exhibited 
a much faster and greater internalization of EGFR than individual mAbs. Moreover, it was 
interesting to observe that though the initial rate of EGFR internalization for C225 and mAb 
combination was almost the same, EGFR internalization was significantly reduced for C225 after 
30min. So, we wanted to check whether this difference in the kinetics of EGFR downregulation is 
the result of difference in receptor trafficking, especially in receptor recycling.  
Exponentially growing MDA-MB-468 cells were serum starved overnight followed by 
pulsing them on ice for 1hr with 100nM concentration of Alexafluor660 conjugated mAb425, 
Alexafluor594 conjugated C225 or their combination. Unbound mAbs were removed and the 
cells were chased at 37ºC for either 30min (Figure D.1) or 60min (Figure D.2). After indicated 
time points, cells were fixed using 1% PFA and cell surface EGFR was stained using 
Alexafluor488 conjugated EGF. Mounted cells were then imaged using a fluorescent confocal 
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microscope. After incubation with C225 for 30min, large numbers of EGFR containing vesicles 
were observed on the cell surface (Figure D.1, arrow heads). Incubation with mAb425 resulted in 
reduced number of membrane associated vesicles that were labeled for EGFR (Figure D.1, arrow 
heads). In contrast to individual mAbs, very limited number of membrane associated vesicles 
containing EGFR was found for the mAb combination. Staining for the cell surface receptors for 
the cells incubated with mAb425 was found to be much brighter than C225 or mAb combination. 
Moreover, the overlay image shows a greater degree of co-location of EGFR and mAb425. Please 
note that since Alexaflour488 conjugated EGF was used for staining surface receptors, only 
unbound EGFR would be stained. High levels of co-localization of mAb425 and EGFR stains 
indicates that 30 min incubation with mAb425 leaves a significantly population of receptors 
unliganded. Such co-localization however, is not observed for C225and mAb combination. The 
insets in Figure D.1 represent the high magnification overlay image of the correspondingly 
numbered area in the white box. Minimal co-localization of labeled mAbs (neither single nor 
combination) was observed with the receptors present in the vesicles. 
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Figure D.1  Confocal images showing EGFR recycling after 30min. 
Cells were incubated with Alexa conjugated mAbs for 1 hr on ice. Unbound mAbs were 
washed out and the bound mAbs were chased for 30min. Following cell fixation, surface 
EGFR was labeled with Alexafluor488 conjugated EGF. 
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Figure D.2  Confocal images showing mAb mediated EGFR downregulation after 60min. 
Cells were incubated with Alexa conjugated mAbs for 1 hr on ice. Unbound mAbs were 
washed out and the bound mAbs were chased for 60min. Following cell fixation, surface 
EGFR was labeled with Alexafluor488 conjugated EGF. 
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Continued chasing for another 30min (total 60min) led to the complete removal of 
membrane associated vesicles containing EGFR (Figure D.2). Consistent with the previous 
observation, surface EGFR was stained brighter for mAb425. Larger vesicles containing labeled 
mAbs were observed for mAb425 and C225. Most of these aggregates appear to be membrane 
bound, but this observation needs to be further validated by staining the cell membrane and 
studying the colocalization with labeled mAbs. In the case of the mAb combination on the other 
hand, the EGFR complexes were present in much smaller aggregates which looks more like 
endosomal and lysosomal compartments. Both mAb425 and C225 largely co-localized with 
surface EGFR stains, but reduced degree of co-localization in the case of mAb combination was 
observed. 
 EGFR downregulation data (Figure 6.2) showed that binding of mAb to cell surface 
receptors results in receptor internalization. The rate of internalization in the first 30min is slower 
for mAb425, but rapid for C225 and combination. After 30min of incubation, the rate of C225 
mediated EGFR downregulation is significantly reduced, in contrast to the continually high 
downregulation for mAb combination. Based on the data presented, it could be inferred that the 
large number of membrane associated vesicles observed in Figure D.1 could possibly be 
recycling endosomes that lack bound ligands. Efficient receptor recycling of internalized C225 
has also been previously reported (Jaramillo et al., 2006) and is consistent with our 
interpretation. Once the receptor-mAb complexes are internalized, mAbs might dissociate from 
the complex in the early endosome. Disruption of the mAb-EGFR complex might result in the 
fusion of the endocytotic vesicle into a recycling compartment, a phenomenon previously 
reported for EGF and TGF- (Decker, 1990; Ebner and Derynck, 1991; Masui et al., 1993). 
Recycling endosomes containing unliganded EGFR would then traverse back to the cell 
membrane and be observed as vesicles containing unliganded EGFR. Such receptor recycling is 
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more prominently seen in the case of C225 compared to mAb425. In contrast, mAb combination 
results in minimal recycling, thus exhibiting continuously high rate of EGFR downregulation.  
D.3.2  Dynamics of mAb mediated EGFR trafficking using live cell confocal imaging 
 Most of the above interpretations were based on confocal images of fixed cells. Though 
they provide some glimpses about receptor trafficking, there is a great possibility that the washing 
steps along with cell fixation using ice-cold 1% PFA might perturb the dynamics of receptor 
movement and introduce some unwanted artifacts in the observation. We therefore moved on to 
study mAb mediated EGFR trafficking in live cells using an inverted confocal microscope. A431 
cells stably transfected to express sEGFR-EGFP (a generous gift from Dr. Donna Arndt-Jovin, 
Max Planck Institute for Biophysical Chemistry, Germany) were used. Cells were first incubated 
with 100nM of labeled mAb – Alexafluor594 conjugated C225 and/or Alexafluor660 conjugated 
mAb425 for 1hr on ice. Unbound mAbs were washed three times with chilled Tyrode buffer. 
Fresh, warm buffer without any mAb was added and the cells were imaged on an inverted 
Olympus FV1000 confocal microscope. A number of different dynamic cellular processes were 
monitored and compared for cells treated with single mAb and mAb425/C225 combination.  
D.3.2.1  EGFR trafficking mediated by C225 
 The initial dynamics of C225 mediated EGFR trafficking are represented in the confocal 
images shown in Figure D.3. In the figure, C225 is pseudo colored red while EGFR-EGFP is 
pseudo colored green. Incubation of cells with C225 resulted in rapid clustering of the receptor 
(Figure D.3). Within 5min, large clusters of receptors were found to be colocalized with C225 on 
the cell membrane (Figure D.3, 1min – 5min). Receptor clustering was immediately followed by 
fast internalization of C225-sEGFR complex and the colocalization of C225 and the receptor was 
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observed to be localized inside the cell (Figure D.3, 10-14 min). During the entire process of 
endocytosis, extensive membrane ruffling was observed indicating that this process is mediated 
by the pathways that are connected to the cytoskeleton. Demonstration of rapid internalization by 
C225 during the first 30min of incubation also matched with the EGFR downregulation studies 
performed earlier (Figure 6.2).  
 C225 mediated receptor internalization was found to be very dynamic in both space and 
time. C225 localized in the endocytotic vesicles were observed to follow Brownian motion, 
which could possibly be mediated by microtubule associated motor proteins, a phenomenon that 
is commonly observed and reported for EGF mediated receptor trafficking (Lidke et al., 2004). 
However, in contrast to EGF, C225 mediated trafficking showed continuous escape of the mAb 
from the vesicular compartments, resulting in recycling of mAb molecules (Figure D.4). 
Recycling of C225 was generally observed after around 45min of incubation. The insets shown in 
Figure D.4 clearly show sorting of C225 out of the endocytotic vesicle present inside the cell. 
The large vesicle having high degree of colocalization of C225 and EGFR was stationary during 
the entire time frame shown in Figure D.4. At around 47min, a small vesicle (white arrow head) 
containing moved out of the large multivesicular body, which was immediately followed by 
another vesicle at 48min (white arrow head). It should be noted that both these vesicles contained 
labeled C225 and did not demonstrate high levels of colocalization with EGFR. These two 
vesicles fused together at 50min and continued to travel away from the multivesicular body. In 
the mean time, few other vesicles started escaping from the multivesicular body (white arrow and 
red arrow heads) towards the cell membrane. These results show that C225 binding to the cell 
surface receptors results in rapid internalization, followed by recycling of the endocytosed mAb 
back to the cell surface. 
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Figure D.3  Live cell confocal images showing C225 mediated endocytosis. 
C225 and EGFR are pseudo colored red and green respectively. A detailed explanation of the 
confocal images is provided in the body of the thesis. 
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Figure D.4  Live cell confocal images showing EGFR recycling by C225. 
C225 and EGFR are pseudo colored red and green respectively. 
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D.3.2.2  EGFR trafficking mediated by mAb425 
 In contrast to rapid clustering and internalization observed for C225, mAb425 failed to 
induce endocytosis. EGFR expressed on the cell membrane (C, pseudo colored in green) were 
uniformly labeled with mAb425 (Figure D.5, pseudo colored in red) and high levels of 
colocalization between EGFR and mAb425 was observed. However, as opposed to receptor 
clustering seen in the case of C225, no noticeably large clusters of EGFR-mAb425 complexes 
were observed on the cell membrane. Incubation of cells with mAb425 however, induced raffling 
of the cell membrane. Apart from its failure to undergo rapid internalization, we observed a 
continuous movement of mAb425 out of the cell, suggesting that binding of mAb425 to the cell 
surface receptor results in rapid recycling. The insets in Figure D.6 showing the image sequence 
of single filopodia demonstrate the migration of mAb425 away from the cell body (white arrow 
head). A small particle containing mAb425 highlighted with white arrow head at 18min (Figure 
D.6) was transported away from the cell body (Figure D.6, 19min) which was followed by two 
more particles (white arrow head) on their way outside the cell. Similar recycling of C225 was 
observed, but the route was from endocytotic compartments to the cell membrane and finally 
outside the cell through the filopodia. 
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Figure D.5  Live cell confocal images showing mAb425 mediated EGFR trafficking. 
mAb425 and EGFR are pseudo colored red and green respectively. 
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Figure D.6  Live cell confocal images showing EGFR recycling by mAb425. 
mAb425 and EGFR are pseudo colored red and green respectively. 
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D.3.2.3  EGFR trafficking mediated by mAb425/C225 combination 
 Receptor movement following the incubation with mAb425/C225 combination was 
found to be completely different from individual mAbs. Initial dynamics of EGFR movement – 
rapid clustering and receptor endocytosis, were similar to that observed for C225. However, the 
mAb425/C225 combination exhibited continuous vesicular fusion of early endosomes instead of 
recycling as observed for C225 (Figure D.7). Cells were imaged 30min after the addition of 
warm Tyrode buffer. Vesicles stained as white represent colocalization of EGFR-EGFP (pseudo 
colored in green), C225 (pseudo colored in blue) and mAb425 (pseudo colored in red). Vesicles 
stained as magenta represent colocalization of C225 and EGFR, while those stained as cyan 
indicates mAb425-EGFR colocalization. The sequence of confocal images clearly show that 
majority of the vesicles are stained white. These vesicles are also larger in size compared to other 
vesicles stained as magenta or cyan, suggesting that these vesicles might have gone through 
multiple rounds of endosomal fusion. A large number of smaller sized vesicles stained as 
magenta were also observed. On the other hand, the cell membrane was found to be stained as 
cyan indicating that most of the mAb425 bound receptors were localized on the cell membrane. 
The insets shown in the figure shows the fusion of endocytotic vesicles (white arrows). The white 
arrows present in the inset of second panel (24min – 26min) highlight two different vesicles that 
got fused together within 2 minutes. The lower panel (27min – 30min) shows the movement of 
vesicles (yellow arrow) and their fusion with other vesicles. No significant amount of recycling 
was observed for mAb425/C225 combination compared to individual mAbs. 
 Though the results of live cell imaging presented so far clearly demonstrate the difference 
in EGFR trafficking mediated by mAb425, C225 and their combination, an extensive study of 
receptor sorting and route of mAb mediated endocytosis needs to be performed to further validate 
the observations. 
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Figure D.7  Live cell confocal images showing endocytotic vesicular fusion for 
mAb425/C225 combination. 
mAb425, C225 and EGFR are pseudo colored red, blue and green respectively. 
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APPENDIX E 
TESTING THE MODEL USING COMBINATION OF DIFFERENT 
MONOCLONAL ANTIBODIES TARGETING EGFR 
E.1  INTRODUCTION 
 The data presented till now showed that the combination of mAb425 and C225 
synergistically inhibits growth and EGF dependent downstream signaling. During the course of 
the study, two distinct mechanisms of synergy have been demonstrated – (i) efficient inhibition of 
EGF binding and (ii) faster EGFR downregulation by mAb425/C225 combination. These 
observations were instrumental towards the development of the model on the design of novel 
biologic drugs presented in Chapter 7. We wanted to further validate this model and check 
whether similar synergistic behavior is observed in any other combinations of EGFR targeting 
mAbs. 
 Apart from the 10-fold difference in the binding affinities, one of the most important 
features of the pair of mAb425 and C225 was that they have distinct binding epitopes. Both the 
mAbs simultaneously bind to the receptor without interfering with their inherent EGFR binding 
properties. So the third mAb that is a clinically relevant therapeutic drug and does not satisfy at 
least one of the above conditions would be required to test the model. In pursuit of such a 
candidate, we were found that Panitumumab (Vectibix™/ABX-EGF, Amgen, Inc) fits into our 
criteria. Panitumumab is FDA approved for the treatment of patients with EGFR expressing 
metastatic colorectal carcinoma with disease progression on or following fluoropyrimidine-, 
oxaliplatin-, and irinotecan-containing chemotherapy regimens (Giusti et al., 2008; Giusti et al., 
2007). Panitumumab binds to EGFR ectodomain and is known to inhibit EGF binding, thus 
preventing ligand induced receptor autophosphorylation and activation of receptor associated 
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kinases, resulting in inhibition of cell growth. Non-clinical studies show that Panitumumab 
exhibits a wide range of mechanisms of action that would inhibit tumor progression, similar to 
those observed in the case of C225 – (i) induction of apoptosis, (ii) decreased pro-inflammatory 
cytokine and vascular growth factor production, and (iii) internalization of EGFR (Mendelsohn 
and Baselga, 2000; Zhu, 2007). This chapter focuses on characterization of the binding 
interaction of Panitumumab; as performed in Chapter 2 and Chapter 3. Any change in its 
efficacy in inhibiting the growth of A431 cells after combining it with mAb425 and C225 would 
be investigated and the model presented in Chapter 4 and Chapter 5 would be validated. 
E.2  RESULTS AND DISCUSSION 
E.2.1  SPR Analysis to Study Panitumumab Binding Kinetics 
 The real time sensorgram of sEGFR binding to immobilized Panitumumab shown in 
Figure E.1 A-C (black) was fit to a 1:1 binding model and the fitted data was plotted in red. For 
comparison of the binding characteristics, sensorgrams for sEGFR binding to C225 (Figure E.1 
D-F) and mAb425 (Figure E.1 G-I) are also shown. The average values of the calculated kinetic 
parameters obtained from three independent experiments are tabulated in Table E.1. Kinetic 
parameters of sEGFR binding to mAb425 and C225, previously obtained are also provided for 
comparison. Panitumumab was found to bind to sEGFR with ~30-fold higher affinity than 
mAb425, in contrast to ~15-fold higher affinity for C225 binding. Once bound to sEGFR, 
Panitumumab dissociates almost 4-fold slower than C225. However, Panitumumab has a 
comparatively slower association rate and binds to sEGFR almost two times slower than C225; 
thus exhibiting almost 2-times higher sEGFR binding affinity than C225. 
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Figure E.1  Comparing the sensorgrams of mAb binding to sEGFR 
The real time sensorgrams (black) of sEGFR binding to Panitumumab (A-C), C225 (D-F) and 
mAb425 (G-I) are shown. The kinetic fits of the sensorgram using 1:1 binding model with mass 
transport limitation are shown in red. 
(A) (B) 
(G) 
(C) 
(D) (E) (F) 
(H) (I) 
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E.2.2  Effect of Temperature on Panitumumab Binding 
 The binding of sEGFR to immobilized Panitumumab at different temperatures are shown 
in Figure E.2. It was observed that temperature did not significantly affect the binding 
characteristics of Panitumumab as previously observed for mAb425 and C225 (Figure 2.16 A, 
Figure 2.16 B). Till 25ºC, no significant change in the binding of Panitumumab was observed, 
unlike mAb425 and C225. The gradual increase in kon for Panitumumab was found to similar to 
that seen for mAb425 and C225. The major difference in the binding characteristic for these 
mAbs is that Panitumumab-sEGFR complex is the most stable complex among the three mAbs. 
Compared to only 500% increase in the value of koff for Panitumumab (with respect to the koff at 
5ºC), more than 1000% and 1500% increase was observed for C225 and mAb425 respectively. 
Overall, these results demonstrate that Panitumumab binds to sEGFR more tightly than C225 and 
mAb425 and at physiological temperature; the complex of sEGFR with Panitumumab is the most 
stable complex compared to C225-sEGFR and mAb425-sEGFR complexes. 
 
mAb ka (1/Ms) kd (1/s) KD (nM) 
mAb425 (6.05 ± 0.25) E+05 (7.93 ± 0.16) E-03 13.1 ± 0.04 
C225 (8.81 ± 0.31) E+05 (7.44 ± 0.09) E-04 0.85 ± 0.02 
Panitumumab (3.42 ± 0.32) E+05 (1.44 ± 0.06) E-04 0.43 ± 0.4 
 
Table E.1  Comparison of mAb binding kinetic parameters. 
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Figure E.2  Comparison on the stability of mAb-sEGFR complex between mAb425, C225 
and Panitumumab 
The real time sensorgrams of sEGFR binding to Panitumumab (A), mAb425 (B) and C225 (C) 
at different temperatures are shown. Change in the values of kon (D), koff (E) and KD (F) of 
Panitumumab are compared with mAb425 and C225. Panitumumab-sEGFR complex was 
found to be most stable at physiological temperature. 
(A) (B) 
(C) (D) 
(E) (F) 
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E.2.3  Thermodynamics studies of mAbs 
 Thermodynamic properties of Panitumumab-sEGFR interaction was determined using 
SPR analysis as obtained for mAb425 and C225. Equilibrium dissociation constants determined 
at different temperatures were used to obtain the thermodynamic parameters by plotting ln(KD) 
versus 1/T. For direct comparison, the graph for Panitumumab is plotted with those previously 
obtained for mAb425 and C225 (Figure E.3). Similar to mAb425 and C225, within the 
temperature range relevant for this study, a linear relation between ln(KD) and 1/T was obtained 
for Panitumumab. This suggests that both the changes in enthalpy and entropy are not affected by 
temperature. So the van’t Hoff analysis model was adopted to determine the values of H and 
S. The plots were fit using the non- integrated form of the van’t Hoff equation and the values of 
G, H and S calculated are provided in Table E.2 and plotted in Figure E.3 B. There is no 
significant difference in the free energy of the interaction between C225 and Panitumumab. Both 
the mAbs are more favorable for sEGFR binding than mAb425. However, the enthalpy of 
interaction for Panitumumab is less favorable compared to mAb425 and C225. Surprisingly, the 
lower value of enthalpy observed in the case of Panitumumab seems to be compensated by the 
significantly lower level of entropy; which makes its interaction more favorable towards sEGFR 
binding. However, this would need further validation using ITC which is more universally 
accepted technique to evaluate the thermodynamics of interaction. 
AppendixE
 
214 
 
 
 
 
 
 
Figure E.3 Thermodynamic studies of mAb425, C225 and Panitumumab 
The Van’t Hoff graph shown above in (A) was graphed by plotting the values of the binding 
kinetics (KD) calculated at different temperatures against the inverse of temperature. Values of 
the change in enthalpy (H) and the change in entropy (S) obtained from the Van’t Hoff plot 
are shown in (B). 
(A) 
(B) 
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E.2.4  mAb Binding Competition Studies 
 Since we observed that Panitumumab exhibits different EGFR binding properties 
compared to mAb425 and C225, we wanted to check whether Panitumumab competes with 
mAb425 or C225. mAb binding competition studies were performed as done previously in 
Chapter 3. MDA-MB-468 cells were incubated on ice for 30min in a premix of labeled and 
unlabeled mAbs and the amount of labeled mAb bound to the cell surface receptors was 
measured using flow cytometry and plotted as percent binding of labeled mAb (Figure E.4 A-C). 
The results of mAb425-C225 binding competition studies were found to be consistent with those 
previously reported in Chapter 3. Neither mAb25 nor C225 compete with each other for binding 
to cell surface receptors. Panitumumab was found to compete with the binding of C225 and 
decreased binding of labeled C225 (Figure E.4 B) and labeled Panitumumab (Figure E.4 C) was 
observed in the presence of C225 and Panitumumab. In contrast to the results observed for 
binding competition between mAb425-C225 and C225-Panitumumab, it was intriguing to find 
that mAb425-Panitumumab binding competition follow a different pattern. Binding of labeled 
mAb425 was significantly reduced in the presence of unlabeled Panitumumab (Figure E.4 A) 
Antibody G (kcal/mol) H (kcal/mol) -TS (kcal/mol)
mAb425 -9.66 -13.70 4.04 
C225 -11.33 -12.31 0.98 
Panitumumab -11.88 -7.64 -14.23 
 
Table E.2  Values of thermodynamic parameters of mAb binding to sEGFR 
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while no inhibition in the binding of labeled Panitumumab was observed in the presence of 
unlabeled mAb425. 
 Crystal structure of the Fab fragments of mAb425 and C225 bound to sEGFR showed 
that mAb binding does not induce any change in the intradomain conformation of the receptor. 
However, such information is not available for Panitumumab. The results of mAb425-
Panitumumab binding competition studies presented above raises the possibility that 
Panitumumab binding could induce some structural alterations in the receptor, resulting in a much 
faster dissociation of mAb425. So in order to enhance our understanding and further explore the 
competitive behavior between mAb425 and Panitumumab, cells were first incubated with 
different concentrations of unlabeled mAb and then fixed with freshly prepared 1% PFA. Fixed 
cells were then incubated with labeled mAb and the fluorescence measured using flow cytometry 
was plotted as shown in Figure E.4 D-F. The results of binding competition between mAb425-
C225 and C225-Panitumumab following this protocol (Figure E.4 D, Figure E.4 E) were found 
to be similar to that observed without cell fixation. No competition was observed between 
mAb425 and C225, while C225 and Panitumumab competed for binding to EGFR. However, an 
order dependent inhibition of Panitumumab was observed. Binding of Panitumumab first 
completely blocked the binding of mAb425 (Figure E.4 D). In contrast, binding of mAb425 
inhibited Panitumumab binding by around 30% (Figure E.4 F). Thus it seems that binding 
competition between mAb425 and Panitumumab is dependent on the sequence of mAb addition. 
Binding of Panitumumab to cell surface receptors first, completely blocks mAb425 binding 
(Figure E.4 D). However, in the other set-up, Panitumumab continues to recognize most of the 
sEGFR-mAb425 complexes and its binding is inhibited by only 30% (Figure E.4 F). This 
sequence dependent competition between mAb425-Panitumumab was also reported previously by 
Dechant et al. (Dechant et al., 2008). 
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Figure E.4  mAb binding competition studies using flow cytometry 
MDA-MB-468 cells were incubated for 30min either in a premix of unlabeled and labeled 
mAbs (A-C) or incubated with unlabeled mAbs first, followed by the fixation with 1% PFA 
and then further incubation for 30min with labeled mAb (D-F). The fluorescence of labeled 
mAb bound to the cell surface was then measured using flow cytometry and the amount of 
bound mAb425 (A,D), C225 (B,E) and Panitumumab (C,F) is plotted. 
(A) 
(B) 
(C) 
(D) 
(E) 
(F) 
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Figure E.5  mAb binding competition studies using SPR analysis  
C225 (A-C), Panitumumab (D, E) or mAb425 (F) were immobilized on a CM5 sensor chip. 
sEGFR was captured using immobilized mAbs followed by the injection of different 
concentrations of Panitumumab (C, F), C225 (A, D) or mAb425 (B, E) as analyte for the 
captured sEGFR ligand. The real time sensorgrams are shown. 
(A) (B) 
(C) (D) 
(E) (F) 
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 Though it was intriguing to find that the binding inhibition between mAb425 and 
Panitumumab depends on the sequence of addition of mAbs, the molecular mechanism of 
mAb425 binding inhibition by Panitumumab continued to remain a mystery. So we wanted to 
investigate the mode of binding inhibition between this pair. SPR binding competition studies 
were performed using pure recombinant proteins. A CM5 chip immobilized with mAb425, C225 
and Panitumumab was used to capture sEGFR. Different concentrations of mAb425, C225 or 
Panitumumab were then injected as analyte for the captured sEGFR ligand. The real time 
sensorgram of mAb binding at indicated concentrations is shown in Figure E.5. As expected, 
C225 failed to interact with sEGFR-C225 complex (Figure E.5 A), showing a representative 
sensorgram for a competitive mAbs. As observed earlier, mAb425 was able to recognize sEGFR-
C225 complex (Figure E.5 B). Neither C225 nor Panitumumab were able to bind to the 
complexes of sEGFR-Panitumumab (Figure E.5 D) and sEGFR-C225 (Figure E.5 C) 
respectively. The real time sensorgrams of the binding competition between C225 and 
Panitumumab looked similar to that observed for competitive mAbs suggesting that the binding 
epitopes of C225 and Panitumumab might overlap. However, we cannot neglect the possibility 
that these mAb pair could be allosteric inhibitor and that binding of sEGFR to either C225 or 
Panitumumab might change receptor conformation and thus inhibit the binding of another mAb. 
But this possibility is less likely to occur as C225 binding does not induce any conformational 
change in the receptor (Li et al., 2005). mAb425 failed to interact with Panitumumab-sEGFR 
complex (Figure E.5 E). In contrast, Panitumumab injection resulted in increased dissociation of 
sEGFR from mAb425-sEGFR complex, in a concentration dependent manner (Figure E.5 F).  
 The results presented above on mAb binding competition using flow cytometry and SPR 
showed that C225 competes with Panitumumab irrespective of the sequence of addition as 
opposed to the sequence dependent competition observed between mAb425 and Panitumumab. 
Though we do not have enough information regarding the conformational alterations of the 
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receptor following Panitumumab binding, we believe that Panitumumab-sEGFR interaction might 
involve more than one binding interaction step. We have previously demonstrated in Chapter 4 
that PFA fixation locks the receptor in its native conformation and that the binding of ligand to 
the receptor located on the surface of fixed cells would not be able to induce any change in 
receptor conformation. Incubation with PFA results in covalent linkage with exposed amino and 
imino groups (notably in lysine and arginine sidechains). So exposure of living cells to PFA 
following mAb incubation would crosslink the bound mAb to the cell surface receptors. The 
observation that binding of Panitumumab to mAb425-EGFR complex on fixed cells (Figure E.4 
F) was partially inhibited and the sensorgrams showing that injection of Panitumumab results in 
increase in the dissociation of sEGFR from its complex with mAb425 strongly supports our 
hypothesis regarding Panitumumab-sEGFR interaction. Based on these results we feel that 
Panitumumab is able to recognize most of the mAb425 bound receptor conformations on the cell 
surface. Binding of Panitumumab induces some conformational changes in the receptor which is 
not conducive for mAb425 binding, thus resulting in increased dissociation of sEGFR (Figure 
E.5 F) in a concentration dependent manner. Though Panitumumab-sEGFR interaction requires 
further characterization, overall, our results on mAb binding competition performed using SPR 
were found to be consistent with those obtained using flow cytometer. 
E.2.5  Growth Inhibition Studies by Matuzumab, Cetuximab, Panitumumab and their 
Combination 
 After characterization of molecular interaction of Panitumumab, we tested its efficacy in 
inhibiting the growth of A431 cells either alone or with the combination of Matuzumab or C225. 
Experiment similar to that performed previously in Chapter 5 was done. Cells were incubated 
with different concentrations of Matuzumab, C225, Panitumumab or their respective 
combinations for 72hr and the metabolic activity of the cells was measured using WST-1 assay. 
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The percent growth inhibition of the cells was calculated and plotted (Figure E.6). Among 
individual mAbs, Panitumumab was found to be the best inhibitor of growth compared to both 
Matuzumab and C225. Surprisingly, all the mAb combinations were found to demonstrate 
enhanced inhibition of growth compared to individual mAbs. Matuzumab/C225 combination 
exhibited inferior growth inhibition compared to other combinations at lower concentrations (< 
10nM). But no significant difference in the efficacy was observed at higher concentrations. Both 
Matuzumab/Panitumumab and C225/Panitumumab combinations demonstrated similar inhibition 
of cell growth. However, it should be noted that Panitumumab on itself demonstrated a 
significantly high inhibition and at higher concentrations (>10nM) is comparable to that observed 
in its combination with Matuzumab and C225. These results collectively suggest that 
combination of non-competing mAbs is not required to achieve enhanced growth inhibition. 
Panitumumab along with its combination with competing mAb (C225) and partially competing 
mAb (Matuzumab/mAb425) were found to exhibit enhanced inhibition of A431 growth similar to 
that observed for Matuzumab/C225 combination. 
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E.2.6  EGF Binding Inhibition Studies – Single vs mAb Combination 
 The growth inhibition studies clearly showed that combination of non-competing mAbs 
is not necessary to obtain enhanced/synergistic growth inhibition. So we wanted to check whether 
these mAb combinations fit into any one of the two models developed in Chapter 5 and Chapter 
6. To achieve this, we first investigated the difference in EGF binding inhibition by Panitumumab 
 
Figure E.6  Growth inhibition of A431cells by Matuzumab, C225, Panitumumab and their 
respective combinations.  
A431 cells were treated with different concentrations of mAbs – single and in combination 
and the metabolic activity were measured after 72hr using WST-1 assay. The average values 
of growth inhibition from two independent experiments are plotted with ± S.E.M. 
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and its combination with C225 and mAb425 and compared it with those obtained for 
mAb25/C225 combination. Similar EGF binding inhibition experiments were performed and the 
results of EGF binding inhibition obtained at 37ºC (Figure E.7) and at 4ºC (Figure E.8) are 
plotted. The average values of percent FITC-EGF binding inhibition obtained at 100nM IgG 
concentration – single and in combination at two different temperatures are tabulated in Table 
5.1. The values of mAb concentration for 50% binding inhibition (IC50) were also calculated and 
the mean values from at least three independent experiments are listed in Table 5.1. Lower 
concentrations of Panitumumab were required to inhibit EGF binding and the IC50 value for 
Panitumumab was smaller compared to individual mAbs and mAb combinations. Among 
individual mAbs, C225 was found to be the best mAb that almost completely inhibits EGF 
binding, both at 37ºC and at 4ºC. Unlike mAb425/C225 combination, neither 
mAb425/Panitumumab combination nor C225/Panitumumab combination were able to achieve 
complete blockade of EGF binding at physiological temperature. In contrast, at 4ºC any 
combination of C225 – mAb425/C225 and Panitumumab/C225 almost completely blocked EGF 
binding.  
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Figure E.7  EGF binding inhibition by mAb425, C225, Panitumumab and their respective 
combinations at 37ºC. 
MDA-MB-468 cells were incubated with different concentrations of unlabeled mAbs – single 
(A) and in combination (C) for 1hr on ice. FITC-EGF (10nM) was added and the cells were 
incubated at 37ºC for 1hr. Amount of bound FITC-EGF was later measured using flow 
cytometry and the percent binding of FITC-EGF was calculated. The mean values from three 
independent experiments are plotted, ± S.E.M. The magnified view of the rectangular box in 
(A) and (C) is shown in (B) and (D) respectively. Only mAb425/C225 combination was able 
to achieve almost complete inhibition of EGF binding.  
  
(A) (C) 
(B) (D) 
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Figure E.8  EGF binding inhibition by mAb425, C225, Panitumumab and their respective 
combinations at 4ºC. 
MDA-MB-468 cells were incubated with different concentrations of unlabeled mAbs – single 
(A) and in combination (C) for 1hr on ice. FITC-EGF (10nM) was added and after further 
incubation for 1hr on ice, amount of bound FITC-EGF was measured using flow cytometry. 
The percent binding of FITC-EGF was calculated and the mean values obtained from three 
independent experiments are plotted, ± S.E.M. The magnified view of the rectangular box in 
(A) and (C) is shown in (B) and (D) respectively. At lower temperature, C225 and both of its 
combinations were found to almost completely abrogate EGF binding.  
(A) (C)
(B) (D)
AppendixE
 
226 
 
 
 FITC-EGF Binding Inhibition 
Antibody 37ºC 4ºC 
mAb425 86.81 ± 3.42 97.62 ± 0.13 
C225 95.34 ± 0.90 99.58 ± 0.45 
Panitumumab 94.79 ± 0.77 97.22 ± 0.59 
mAb425/C225 98.43 ± 0.78 99.83 ± 0.48 
mAb425/Panitumumab 95.32 ± 1.06 98.30 ± 0.28 
C225/Panitumumab 94.77 ± 0.64 99.08 ± 0.48 
 
Table E.3  Comparison of EGF binding inhibition at different temperatures by mAb425, 
C225, Panitumumab and their combinations. 
The mean values from at least three independent experiments at 100nM mAb concentration 
are provided, ± S.E.M. 
AppendixE
 
227 
 
 
 We had previously presented in Chapter 5 that since mAb425 does not directly compete 
with EGF, it fails to achieve 100% EGF binding inhibition even at 4ºC. But for a direct 
competitor like C225, 50nM was found to be sufficient for blocking EGF binding (Figure E.8 
B). The binding inhibition profile for Panitumumab was found to be similar to that of mAb425, 
which makes us believe the mode of EGF binding inhibition for Panitumumab might be similar to 
that of mAb425. The binding epitope of Panitumumab might probably be distinct from that of 
EGF and that Panitumumab binding might sterically inhibit EGFR to attain the active 
conformation which is required for EGF binding. In order to validate this hypothesis, further 
characterization Panitumumab-sEGFR interaction using ITC would be required and the binding 
epitope or the crystal structure of Panitumumab bound sEGFR would also need to be resolved. 
 IC50 (nM) 
Antibody 37ºC 4ºC 
mAb425 17.52 ± 3.65 14.50 ± 2.25 
C225 13.28 ± 2.06 11.57 ± 1.97 
Panitumumab 8.85 ± 1.00 7.90 ± 1.41 
mAb425/C225 20.93 ± 4.19 15.57 ± 3.51 
mAb425/Panitumumab 10.74 ± 1.48 10.25 ± 2.18 
C225/Panitumumab 9.37 ± 1.36 9.97 ± 1.58 
 
Table E.4  Values of IC50 for mAb425, C225, Panitumumab and their combinations. 
The mean values from at least three independent experiments are shown, ± S.E.M. 
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E.2.7  EGFR Downregulation Studies – Single vs mAb Combination 
 The mechanism of faster EGFR downregulation followed by mAb425/C225 combination 
to achieve synergistic growth inhibition of cancer cells was also tested for Panitumumab and its 
combinations with mAb425 and C225. Similar downregulation assay was performed. In short, 
MDA-MB-468 cells were incubated with 100nM of mAb (Single and combination) for indicated 
time points (Figure E.9). Surface receptor bound mAbs were acid-stripped followed by labeling 
the unbound receptor with Alexafluor488 conjugated C225. Labeled cells were analyzed using 
flow cytometry and then amount of cell surface receptors was plotted (Figure E.9). Among 
individual mAbs, receptor downregulation was slowest for mAb425. The kinetics of EGFR 
downregulation for C225 and Panitumumab were found to be similar – rapid initial 
downregulation in the first 30min which gradually decreases; resulting is slow and steady 
internalization.  Among mAb combinations, mAb425/C225 exhibited the fastest EGFR 
downregulation. No significant difference in the kinetics was observed for 
mAb425/Panitumumab and C225/Panitumumab combinations. The total amount of receptors 
expressed on cell surface after 10hr of incubation with different ligands is provided in Table E.5. 
After 10hr, except for mAb425 and mAb425/C225 combination, the amount of EGFR expressed 
on the cell surface ranged from 67-76%. Thus enhanced growth inhibition observed by 
Panitumumab combinations failed to synergize faster EGFR downregulation.  
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Figure E.9  Kinetics of mAb mediated EGFR downregulation – single vs combination. 
MDA-MB-468 cells were incubated with 100nM of individual mAbs (A), mAb combination 
(B) or 10ng/ml of EGF. At the indicated time points, ligands bound to cell surface receptors 
were acid-stripped and then stained using Alexafluor488 conjugated C225. The amount of cell 
surface receptors was later quantified using flow cytometry. 
(B) 
(A) 
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E.3  CONCLUSION 
 In this study, the two models developed in Chapter 5 and Chapter 6 were tested by 
including another EGFR targeting mAb, Panitumumab. Results presented in this chapter suggest 
that the two models that elucidate the mechanisms of synergy are specific only to mAb425/C225 
combination. Combinations of Panitumumab with other mAb though showed increased growth 
inhibition of A431 cells, they failed to completely abrogate EGF binding and did not demonstrate 
Ligands 
Cell Surface Receptors 
(% of Control) 
EGF 97.49 ± 0.48 
mAb425 86.26 ± 2.47 
C225 76.00 ± 1.54 
Panitumumab 71.97 ± 0.34 
mAb425/C225 40.80 ± 0.02 
mAb425/Panitumumab 67.61 ± 1.26 
C225/Panitumumab 72.34 ± 0.62 
 
Table E.5  Comparison of ligand mediated EGFR downregulation. 
The net internalization of cell surface receptors after 10hr incubation with ligands is shown. In 
10hr, mAb425/C225 internalizes almost 60% of surface receptors compared to ~14-30% 
internalization for other mAbs and their combinations. The mean values from three 
independent experiments are shown, ± S.E.M. 
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faster EGFR downregulation; as observed by the synergistic combination of mAb425 and C225. 
These observations suggest the existence of some other mechanism of synergy apart from those 
exhibited by mAb425/C225 combination. It should be noted that though thes binding affinities for 
C225 and Panitumumab are similar; their kinetic parameters are completely different. 
Panitumumab exhibits almost 4-fold slower dissociation rate compared to C225, which shows 
that once bound to the receptor, Panitumumab-EGFR complex is stable for longer period of time. 
Once bound, Panitumumab will continue to remain bound and thus would block EGF binding 
better than C225, as depicted through the difference the values of IC50, shown in Table E.4. This 
could be one of the possibilities to explain why Panitumumab is a better inhibitor of cell growth 
compared to either Matuzumab or C225 (Figure E.6). 
 Apart from the two models presented in this study to elucidate synergistic behavior of 
mAb425/C225 combination, recent studies showed that the use of C225/Matuzumab combination 
also results in triggering the complement activation for cell lysis (Dechant et al., 2008). Cells 
incubated with this mAb combination showed increased deposition of C1q and C4c on the cell 
surface, the key players that trigger cell dependent cytotoxicity (CDC). During this study, a wide 
range of EGFR targeting human mAbs were selected, including Panitumumab and their 
combinations were screened to understand the activation of complement pathway. It was 
observed that only the combinations of non-competing mAbs were able to demonstrate strong 
synergism for complement-mediated cell lysis and none of the Panitumumab combinations with 
Matuzumab and C225 were able to enhance CDC. These results, thus forces us to believe that 
there is some mechanism that governs the observed enhanced inhibition of cell growth by the 
combinations of Panitumumab with Matuzumab and C225. 
 Overall, based on this study and other reports, we believe that the bispecific mAb roposed 
in Figure 7.4 with one arm targeting mAb425 epitope and the other with C225 epitope would be 
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more efficacious than the parent molecule. Though the same could not be predicted for 
Panitumumab, further understanding of the mechanism of enhanced growth inhibition by 
Panitumumab combinations is required. 
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APPENDIX F 
SUPPLEMENTARY DATA 
F.1  INTRODUCTION 
This appendix provides the values for the important graphs presented in the thesis. 
  
 
 
IgG concentration 
(nM) 
mAb425 C225 mAb425/C225 
0.1 6.95 ± 1.68 5.33 ± 1.49 3.15 ± 0.96 
0.5 11.13 ± 1.57 14.82 ± 1.11 14.03 ± 1.28 
1 12.15 ± 1.53 19.58 ± 1.41 24.04 ± 1.35 
5 15.23 ± 1.28 23.46 ± 1.65 34.35 ± 2.09 
10 16.06 ± 1.01 24.15 ± 1.46 34.93 ± 2.43 
50 20.98 ± 1.61  27.34 ± 0.81 34.29 ± 1.55 
100 24.90 ± 1.47 31.68 ± 1.68 37.92 ± 1.37 
1000 32.85 ± 1.94 35.18 ± 0.94 41.67 ± 1.2 
 
 
Table F.1  Values of growth inhibition of MDA-MB-468 cells for Figure 4.1 A. 
The average values of growth inhibition of MDA-MB-468 cells from three independent 
experiments with at least triplicate wells per experiment are provided, ± S.E.M. 
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 mAb425 Binding (% of Control) 
 EGF Concentration 
IgG Conc. (nM) 0nM 1nM 10nM 400nM 
0.5625 12.63 ± 0.79 13.39 ± 0.58 12.74 ± 0.64 4.56 ± 0.58 
6.25 43.38 ± 2.29 41.77 ± 1.98 39.25 ± 1.79 15.09 ± 2.89 
25 84.66 ± 2.13 81.84 ± 1.66 75.90 ± 2.41 29.68 ± 4.65 
100 89.20 ± 1.56 87.40 ± 2.00 84.39 ± 2.42 42.46 ± 1.96 
400 100.00 100.55 ± 0.94 99.26 ± 2.14 72.27 ± 2.84 
 
 
 C225 Binding (% of Control) 
 EGF Concentration 
IgG Conc. (nM) 0nM 1nM 10nM 400nM 
0.5625 11.71 ± 0.90 11.79 ± 0.79 12.35 ± 1.09 6.52 ± 1.13 
6.25 37.58 ± 1.88 38.30 ± 1.78 37.45 ± 0.84 17.26 ± 1.13 
25 79.52 ± 0.22 69.54 ± 0.36 68.29 ± 0.46 35.56 ± 1.96 
100 89.56 ± 0.92 84.34 ± 1.42 74.74 ± 0.51 47.16 ± 3.00 
400 100.00 96.66 ± 3.58 94.19 ± 1.99 69.69 ± 3.12 
 
 
 mAb425/C225 Binding (% of Control) 
 EGF Concentration 
IgG Conc. (nM) 0nM 1nM 10nM 400nM 
0.5625 10.16 ± 0.57 10.87 ± 0.77 10.48 ± 0.74 6.73 ± 0.64 
6.25 32.55 ± 1.92 33.38 ± 2.26 31.55 ± 1.95 20.56 ± 1.28 
25 69.37 ± 1.12 65.15 ± 0.62 68.09 ± 3.40 59.15 ± 2.83 
100 91.83 ± 0.74 92.57 ± 1.23 92.27 ± 2.10 87.27 ± 2.17 
400 100.00 104.01 ± 2.26 105.09 ± 1.74 99.75 ± 0.85 
 
 
Table F.2  Values of growth inhibition of MDA-MB-468 cells for Figure 5.3. 
The average values of mAb binding from three independent experiments at different EGF 
concentrations are provided, ± S.E.M. 
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          Matuzumab          C225    Matuzumab/C225 
 
Concentration 
(nM) 
IgG Fab IgG Fab IgG Fab 
5 6.65 ± 1.37 -3.29 ± 0.92 9.85 ± 1.24 -3.06 ± 1.11 13.79 ± 1.01 -4.88 ± 1.73 
10 6.73 ± 1.53 -3.79 ± 1.74 12.39 ± 1.22 -4.16 ± 1.64 14.49 ± 1.04 -8.31 ± 1.12 
50 7.94 ± 1.70 -2.94 ± 1.44 10.80 ± 1.19 -4.00 ± 1.61 16.78 ± 1.22 -4.66 ± 1.36 
100 8.85 ± 1.04 -0.77 ± 1.49 13.84 ± 0.95 -3.26 ± 1.76 18.04 ± 1.41 -4.46 ± 2.12 
 
 
Table F.4  Values of growth inhibition of A431cells for Figure 6.4. 
The average values of growth inhibition of A431 cells from three independent experiments with at 
least triplicate wells per experiment are provided, ± S.E.M. 
IgG concentration 
(nM) 
Matuzumab C225 Matuzumab/C225 
5 3.69 ± 1.24 9.18 ± 1.06 14.47 ± 0.76 
10 5.35 ± 1.19 11.79 ± 0.90 15.83 ± 0.89 
50 7.70 ± 1.20  12.25 ± 1.00 18.61 ± 0.98 
100 8.82 ± 0.69 14.88 ± 0.83 20.64 ± 1.18 
 
 
Table F.3  Values of growth inhibition of A431cells for Figure 6.1. 
The average values of growth inhibition of A431 cells from five independent experiments with 
at least triplicate wells per experiment are provided, ± S.E.M. 
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Time (hr) Matuzumab C225 Matuzumab/C225 EGF 
0.5 102.35 ± 1.15 87.90 ± 1.29 81.37 ± 1.74 76.22 ± 1.91 
1 99.69 ± 1.38 88.95 ± 2.79 76.14 ± 1.51 78.36 ± 1.93 
2 99.86 ± 1.81 86.71 ± 0.62 69.29 ± 2.01 78.10 ± 3.20 
4 95.42 ± 2.79 81.97 ± 0.12 49.61 ± 0.07 69.75 ± 2.22 
6 92.85 ± 1.50 80.27 ± 0.18 49.26 ± 2.66 82.51 ± 4.26 
10 86.26 ± 2.47 76.00 ± 1.54 40.80 ± 0.02 97.49 ± 0.48 
 
 
Table F.5  Values of mAb mediated EGFR downregulation for Figure 6.2. 
The average values of EGFR downregulation from 3 independent experiments are provided, ± 
S.E.M. 
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